Non-benzodiazepine hypnotic use for sleep disturbance in people aged over 55 years living with dementia: a series of cohort studies by Richardson, Kathryn et al.
Journals Library
DOI 10.3310/hta25010
Non-benzodiazepine hypnotic use for 
sleep disturbance in people aged over  
55 years living with dementia: a series  
of cohort studies 
Kathryn Richardson, George M Savva, Penelope J Boyd, Clare Aldus, Ian Maidment, 
Eduwin Pakpahan, Yoon K Loke, Antony Arthur, Nicholas Steel, Clive Ballard,  
Robert Howard and Chris Fox
Health Technology Assessment
Volume 25 • Issue 1 • January 2021
ISSN 1366-5278

Non-benzodiazepine hypnotic use for
sleep disturbance in people aged over
55 years living with dementia: a series
of cohort studies
Kathryn Richardsono ,1 George M Savvao ,1,2
Penelope J Boydo ,1,3 Clare Alduso ,1 Ian Maidmento ,4
Eduwin Pakpahano ,5 Yoon K Lokeo ,3
Antony Arthuro ,1 Nicholas Steelo ,3 Clive Ballardo ,6
Robert Howardo7 and Chris Foxo 3*
1School of Health Sciences, University of East Anglia, Norwich, UK
2Quadram Institute, Norwich, UK
3Norwich Medical School, University of East Anglia, Norwich, UK
4School of Life and Health Sciences, Aston University, Birmingham, UK
5Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
6Medical School, University of Exeter, Exeter, UK
7Division of Psychiatry, University College London, London, UK
*Corresponding author
Declared competing interests of authors: George M Savva reports grants from the National Institute for
Health Research Health Technology Assessment programme during the conduct of the study (for Health
Services and Delivery Research 14/70/96). Yoon K Loke reports personal fees from Thame Laboratories
(London, UK) outside of the submitted work. Clive Ballard reports grants and personal fees from Acadia
Pharmaceuticals (San Diego, CA, USA) and Lundbeck (Copenhagen, Denmark), and personal fees from
Roche (Basel, Switzerland), Otsuka Pharmaceutical (Tokyo, Japan), Novartis (Basel, Switzerland), Eli Lilly and
Company (Indianapolis, IN, USA) and Pfizer Inc. (Pfizer Inc., New York, NY, USA).
Published January 2021
DOI: 10.3310/hta25010
This report should be referenced as follows:
Richardson K, Savva GM, Boyd PJ, Aldus C, Maidment I, Pakpahan E, et al. Non-benzodiazepine
hypnotic use for sleep disturbance in people aged over 55 years living with dementia: a series
of cohort studies. Health Technol Assess 2021;25(1).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.





Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics,
Science Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods
(to minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective
and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in
the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit
to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation
or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 14/221/02. The contractual start
date was in June 2016. The draft report began editorial review in November 2018 and was accepted for publication in July 2019. The authors
have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher
have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft
document. However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed
by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC,
the HTA programme or the Department of Health and Social Care.
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Richardson et al. under the terms of a
commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the
purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided
that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation,
Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief
Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK
NIHR Journals Library Editors
Professor John Powell  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. 
Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of 
Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK
Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and 
Editor-in-Chief of HS&DR, PGfAR, PHR journals
Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management 
and Marketing, University College Cork, Ireland
Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK
Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK
Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK
Ms Tara Lamont  Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK
Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, 
University of York, UK 
Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads  Emeritus Professor of Wellbeing Research, University of Winchester, UK
Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK
Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK
Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences,  
University of Nottingham, UK
Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: journals.library@nihr.ac.uk
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Non-benzodiazepine hypnotic use for sleep disturbance in
people aged over 55 years living with dementia: a series
of cohort studies
Kathryn Richardsono ,1 George M Savvao ,1,2 Penelope J Boydo ,1,3
Clare Alduso ,1 Ian Maidmento ,4 Eduwin Pakpahano ,5
Yoon K Lokeo ,3 Antony Arthuro ,1 Nicholas Steelo ,3 Clive Ballardo ,6
Robert Howardo 7 and Chris Foxo 3*
1School of Health Sciences, University of East Anglia, Norwich, UK
2Quadram Institute, Norwich, UK
3Norwich Medical School, University of East Anglia, Norwich, UK
4School of Life and Health Sciences, Aston University, Birmingham, UK
5Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
6Medical School, University of Exeter, Exeter, UK
7Division of Psychiatry, University College London, London, UK
*Corresponding author Chris.Fox@uea.ac.uk
Background: Sleep disturbance affects around 60% of people living with dementia and can negatively
affect their quality of life and that of their carers. Hypnotic Z-drugs (zolpidem, zopiclone and zaleplon)
are commonly used to treat insomnia, but their safety and efficacy have not been evaluated for people
living with dementia.
Objectives: To estimate the benefits and harms of Z-drugs in people living with dementia with
sleep disturbance.
Design: A series of observational cohort studies using existing data from (1) primary care linked to hospital
admission data and (2) clinical cohort studies of people living with dementia.
Data sources: Primary care study – Clinical Practice Research Datalink linked to Hospital Episode Statistics
and Office for National Statistics mortality data. Clinical cohort studies – the Resource Use and Disease
Course in Dementia – Nursing Homes (REDIC) study, National Alzheimer’s Coordinating Centre (NACC)
clinical data set and the Improving Well-being and Health for People with Dementia (WHELD) in nursing
homes randomised controlled trial.
Setting: Primary care study – 371 primary care practices in England. Clinical cohort studies – 47 nursing
homes in Norway, 34 Alzheimer’s disease centres in the USA and 69 care homes in England.
Participants: Primary care study – NHS England primary care patients diagnosed with dementia and aged
> 55 years, with sleep disturbance or prescribed Z-drugs or low-dose tricyclic antidepressants, followed
over 2 years. Clinical cohort studies – people living with dementia consenting to participate, followed over
3 years, 12 years and 9 months, for REDIC, NACC and WHELD, respectively.
Interventions: The primary exposure was prescription or use of Z-drugs. Secondary exposures included
prescription or use of benzodiazepines, low-dose tricyclic antidepressants and antipsychotics.
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Main outcome measures: Falls, fractures, infection, stroke, venous thromboembolism, mortality,
cognitive function and quality of life. There were insufficient data to investigate sleep disturbance.
Results: The primary care study and combined clinical cohort studies included 6809 and 18,659 people
living with dementia, with 3089 and 914 taking Z-drugs, respectively. New Z-drug use was associated with
a greater risk of fractures (hazard ratio 1.40, 95% confidence interval 1.01 to 1.94), with risk increasing
with greater cumulative dose (p = 0.002). The hazard ratio for Z-drug use and hip fracture was 1.59
(95% confidence interval 1.00 to 2.53) and for mortality was 1.34 (95% confidence interval 1.10 to 1.64).
No excess risks of falls, infections, stroke or venous thromboembolism were detected. Z-drug use also did
not have an impact on cognition, neuropsychiatric symptoms, disability or quality of life.
Limitations: Primary care study – possible residual confounding because of difficulties in identifying
patients with sleep disturbance and by dementia severity. Clinical cohort studies – the small numbers of
people living with dementia taking Z-drugs and outcomes not necessarily being measured before Z-drug
initiation restricted analyses.
Conclusions: We observed a dose-dependent increase in fracture risk, but no other harms, with Z-drug
use in dementia. However, multiple outcomes were examined, increasing the risk of false-positive findings.
The mortality association was unlikely to be causal. Further research is needed to confirm the increased
fracture risk. Decisions to prescribe Z-drugs may need to consider the risk of fractures, balanced against
the impact of improved sleep for people living with dementia and that of their carers. Our findings suggest
that when Z-drugs are prescribed, falls prevention strategies may be needed, and that the prescription
should be regularly reviewed.
Future work: More research is needed on safe and effective management strategies for sleep disturbance
in people living with dementia.
Study registration: This study is registered as European Union electronic Register of Post-Authorisation
Studies (EU PAS) 18006.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 1.
See the NIHR Journals Library website for further project information.
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What was the problem?
Poor sleep is common in people living with dementia. It can worsen their own and their carer’s quality
of life. Sleeping tablets called Z-drugs (zolpidem, zopiclone and zaleplon) are often given to people
with dementia.
Some studies suggest that Z-drugs may be harmful, but no studies have looked into the effects of Z-drugs
for people with dementia. Good sleep is important, but we need to understand if Z-drugs cause harm.
What did we do?
Using existing medical records, we compared the quality of life, memory and number of falls, infections,
strokes, broken bones and deaths for a group of people living with dementia taking a Z-drug, with those
for a group not taking any sleep drug.
What did we find?
Z-drug users were no more likely to suffer falls, infection or stroke, but they were more likely to break a
bone. We also found that Z-drug users died earlier, but we could not be sure that this was as a result of
taking the Z-drug. Using Z-drugs did not appear to affect quality of life or memory.
We talked to carers and health-care practitioners, who told us that decisions about Z-drugs need to
balance a range of complicated health and social factors.
What does this mean?
We found that people living with dementia who take Z-drugs are more likely to break a bone or to die
sooner than similar people with dementia who are not taking Z-drugs. However, we cannot be certain that
these problems are caused by Z-drugs, as many other factors can also lead to broken bones and death.
Further work is needed to clarify the risk of broken bones, but if sleep problems can be managed in other
ways then this may be preferable. Patients and family carers should be involved in decisions about Z-drugs,
so that they can balance the possible harms against the benefits.
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Dementia is a debilitating disorder affecting memory and cognition. Many neuropsychiatric symptoms are
also present, including issues with sleep. Sleep disturbance can encompass insomnia, fragmented sleep,
night-time wandering and excessive daytime sleeping, and it affects around 60% of people living with
dementia. Sleep is critical for body function, cognitive performance, mood and memory consolidation. This
reduction in sleep can have a devastating impact on the quality of life of people living with dementia and
their carers, and can hasten care home admission. Pharmacological intervention is commonly used to help
initiate and maintain sleep, including the use of hypnotic Z-drugs (zolpidem, zopiclone and zaleplon).
These drugs are similar to benzodiazepine hypnotics but were thought to have fewer of the associated side
effects, including increased risk of falls, fractures, infections and death, particularly in the older population.
There is now emerging evidence that Z-drug use is also significantly associated with increased risk of falls,
fractures, death, infections and cerebrovascular events. Although these drugs are widely prescribed to
people living with dementia, there has been little evidence showing their harms and benefits in this
population. People living with dementia are already at higher risk of falls and fractures, so understanding
any additional harms of Z-drug use is important.
There have also not been studies to address whether or not these drugs are actually effective in people
living with dementia (e.g. we do not know if their use improves cognition or quality of life). Improving
sleep could be a critical intervention to increase quality of life and improve daily functioning of both
patient and carer; however, the risks associated with hypnotic use must be understood to allow a
balanced decision-making process when prescribing Z-drugs to people living with dementia.
Objectives
Primary care study
This study was designed to target people living with dementia suffering with sleep disturbance who were
prescribed Z-drugs, to estimate the harms associated with first prescription of Z-drugs compared with
alternative treatments and no treatment. We also performed a general practitioner validation study to
investigate the validity of dementia and sleep disturbance coding in primary care data sets.
Clinical cohort studies
We also investigated what the potential benefits of concurrent use of these medications are, using
patient-reported outcomes (including cognition and quality of life) and dementia-based clinical data sets
(which were repurposed for analysis in this study).
Design
A series of observational cohort studies using existing data from (1) primary care, linked to hospital
admission data and Office for National Statistics data and (2) three clinical cohort studies of people living
with dementia.
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Clinical Practice Research Datalink from English practices, representing 7% of the population linked to
Hospital Episode Statistics and Office for National Statistics mortality data.
Clinical cohort studies
1. Resource Use and Disease Course in Dementia – Nursing Homes (REDIC): a longitudinal study of
patients admitted to a nursing home who were followed for 3 years and assessed every 6 months,
based in Norway.
2. Improving Well-being and Health for People with Dementia (WHELD) in nursing homes: a randomised
controlled trial that evaluated an intervention to improve the quality of life of people with dementia
living in care homes, based in the UK.
3. National Alzheimer’s Coordinating Centre (NACC) clinical data set: a clinical data set based in the USA.
Setting
Primary care study
A total of 371 primary care practices in England.
Clinical cohort studies




NHS England primary care patients from January 2000 to March 2016, followed for up to 2 years.
Patients were included if they satisfied all the following criteria:
l Their general practice was in England.
l They were diagnosed with dementia, defined as the first of a code for dementia or prescription of a
cognitive enhancer (memantine, donepezil, rivastigmine or galantamine), occurring after 1 January 2000.
l They were aged ≥ 55 years when diagnosed with dementia.
l There was evidence of a sleep disorder, defined as the first record of a Read code for sleep disorder
diagnosis, symptom or referral, or prescription of a Z-drug, low-dose tricyclic antidepressant or
melatonin, on or after the dementia diagnosis date and before 31 March 2016 (this first sleep
disturbance date defined the ‘index date’).
l Their records contained at least 3 months of good-quality data before the dementia diagnosis and at
least 12 months of data before the index date.
Patients were excluded if there was:
l uncertainty regarding the timing of dementia diagnosis
l a diagnosis of severe mental illness or Down syndrome prior to dementia diagnosis
l a diagnosis of sleep apnoea, sleep-related respiratory failure or alcohol abuse prior to the index date
l a diagnosis of neuropathic pain in the 12 months prior to the index date
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l a prescription of sedatives, tricyclic antidepressants or benzodiazepines in the 12 months prior to the
index date
l a prescription of multiple sleep medications on the index date
l a prescription of a new antipsychotic, other sedative or other tricyclic antidepressant on the index date
l no linkage possible between Clinical Practice Research Datalink and Hospital Episode Statistics data.
Clinical cohort studies
The REDIC study included people living with dementia or mild cognitive impairment admitted to a nursing
home in Norway, with follow-up every 6 months for up to 3 years. The NACC data set included people
living with dementia in the USA, followed up annually for up to 12 years. The WHELD trial included people
living with dementia admitted to a nursing home in England, with follow-up at 9 months.
Exposures
The primary exposure was prescription or use of Z-drugs. Secondary exposures included prescription or use
of benzodiazepines, low-dose tricyclic antidepressants and antipsychotics. Details were extracted for sleep
medication prescribed during the follow-up period, including prescription date, dose and duration.
Main outcome measures
In the primary care study, the 16 outcomes assessed were incident (1) fracture in any location; (2) hip
fracture; (3) forearm/wrist/hand fracture; (4) fall; (5) mortality; (6) acute bacterial infection; (7) urinary
tract infection or acute lower respiratory tract infection; (8) ischaemic stroke/transient ischaemic attack;
(9) venous thromboembolism; (10) agitation or psychosis; and additional use of (11) sedatives and other
sleep medications; (12) antipsychotics; (13) antidepressants; (14) antibiotics; and health-care utilisation of
the number of (15) general practitioner visits and (16) hospital admissions.
The clinical cohort studies examined outcomes of cognition, quality of life, neuropsychiatric symptoms
and disability. Specifically, the REDIC study included cognitive outcomes (using the Mini-Mental State
Examination, a short eight-item version of the Severe Impairment Battery and the Clinical Dementia Rating –
Sum of Boxes); neuropsychiatric symptoms (sleep, anxiety, agitation measured using the Neuropsychiatric
Inventory and as part of the Cornell Scale for Depression in Dementia); quality of life (using the Quality of
Life in Late-Stage Dementia, using the EuroQol-5 Dimensions and the visual analogue scale); and disability
(using the Lawton Physical Self-Maintenance Scale). The NACC data set measured outcomes of cognition
(using the Clinical Dementia Rating – Sum of Boxes, Mini Mental State Examination, animal naming and the
Trail Making Test delta trail time); neuropsychiatric outcomes (using the Neuropsychiatric Inventory sleep
scores, anxiety, agitation and Neuropsychiatric Inventory excluding sleep); the Geriatric Depression Scale
(as a proxy of quality of life); and disability (measured using 10 questions on the amount of help needed
with each of 10 different activities). The WHELD trial measured neuropsychiatric outcomes (using the
Neuropsychiatric Inventory excluding sleep and Neuropsychiatric Inventory sleep scores) and quality of life
(using the Quality of Life in Late-Stage Dementia).
Analysis
In the primary care study, Cox proportional hazards regression was used to estimate the association
between sleep medication prescription and binary outcomes adjusted for the potential confounders.
Negative binomial regression was used to estimate the association between sleep medication and number
of general practitioner visits and hospital admissions.
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Using the REDIC and NACC data sets, we explored the dynamics and predictors of use of any of three
hypnotics (Z-drugs, benzodiazepines or antipsychotics). We used several different analytical approaches to
explore associations between use or change in use of hypnotics with changes in cognitive, neuropsychiatric
characteristics and quality-of-life outcomes.
In the REDIC study and the NACC data set, linear regression models were used to estimate the association
between pattern of hypnotic use and change in each outcome, adjusting for participant age, their baseline
cognitive function and visit number. Clustered standard errors were estimated to account for multiple
observations per patient. To control for time-varying covariates, inverse probability of treatment weights
were also generated, using logistic regression models estimating the probability of treatment at each visit,
conditional on previous treatment and previous values of all covariates. Following the method of marginal
structural models, these models were used to generate weights reflecting the inverse probability of
observed treatment at the current visit, and these weights were applied to simple linear regression models
estimating the effect of current hypnotic use on change in outcome measures between waves.
In the WHELD trial, negative binomial regression was used to estimate the association between Z-drug use
at baseline and the Quality of Life in Late-Stage Dementia, Neuropsychiatric Inventory excluding sleep and
Neuropsychiatric Inventory sleep scores at baseline. Logistic regression was used to estimate the association
between baseline Z-drug use and mortality by 9 months’ follow-up. Linear regression was used to estimate
the mean decline in the Quality of Life in Late-Stage Dementia, Neuropsychiatric Inventory excluding sleep
and Neuropsychiatric Inventory sleep scores from baseline to 9 months’ follow-up.
Results
A total of 6809 patients were included in the primary care study and 3089 were prescribed Z-drugs.
New use of Z-drugs was associated with a greater risk of fractures (hazard ratio 1.40, 95% confidence
interval 1.01 to 1.94), with risk increasing with greater cumulative dose (p = 0.002). For 42 prescribed
defined daily doses onwards, the hazard ratio for a fracture increased to 1.70 (95% confidence interval
1.17 to 2.48). We found evidence of Z-drug use associated with an increased risk of hip fracture (hazard
ratio 1.59, 95% confidence interval 1.00 to 2.53) and this rose to a hazard ratio of 2.24 (95% confidence
interval 1.29 to 3.91) when cumulatively prescribed ≥ 42 defined daily doses. We also found evidence
of Z-drug use associated with mortality (hazard ratio 1.34, 95% confidence interval 1.10 to 1.64), but
this association was similar regardless of cumulative exposure to Z-drugs. We also found that people
living with dementia who were prescribed Z-drugs were more likely to be initiated on antipsychotics and
antidepressants and have more general practitioner and hospital visits. There was no excess risks of falls
(hazard ratio 1.05, 95% confidence interval 0.87 to 1.25), acute bacterial infections (hazard ratio 1.09,
95% confidence interval 0.92 to 1.29), ischaemic stroke/transient ischaemic attack (hazard ratio 1.33,
95% confidence interval 0.85 to 2.07), or venous thromboembolism (hazard ratio 1.66, 95% confidence
interval 0.69 to 3.98) detected.
In the general practitioner validation study, we found good validity of dementia diagnoses, with 96% of
selected patients confirmed to have dementia by their general practitioner. However, we found less validity
for sleep disturbance, as only 63% of patients had sleep disturbance confirmed.
In 678 people living with dementia or mild cognitive impairment in the REDIC study, we found that those
with better cognitive function were more likely to start using Z-drugs, whereas those with worse cognitive
function were more likely to start antipsychotics. Neuropsychiatric symptoms (sleep disturbance, agitation
and anxiety) predicted the new use of hypnotics, but there was no evidence that the use of hypnotics
causes any significant change in any of the measures that we examined.
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In the 17,055 people living with dementia in the NACC data set, we did not observe any significant additional
cognitive impairment associated with the use or initiation of Z-drugs, whereas we observed cognitive decline
among those taking benzodiazepines or antipsychotics, and those with more severe cognitive function were
more likely to be initiated on these drugs. With respect to neuropsychiatric symptoms, there was a significant
association between symptom levels and subsequently starting an associated medication, and between
starting medications and a concurrent increase in symptoms. As with the REDIC study, there also appears
to be no wider impact of hypnotics on quality of life (here as measured by the Geriatric Depression Scale,
capturing a patient’s own assessment of their mood).
In 926 people living with dementia in the WHELD trial, we observed greater neuropsychiatric symptoms in
those taking Z-drugs at baseline (rate ratio 1.24, 95% confidence interval 1.00 to 1.54), but Z-drug use at
baseline was not associated with greater improvement in neuropsychiatric symptoms over the following
9 months (mean additional improvement of 0.60 points, 95% confidence interval –3.26 to 4.46 points).
We also observed no greater mortality risk in those taking Z-drugs (odds ratio 0.66, 95% confidence
interval 0.38 to 1.15).
Limitations
Residual confounding may be possible in the primary care study because of difficulties identifying patients
with sleep disturbance and by dementia severity. The limited numbers of people living with dementia
taking Z-drugs and not recording medication use and the outcomes continuously restricted analyses in the
clinical cohort studies.
Conclusions
Sleep is critical for the health and well-being of an individual; however, in people living with dementia,
sleep disturbance is common and often treated with hypnotic medications. To the best of our knowledge,
the clinical effectiveness and safety of these drugs have not been assessed in people living with dementia.
Using primary care patient data, we observed a dose-dependent increase in fracture and hip fracture risk
with Z-drug use in dementia; however, multiple outcomes were examined, increasing the risk of false-positive
findings. We also found an association between Z-drug use and mortality, but findings suggest that this is not
a causal association. There was also an increase in other prescriptions and higher health-care utilisation in those
taking a Z-drug. However, there were no increased risks detected for falls, infections or cerebrovascular events
in people living with dementia with sleep disturbance. Further research is needed to confirm the associations
observed with Z-drugs and fracture risk, in order to establish whether or not these risks need consideration
when prescribing Z-drugs, when balancing the impact of improved sleep of the patient and the carer.
Our clinical studies found no evidence for improved quality of life or cognition with Z-drug use in people
living with dementia, but the studies were of insufficient power to address this. Our findings suggest that
further research is needed into non-pharmacological alternatives for sleep disturbance in dementia, and
into whether or not the prescription of Z-drugs concurrently needs inclusion of risk management strategies
to minimise potential fracture risks and adverse health outcomes.
Study registration
This study is registered as European Union electronic Register of Post-Authorisation Studies (EU PAS) 18006.
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In the UK, over 800,000 people are living with dementia1 and it is estimated that global prevalence of
dementia will be 65.7 million by 2030.2 In England and Wales, the number of people living with dementia
will increase by 57% between 2016 and 2040, increasing future care demands substantially.3 Dementia is
a debilitating condition predominantly affecting older people, resulting in progressive decline in cognitive
and daily function. People living with dementia have higher rates of hospital admission and readmission,
worse health outcomes and higher rates of mortality than people without dementia.4
Many neuropsychiatric symptoms are also associated with dementia, including aggression, agitation,
depression, apathy and sleep disturbance, with nearly all patients developing some neuropsychiatric
symptoms during the course of the disease.5 There are currently no curative treatments for dementia,
available treatment options generally manage symptoms.6 As the disease progresses, disability increases
and independence declines, leading to increased use of health and social services. Neuropsychiatric
symptoms can cause great distress to family members and carers, contributing hugely to carer burden,
stress and poor health,7 and increases the rate of institutionalisation.8
Sleep disturbance in people with dementia
Sleep disturbance can include insomnia, fragmented night-time sleep, night-time wandering and excessive
daytime sleeping. The incidence of sleep disturbance in the older population is common, with many older
adults reporting insomnia.9
Studies show that chronic insomnia predicts poor health, with better health leading to improved sleep
patterns,9 and that disturbed sleep is actually a rarity in older adults who are healthy.10 Reasons for
age-related decline in sleep duration and quality include physical and psychiatric illness.11,12 Therefore,
it is unsurprising that in people living with dementia, sleep disturbance is high, with around 60% of
people living with dementia affected.13,14
Sleep disturbance in Alzheimer’s disease is correlated with further cognitive dysfunction, suggesting that
treatment of sleep disturbance could be a strategy to improve cognition in patients.15 Poor sleep impacts
greatly on the quality of life (QoL) of both the patient and their informal carer.16,17 Furthermore, frequent
night-time waking can cause further risks to the individual, including wandering outside (which contributes
to significant reductions in carer sleep and increases carer burden),18–20 and increases the rate of care home
admissions for people living with dementia.21 Sleep disturbance is highly prevalent in people living in care
homes, and residents with dementia are reported to have more sleep disturbance then those without
dementia.22 In many cases, this leads to pharmacological interventions being commonly used to manage
sleep disturbance in community, hospital and care home settings.23
Pharmacological treatment of sleep disturbance: benzodiazepines and Z-drugs
There are several pharmacological treatments available for the management of sleep disturbance in the
older population, including hypnotic benzodiazepines (BZDs) and Z-drugs (e.g. zolpidem, zaleplon and
zopiclone), hormones (melatonin), antidepressants [typically low-dose tricyclic antidepressant (TCAs)]
and antihistamines. The most widely used medications for sleep disturbances in older people are BZDs,
low-dose TCAs and Z-drugs.24
Low-dose TCAs have sedation effects due to their pharmacological effects of blocking histamine-1
receptors and are used for promoting sleep, but also in pain management and at higher doses for treating
depression.25 BZDs are long acting and act to enhance the effect of gamma-aminobutyric acid (GABA),
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an inhibitory neurotransmitter, causing sedation and thus promoting sleep.26 BZDs are not only given for
sleep disturbance, but are also prescribed for a wide range of conditions, including anxiety and agitation.27
BZDs are associated with a range of adverse side effects, including cognitive impairment, daytime sedation,
tolerance, dependence and falls.28–31 Z-drugs are a newer generation of BZD-like drugs, prescribed exclusively
for sleep disturbance. Z-drugs were introduced in the late 1980s, also targeting GABA receptors (similarly to
BZDs), to enhance GABA transmission, but with shorter half-lives and claiming to have fewer side effects.32
However, there is increasing emerging evidence of adverse effects.33 The National Institute for Health
and Care Excellence Guidance on the Use of Zalepon, Zolpidem and Zopiclone for the Short-Term
Management of Insomnia recommends that non-pharmacological approaches should be considered first,
but that short-acting BZD or Z-drugs can be used for up to 4 weeks, if appropriate.34 There is no explicit
recommendation in these guidelines for use in people living with dementia. Updated guidelines35 for
hypnotics discuss the growing evidence of increased risk of cognitive impairment associated with hypnotic
use, but do not specifically address if they are safe for use in people living with dementia. There are no
recommendations for pharmacological interventions for sleep disturbance in National Institute for Health
and Care Excellence dementia guidelines. A Cochrane systematic review in 2016 concluded that there was
a distinct lack of evidence to help guide drug treatment of sleep problems in people living with dementia.36
Adverse effects of hypnotic use in the older population
Benzodiazepines and Z-drugs can improve sleep quality, but clinically relevant adverse events are a cause
for concern.37 Risks in people living with dementia have been largely unexplored, but findings from the
older population suggest that the consequences of any side effects in people living with dementia could
be more severe.
Falls and fractures
It is estimated that 30% of adults aged > 65 years living in the community have at least one fall each
year38 and this is higher for people living with dementia, for whom it is estimated that 50–80% have a
fall each year.39,40 A recent study showed that, over an average of 2.5 years, one-third of people living with
dementia had a fall, leading to hospitalisation.41
Falls can cause a loss of confidence, potentially resulting in a decline of activity, which can cause further
instability and negatively impact QoL.42 Additionally, fall-related injuries can have a huge impact on
subsequent health recovery, leading to a loss of independence, reduced QoL, and are a prominent cause
of death and care home admission. Furthermore, fractures, particularly hip fractures, are a significant
economic burden to the NHS.43–46
There are several risk factors for falls, including medications. BZDs are associated with a 20% increased risk
of falls in older people.47–49 A study of > 9000 patients suffering from Alzheimer’s disease and age- and
sex-matched controls reported a hazard ratio (HR) of 1.9 [95% confidence interval (CI) 1.0 to 3.6] for BZD
prescription and risk of hip fracture,50 but did not disaggregate Z-drugs. Z-drugs are claimed to have fewer
adverse effects, including fewer falls;51 however, recent studies have shown that Z-drug use is also associated
with an increased risk of falls52,53 and fractures,54–59 particularly with new Z-drug use.57,59 A recent systematic
review and meta-analysis of 14 studies confirmed these risks, in which Z-drug use was associated with a
statistically significant increased risk of fractures, with an odds ratio (OR) of 1.63 (95% CI 1.42 to 1.87)
reported.60 This same study did not, however, find a statistically significant increased risk of falls from Z-drug
use. Similarly, a meta-analysis found that Z-drug use was significantly associated with increased risk of hip
fracture [risk ratio (RR) 1.90, 95% CI 1.68 to 2.13].61 These studies have provided key evidence that there is
an association between falls and injuries, with hypnotic use particularly in the older population. However,
there has been little evidence of the specific effects of hypnotic use in people living with dementia.62
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Infections
A meta-analysis of randomised controlled trials (RCTs), identified through searches of published sources
and US Food and Drug Administration records, found a 1.4- to twofold increased risk of infection in adults
exposed to Z-drugs.63 Some observational studies have similar findings.64–67 The reason for this finding is
unknown, but it has been speculated that hypnotics may impair immune surveillance or the clearing of oral
secretions during sleep.63,68 Infection is more common in people living with dementia than in older persons
without dementia, and infection in people living with dementia is a leading cause of mortality, hospitalisation
and high cost burden.4,69
Mortality
Evidence from studies investigating the association of Z-drug or BZD use with mortality is conflicting,70–72
with reported associations possibly due to confounding.73 A US study found that crude mortality rates were
higher in people living with dementia taking hypnotics, but the association was not statistically tested.74
Recently, a study of 31,140 community-dwelling persons with Alzheimer’s disease in Finland reported
a HR of 1.59 (95% CI 1.35 to 1.88) for mortality after BZD use.75 The use of Z-drugs, however, was not
associated with increased risk of death (HR 1.06, 95% CI 0.83 to 1.35). The study was unable to adjust for
sleep disturbance or anxiety.
Cerebrovascular events
People living with dementia have a higher risk of stroke than people without dementia.76 Recently, BZD use
has been associated with a 21% (95% CI 4% to 40%) increased risk of ischaemic, but not haemorrhagic,
stroke in 45,050 individuals with Alzheimer’s disease in Finland.77 The study also reported similar stroke risk
for Z-drugs. However, the study was unable to adjust for anxiety, sleep disturbance or dementia severity,
and only compared individuals with Alzheimer’s disease and not specifically those with sleep disturbance.
There has also been a report of an increased risk of ischaemic stroke associated with zolpidem.78
Other possible harms
Adverse behavioural symptoms have been reported with the use of Z-drugs in the older population,
including driving, walking, preparing and eating food, and making telephone calls when asleep.79 Other
symptoms reported include hallucinations, parasomnia and amnesia.80 Behaviours such as these could be
particularly detrimental for people living with dementia, given their vulnerable cognitive state and increased
risk of falls.39
Potential benefits of hypnotic use
Cognitive functioning
Sleep is crucial for cognitive performance, memory consolidation and mood regulation.81,82 Sleep loss is
associated with reduced cognitive performance.83,84 Furthermore, observational and experimental studies
suggest that poor sleep is a risk factor for cognitive decline and dementia.85 The underlying mechanisms
are unknown, but this suggests that improving sleep quality could be an intervention strategy for dementia,
potentially through sedative hypnotics. However, there is evidence that sedative hypnotic use is associated
with cognitive decline, with a stronger association observed with long-term exposure,86–89 although results
are conflicting.90,91 A recent systematic review and meta-analysis suggests that BZD use is associated with
increased dementia risk; however, observational studies cannot determine whether the association is a
causal effect or due to unmeasured confounders.92,93 Evidence is emerging that Z-drug use is also associated
with dementia risk.94,95 Despite these findings, there is a lack of studies addressing whether or not sleep
drugs are safe for individuals already suffering with significant cognitive decline.96 It is therefore important
to understand if increasing sleep in people living with dementia through pharmacological interventions can
maintain cognitive performance.
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Quality of life
Sleep disturbance can have a detrimental impact on QoL and health-related quality of life (HRQoL).97,98
Insomnia has been independently associated with worsened HRQoL to a similar extent as some chronic
conditions, including congestive heart failure.99 Insomnia and sleep disturbance are common in the older
population and are associated with decline in QoL.100 The QoL of carers is also severely reduced when
there is a sleep disturbance.19 Use of hypnotics could be a strategy to increase sleep and thus improve QoL.
There have been studies, however, to suggest that use of hypnotics can have a negative impact. In older
community-dwelling adults requiring pharmacological treatment for insomnia, hypnotics are also associated
with reduced HRQoL.101 A study of 10,430 older women identified that use of sleeping medications was
associated with lower QoL scores in vitality, social functioning, general mental health and bodily pain.102
Improving sleep
In dementia, for which sleep disturbance is common, improving sleep could be a valuable intervention
strategy to improve cognitive performance. Hypnotics are widely prescribed in this population in an
attempt to increase sleep. However, there is increasing evidence that the use of sedating hypnotics in the
general population does not improve sleep, cognitive performance or general health, calling into doubt their
clinical effectiveness.103,104
Study rationale
Sleep disturbance is a common problem in the older population and research suggests that over half of
people living with dementia have sleep disturbance.13 Sleep disturbance affects not only the individual,
but also their carer, subsequently leading to a decline in their health and QoL.17
Studies suggest that pharmacological therapy for sleep disturbance in the older population can lead to
increased rates of falls, fractures and infections. Conversely, untreated sleep disturbance, particularly
insomnia, can further impair cognitive function and daily functioning, increase dementia risk and lead to
worsening of other health problems.85,105 The potential harms of BZD and Z-drugs, such as increased
rates of falls, fractures and infections, could lead to higher rates of hospitalisation, adding additional
financial burden for health systems.106 Furthermore, adverse events quicken the time to institutionalisation,
increasing social care requirements.8,107
In 2016, the NHS spent £6M on Z-drugs with 6.53 million prescriptions dispensed in England,108 and
prescriptions of Z-drugs have almost doubled in the UK between 2000 and 2015.109,110 The proportion of
prescribed Z-drugs used specifically by people living with dementia is unknown,108 but hypnotic prescriptions
are common in people living with dementia.111 Guidance for sleep management in dementia is limited, with
little evidence of the safety and efficacy of pharmacological interventions, specifically for people living with
dementia.112 Indeed, a recent review identified a clear absence of RCTs addressing the use and effectiveness
of Z-drugs for sleep disturbance in dementia.36 Identification of safe and effective sleep medications for
people living with dementia remains an unsolved challenge.113
Together, the personal and societal impact of sleep disturbance for people living with dementia makes it
an important priority to quantify the benefits and harms of current pharmacological treatments used in this
patient group. This study was specifically designed to evaluate the management of sleep disturbance in
people living with dementia, and to provide critical evidence on which clinicians, patients, family members
and carers can base care decisions. If significant adverse events are detected when using Z-drugs, this
will additionally motivate the development of alternative treatments, both pharmacological and person
centred, to improve sleep and outcomes for patients.
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Chapter 2 Aims and objectives
Aims
The broad aims of this study were to:
l estimate the harms of using Z-drugs for the management of sleep disturbance in people living with
dementia, using UK primary care records (primary care study)
l explore the impact of Z-drugs on cognition and QoL for people living with dementia and their carers,
using repurposed clinical study data sets (clinical cohort studies).
Objectives
Primary care study
l To estimate the effects of first prescription of Z-drugs in people living with dementia with sleep
disturbance compared with alternative treatments and no treatment. Patient outcomes included:
¢ incidence of falls and factures
¢ mortality
¢ incidence of infection
¢ incidence of cerebrovascular events, including ischaemic stroke and venous thromboembolism
¢ incidence of behavioural and psychological symptoms
¢ additional medication use, including sedatives, antipsychotics, antidepressants and antibiotics
¢ health-care utilisation [general practitioner (GP) visits and hospital admissions].
l To validate recorded dementia diagnosis and sleep disturbance codes through a GP questionnaire.
Clinical cohort studies
l To repurpose existing clinical data sets to estimate the impact of concurrent use of Z-drugs on
patient- and carer-reported outcomes, including:
¢ QoL for patients and carers
¢ functional ability
¢ cognitive function and sleep disturbance in people with dementia.
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In this chapter we describe separately the methods for the primary care study and each of the clinicalcohort studies.
Study registrations
This work was funded by the National Institute for Health Research (NIHR) under its Health Technology
Assessment (HTA) programme (reference 14/221/02) and was conducted in accordance with protocol
version 1.2 published on 30 January 2018.
The primary care study protocol is registered with the European Network of Centres for Pharmacoepidemiology
and Pharmacovigilance [reference European Union electronic Register of Post-Authorisation Studies (EU PAS)
18006] and approved by the Independent Scientific Advisory Committee for Clinical Practice Research Datalink
(CPRD) research (reference ISAC 16_181).
Primary care study
Study design
This was an inception cohort study of people with dementia and sleep disturbance, using data from a UK
primary care database. The study design is summarised in Figure 1. Briefly, people living with dementia in
cohorts prescribed various treatments were followed for the rate of adverse events from their first prescription
for sleep disturbance in dementia (index date), until they had a different sleep drug or antipsychotic prescribed,
left their general practice, died or at 2 years’ follow-up (censor date).
New Z-drug Rx
New low-dose TCA Rx
Sleep disorder diagnosis
and new BZD Rx
Sleep disorder diagnosis
and no sleep drug Rx
New sleep drug/antipsychotic Rx
90 days
90 days
New sleep drug/antipsychotic Rx
New sleep drug/antipsychotic Rx
90 days
New sleep drug/antipsychotic Rx
Data included from January 2000 to March 2016–1 year
Minimum data history Index date Follow-up time
2 years0
FIGURE 1 Schematic of study design for the primary care cohort study of people living with dementia (n= 6809).
The four cohorts of patients were followed for at most 2 years or until March 2016. Follow-up for the cohort
diagnosed with sleep disturbance but not prescribed sleep medications ended when they received a first sleep
medication or antipsychotic prescription. The figure displays theoretical patterns of prescriptions for the cohorts
defined by a first Z-drug, BZD or low-dose TCA prescription. Here, follow-up ended if patients had a first sleep
medication or antipsychotic prescription, or if it had been > 90 days since their last prescription for a Z-drug,
BZD or low-dose TCA, respectively. Rx, prescription.
DOI: 10.3310/hta25010 HEALTH TECHNOLOGY ASSESSMENT 2021 VOL. 25 NO. 1
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Richardson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
Setting
This study was undertaken using data extracted from the CPRD. The CPRD includes anonymised diagnosis,
referral and prescribing records for > 11.3 million patients from 674 primary care practices across the UK,
and is broadly representative of the UK population in terms of age, sex and ethnicity.114 CPRD data have
been widely used for pharmacoepidemiology applications.115 The diagnosis information recorded in the
CPRD is entered as computer-recorded Read codes.116 Access to ‘free text’ entered by the GP is not
available because of patient anonymity issues.
We used linked data from the CPRD to Hospital Episode Statistics (HES) data version 14, the Office for
National Statistics (ONS) mortality data and Index of Multiple Deprivation (IMD) data. HES provides records
of all diagnoses made during a hospital admission in England, details on the patient’s demographics and
place of residence. Diagnoses during the hospital stay are recorded using the International Statistical
Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). ONS data include the date
and cause of death in England, with cause of death coded according to ICD-10. The IMD is a weighted
sum of a number of government indicators, including housing, employment, income, education, living
environment and crime levels for each general practice’s neighbourhood.117
The HES and ONS data sets were linked to CPRD patients by NHS number, date of birth, sex and postcode.
The vast majority (92%) of eligible CPRD patients matched to HES, matched on all four characteristics,
whereas a further 8% were matched on all but postcode.
Eligibility criteria
Patients were included if they satisfied all the following criteria:
l Their general practice was in England.
l They were diagnosed with dementia, defined as the first of a code for dementia or prescription of a
cognitive enhancer (memantine, donepezil, rivastigmine or galantamine), occurring after 1 January 2000.
The year 2000 onwards was chosen to exclude historical primary care records when recording was less
reliable,114 and linked mortality and hospital records were only available since 1998.
l They were aged ≥ 55 years when diagnosed with dementia.
l There was evidence of a sleep disorder, defined as the first primary care record for sleep disorder
diagnosis, symptom or referral (see Appendix 1, Table 27, for Read codes), or prescription of a Z-drug,
low-dose TCA or melatonin, on or after the dementia diagnosis date and before 31 March 2016
(this first sleep disturbance date defined the ‘index date’).
l Their records contained at least 3 months of good-quality data before the dementia diagnosis and at
least 12 months of data before the index date.
Record of a dementia diagnosis was identified by Read codes in the CPRD (see Appendix 1, Table 26 for
Read codes) or ICD-10 codes F00-F03, G30, G31.0 or G31.1 in HES.
Patients were excluded if there was:
l uncertainty regarding the timing of dementia diagnosis, specifically Read codes for a dementia annual
review, history of dementia, assessment of psychotic and behavioural symptoms of dementia, or
antipsychotic drug therapy for dementia, prior to meeting our dementia diagnosis definition
l diagnosis of severe mental illness or Down syndrome prior to dementia diagnosis (see Appendix 1,
Table 28 for Read codes)
l diagnosis of sleep apnoea, sleep-related respiratory failure or alcohol abuse prior to the index date
(see Appendix 1, Table 29 for Read codes)
l diagnosis of neuropathic pain in the 12 months prior to the index date (see Appendix 1, Table 30 for
Read codes)
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l a prescription of sedatives, TCAs or BZDs in the 12 months prior to the index date
l a prescription of multiple sleep medications on the index date
l a prescription of a new antipsychotic, other sedative or other TCA on the index date
l no linkage possible between CPRD and HES data.
Patient selection validation
To validate the accuracy of the coding on which our patient selection was based, a GP questionnaire-
based validation study was conducted.118 In collaboration with CPRD validation services we developed a
questionnaire to send to GPs, requesting confirmation of the dementia diagnosis and sleep disturbance
status of their patient. The questionnaire was sent to the GPs of 106 randomly selected patients who
were still registered with their GP in 2017. The patients selected represented those identified as having sleep
disturbance via various Read codes, who were or were not prescribed sleep medications. The questionnaire
(see Report Supplementary Material 1) asked GPs if the patient had been diagnosed with dementia and
the date of diagnosis. It also asked whether or not the patient had a record of a sleep disturbance since
being diagnosed with dementia and, if so, on what date. We reported the number of questionnaires
returned and the proportions of patients, with their dementia and sleep disturbance confirmed by the
GP according to their first medication for sleep disturbance. When the records of dementia or sleep
disturbance were not confirmed by GPs, we explored possible causes. We also performed a sensitivity
analysis restricted to patients with sleep codes with better validity.
Exposures
The primary exposure of interest was treatment with Z-drugs; secondary exposures were treatment with
other medications used for sleep disturbance. The CPRD contains detailed information on all medications
prescribed in primary care, including the date of each prescription, drug name, dose, quantity and frequency.
We extracted the details of all prescriptions for medications for sleep disturbance for patients in our cohort
from their index date up until 31 March 2016.
Sleep disturbance medications were defined according to the World Health Organization (WHO)’s
Anatomical Therapeutic Chemical (ATC) Classification System as:
l Z-drugs (N05CF)
l BZDs (N05BA, N05CD)
l melatonin (N05CH)
l low-dose TCA or related (N06AA09, amitriptyline at ≤ 25 mg/day; N06AX05 trazodone at ≤ 50 mg/day).
Patients were classified according to their prescription class on the index date, or to a ‘no prescription for
sleep disturbance’ group. Patients in the ‘no prescription for sleep disturbance’ group who then went on
to be prescribed any of the medications for sleep disturbance and still met the study eligibility criteria,
were then assigned a second index date as the date of this first prescription.
To test for possible dose–response relationships, we determined the cumulative number of prescribed
defined daily doses (DDDs) of Z-drugs. A DDD is defined as the assumed average maintenance dose
per day for a drug based on its main indication in adults, using the DDD values assigned by the WHO
Collaborating Centre for Drug Statistics Methodology (URL: www.whocc.no/atc_ddd_index; accessed
28 November 2019). For each prescription, we multiplied the number of tablets by the dose strength in
milligrams and converted this into the number of DDDs, using the values assigned by the WHO. We then
summed individual prescriptions to determine the cumulative number of prescribed DDDs, regardless of gaps
in use. If the quantity of tablets prescribed was missing, we assumed that one per day (28 tablets/prescription)
was prescribed. Prescribing instructions for Z-drugs were also categorised according to whether or not
instructions stated pro re nata (PRN) (i.e. use as needed).
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The Z-drugs historically prescribed in the UK are zopiclone, zolpidem and zaleplon. The WHO considers the
DDD of zopiclone to be 7.5 mg per day, and zolpidem and zaleplon to be 10 mg per day. These values are
consistent with the British National Formulary (BNF) prescribing guidelines for the recommended daily dose
in adults with insomnia.119,120 For use in the elderly, the BNF recommends using half these daily doses.
Outcome variables
The selected outcome variables were based on adverse effects of medications used to treat sleep disorders
identified from previous studies or priorities identified by carers, family members and health-care
professionals with direct experience of sleep disturbance in patients.
The 16 outcomes assessed were:
1. incident fracture in any location
2. incident hip fracture
3. incident forearm/wrist/hand fracture
4. incident fall
5. mortality
6. incident acute bacterial infection
7. incident urinary tract infection (UTI) or acute lower respiratory tract infection (LRTI)
8. ischaemic stroke/transient ischaemic attack (TIA)
9. venous thromboembolism
10. incident agitation or psychosis (including symptoms of hallucinations, delusions or aggression)
11. additional use of sedatives and other sleep medications (BNF version 69 subsection 4.1)120
12. additional use of antipsychotics (BNF version 69 subsection 4.2.1)120
13. additional use of antidepressants (BNF version 69 subsection 4.3)120
14. additional use of antibiotics (BNF version 69 subsection 5.1)120
15. health-care utilisation of number of GP visits
16. health-care utilisation of number of hospital admissions.
Patients with each outcome were identified using the first mention of a relevant Read code in the CPRD,
or ICD-10 code in HES or as a cause of death [Part 1(a) or 1(b)] on the death certificate. See Appendix 1,
Tables 31–38, for a list of the codes to identify the outcomes. Read code lists were drawn, when applicable,
from Quality and Outcomes Framework business rules, published studies, keyword searches and UK GP
experience within the study team.
Confounding variables
Potentially confounding variables were coded from the CPRD (unless otherwise stated) at the index date.
Covariates were selected that are potentially linked to sleep disturbance, dementia or sedative use and at
least one of the outcomes, as well as the availability, completeness and reliability of data within CPRD.
Demographic factors
Age, sex, year, care home residence (yes/no/unknown) practice-level IMD quintile, Strategic Health
Authority region of England, index date, ethnicity (white/other/unknown).
Health behaviours
Smoking (current smoker, ex-smoker, non-smoker, missing), alcohol use (yes/no/missing), body mass index
(BMI) (most recent value in last 5 years categorised as < 18.5, 18.5–24.9, 25–29.9, ≥ 30 kg/m2 or missing),
last systolic blood pressure (most recent value in last 5 years categorised as < 110, 110–119, 120–139,
140–159, ≥ 160 mmHg or missing).
Immunisations in last 12 months
Influenza, pneumonia.
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Dementia subtype and proxies for dementia severity
Dementia subtype (Alzheimer’s dementia, vascular dementia, mixed/other dementia, unspecified dementia),
time since dementia diagnosis, cognitive enhancers in last 90 days, antipsychotic use in last 365 days,
history of agitation/psychosis in dementia, end-of-life care (record of palliative care or end-of-life plans
having been discussed).
Proxies for sleep disturbance severity
Sleep disturbance diagnosis before dementia diagnosis, previous Z-drug prescription (prior to 12 months
before index date), previous BZD prescription (prior to 12 months before index date).
Comorbidities
Osteoporosis, other musculoskeletal conditions, depression, depression symptoms, anxiety, anxiety
symptoms, Parkinson’s disease, urinary incontinence, age-related macular degeneration (ARMD), glaucoma,
cataract, other visual impairment, diabetes, hyperlipidaemia, hypertension, heart attack, heart failure, atrial
fibrillation, ischaemic stroke/TIA, angina, venous thromboembolism, osteoarthritis, rheumatoid arthritis,
migraine/headache, back/neck pain, cancer and chronic obstructive pulmonary disease.
Medical history in last 12 months
Number of GP visits (0–3, 4–5, 6–8, 9–13 or 14–77), hospital admissions (0, 1 or ≥ 2 using data from HES),
a fall, a fracture, LRTI/UTI, dizziness/unsteadiness and faints/syncope.
Concurrent medication use
Any prescription in the last 90 days of selective serotonin reuptake inhibitors (SSRIs), non-SSRIs or TCA
antidepressants, other sedatives/hypnotics, antipsychotics, antihistamines, analgesics, antiepileptic drugs,
anticoagulants, antiplatelets, cardiac glycosides, diuretics, calcium channel blockers, angiotensin-converting
enzyme inhibitors, angiotensin II receptor antagonists, beta-blockers, lipid-regulating drugs, non-steroidal
anti-inflammatory drugs (NSAIDs), bisphosphonates, diabetes drugs, inhaled corticosteroids, calcium/
vitamin D and any prescription in the last 30 days for antibiotics.
Data from HES were additionally used to supplement the coding of a history of falls, fractures, LRTI/UTI,
ischaemic stroke/TIA, agitation/psychosis, venous thromboembolism, dementia subtype, ethnicity and care
home residence.
Statistical methods
We described the characteristics, comorbidities and concurrent medications of the patients in the cohort,
using summary statistics according to their initial treatment for sleep disturbance. Using a backwards
stepwise procedure retaining a p-value of < 0.15, we developed a multinomial regression model estimating
the association between patient characteristics at index date and treatment choice for sleep disturbance.
The primary statistical analysis comprised a series of survival analyses to assess the association between
sleep disturbance medication and adverse outcomes. Patients entered the analysis on their index date and
were followed until the earliest of:
l the date they left the general practice
l the last general practice data extraction date
l their date of death
l 90 days after their last prescription for their medication for sleep disturbance
l the date of an additional ‘medication for sleep disturbance’ or other sedative prescription
l the date of a new antipsychotic prescription (for those not prescribed antipsychotics in the year before
the index date)
l 2 years after the index date
l 31 March 2016.
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Patients were excluded from the analysis of each outcome depending on their history of that outcome.
For the fall and fracture outcomes, we excluded patients with a recorded fall or fracture in the 32 days
before index date, because of the chance of repeated coding of the same event.121 For the infections and
antibiotics outcomes, we excluded those with an infection or prescription for a medication for infection in the
previous 30 days. For the ischaemic stroke/TIA and venous thromboembolism outcomes, we excluded those
with a history of these in the previous 30 days. For the analysis of incident agitation/psychosis, we excluded
patients who already had a record of agitation or psychosis. For the antidepressant and antipsychotic outcomes,
we excluded patients with a prescription for these in the 12 months before the index date.
We used Cox regression models to estimate the HR for the effect of sleep disturbance medication class
compared with no prescription on each binary outcome. Sleep medication exposure was modelled as time
varying, such that patients at the index date are included for analysis in the ‘no treatment’ group until
initiation of their first treatment, and re-enter the study at time 0 as exposed thereafter to avoid immortal
time bias and reduce channelling bias. CIs and p-values were calculated using robust standard errors,
accounting for the correlation due to some patients appearing twice in the analysis. We checked the
proportional hazards assumption using Schoenfeld residuals.122
As the number of GP visits and hospital admissions was overdispersed (i.e. the variation was greater than
the mean), we used negative binomial regression to calculate incidence rate ratios (IRRs) for the effect of
sleep disturbance medication class on number of GP visits and hospital admissions in the 2 years after the
index date. For the analysis of GP visits, patients were censored only at the first of either death, leaving the
general practice, 31 March 2016 or 2-year follow-up. For the analysis of hospital admissions, patients were
censored only at the first of either death, 31 March 2016 or 2-year follow-up.
The primary analysis reported associations relative to no sleep disturbance medication use, and secondary
analysis reported associations for the effect of BZDs and low-dose TCAs compared with Z-drug use. Estimates
are provided, adjusted for age and sex, and adjusted for all potential confounders listed above and age2 to
allow non-linear effects with age. A quadratic association between age seemed an appropriate parametrisation
for most outcomes by examining the association between age in 10 equal categories and the outcome. We
performed a sensitivity analysis to this by instead modelling age using fractional polynomials and restricted
cubic splines (with five knots). Owing to a small number of events for forearm fractures we adjusted for other
eye conditions (ARMD, retinal disorders and glaucoma combined), region combined into only five areas
(South, East, Midlands, North and London) and did not adjust for ethnicity or systolic blood pressure.
For statistically significant associations with Z-drugs, interactions between Z-drug and age and sex were
tested. In addition, the absolute risks of adverse events and number needed to harm (NNH) were
estimated using a standard formula for NNH in time-to-event analysis.123
We also carried out analyses of Z-drug exposure according to both time-varying cumulative DDDs
(categorised as 0, 1–13, 14–27, 28–41 and ≥ 42 DDDs) and by Z-drug dosing instructions on the index
date (PRN or not).
Stata® version 14 (StataCorp LP, College Station, TX, USA) was used for data management and statistical
analysis. Owing to examining 16 outcomes, the chance of finding a statistically significant association by
chance alone had increased. To address this, we used a stricter threshold instead of the traditional p-value
threshold of 0.05. We used the Benjamini–Hochberg procedure to estimate this critical p-value threshold
in order to control rate of the false discovery rate (i.e. the proportion of rejected null hypotheses that are
incorrect rejections) at < 5%.124 This is less conservative than the Bonferroni correction,125 which simply
divides the classical p-value threshold of 0.05 by the number of hypotheses tested (so our critical threshold
would be 0.05/16 = 0.003). To control the false discovery rate, the Benjamini–Hochberg procedure depends
on the distribution of p-values resulting from the tests, as well as the number of tests performed.
METHODS
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Missing data
We expected incomplete recording of variables, such as smoking and BMI.126 In the primary analyses,
patients with missing covariate data were coded in a missing data category. For covariates with at least
10% of patients with missing data, we summarised the characteristics of those with and without missing
data and performed sensitivity analyses, including restricting to patients with and without the missing
variable.127 Finally, we estimated a single imputation model predicting the missing variables using the
covariates in Table 2 and in Appendix 2, Table 39. For missing BMI data, we additionally used the most
recent previously recorded BMI record to impute missing BMI value. We repeated our main analyses using
the imputed values.
Sensitivity analyses
We performed various sensitivity analyses of our main analysis. First, based on the findings of the validation
study, we repeated our main analysis with an amended definition of sleep disturbance that included
diagnoses of sleep disturbance only when not accompanied by a record for a ‘satisfactory’ sleep pattern.
Second, to examine the impact of the source of data used to identify outcomes, we restricted our main
analysis to only those outcomes recorded in the CPRD. Third, we compared adverse events in those who
initiated Z-drugs compared with those who had recently discontinued them. From the Z-drug cohort we
created a further ‘discontinued Z-drug’ cohort, who after a 90-day period with no Z-drug prescriptions were
still eligible for entry to the study. We compared the rates of adverse events in the ‘discontinued Z-drug’ to
the ‘Z-drug’ cohort.
Protocol changes
The following changes to the analysis plan were made since our protocol:
l We additionally censored patients at their first antipsychotic prescription. Patients initiated on Z-drugs
or BZDs were more likely to then start antipsychotics. We additionally censored on first antipsychotic
prescription to increase the likelihood that effects observed were due to the Z-drug use and not other
sedating medications.
l In our protocol, we aimed to examine incident ischaemic stroke/TIA and incident venous thromboembolism
and to exclude anyone with a history of these conditions. However, we found more patients had these
histories than expected, so instead we analysed recurrent or incident ischaemic stroke/TIA and venous
thromboembolism, and only excluded patients with a history of these in the last 30 days. Findings
when excluding all patients with a history of these conditions are available from the authors.
l We made minor changes to the list of potential confounders. We omitted the following prespecified
covariates in the analysis due to balance across treatment groups and rare occurrence: phobia, motor
neuron disease, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and
multiple sclerosis. We omitted epilepsy and prescription for medications for Parkinson’s disease and
diabetes, due to collinearity with already included covariates of prescription for antiepileptic medications,
diagnosis of Parkinson’s disease and diabetes, respectively. Finally, we omitted depression severity and
depression duration, as depression diagnosis, depression symptoms, anxiety diagnosis and anxiety
symptoms were considered sufficient. Subsequent to the protocol, we have also included the potential
confounders of recent prescription for calcium or vitamin D and end-of-life care, based on discussions
with our health-care professional advisory panel.
l We omitted a sensitivity analysis using instrumental variables as a result of not finding a sufficiently
strong instrument, such that using it would bring greater uncertainty and risk of bias than the main
analysis (see Report Supplementary Material 2 for further details), but instead completed an additional
analysis of those patients who discontinued Z-drugs.
A priori power calculation
We performed this a priori power calculation before we had access to HES data and made assumptions
as to what the HES data would contain; hence the estimates do not match the final numbers included.
There were 32,961 patients with sleep disturbance post dementia diagnosis in the CPRD (July 2017 version).
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Of these, 10,554 patients met study eligibility criteria and a further 6117 patients were eligible for HES
linkage (HES version 14). Preliminary analysis suggested that on the index date, 2546 patients received a
Z-drug, 68 patients received a melatonin, 255 patients received a BZD, 1745 patients received a low-dose
TCA antidepressant and 1503 patients received none of the above treatments. We estimated that an
additional 50% of dementia patients would be identified via HES (HES set 14 feasibility). Thus, when
comparing 3819 Z-drug patients with 2254 patients with no treatment for a common outcome over
2 years (e.g. falls at 36% per year) we can detect a HR of 1.07 with 90% power (two-sample test, p < 0.05).
For rare outcomes, such as hip fractures at 1.7% per year, we can detect a HR of 1.54 with 90% power.
Clinical cohort studies selection
The second phase of the study utilised data from RCT and cohort studies to estimate how patient-reported
outcomes are affected by sleep medication, which cannot be addressed in data extracted from the primary
care CPRD database. The following describes the process of identifying clinical cohort studies to examine
the outcomes of cognition, neuropsychiatric symptoms, sleep disturbance, disability or QoL of the people
living with dementia or their carer, and also the overarching methods applicable to the three clinical cohort
studies performed.
Potential studies
We identified several RCT and cohort studies for which data were obtained and descriptive analysis
performed to determine their appropriateness for use in this study. Studies were required to have:
l a validated dementia diagnosis for participants
l specific assessment of sleep disturbance for all participants
l at least two assessments per participant, with assessments separated by ≤ 1 year
l at least one key primary outcome (cognition, neuropsychiatric symptoms, sleep disturbance, disability or
QoL of the person living with dementia or their carer) included
l systematic assessment of participant medication use, with a documented protocol
l a well-characterised sample, recruited from a defined population with clear inclusion and
exclusion criteria
l sufficient sample size (in particular sufficient numbers of participants taking Z-drugs).
Data sources explored, with at least one primary outcome measure, are described in Table 1. Those which
were not deemed suitable for use in our study were not explored further from initial descriptive analysis.
Three data sources that fulfilled the required criteria underwent analysis of patient-reported outcomes.
These data sources were:
1. the Resource Use and Disease Course in Dementia – Nursing Homes (REDIC) Norwegian observational
longitudinal study
2. the University of Washington’s National Alzheimer’s Coordinating Centre (NACC) clinical data set
3. the Improving Well-being and Health for People with Dementia (WHELD) RCT based in UK nursing homes.
The REDIC study
Setting
The REDIC study is a longitudinal cohort study of people admitted to nursing homes in Norway. The REDIC
study is fully described elsewhere,133 but in brief the study began in 2012 and recruited 696 patients at
admission to one of 47 nursing homes across four Norwegian counties.
METHODS
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Baseline assessments were made within 1 month of admission to the nursing home and then every 6 months
thereafter. Comprehensive REDIC study assessments included questions on sleep disturbance, medication
use and measures of cognitive function [recorded by the Mini Mental State Examination (MMSE) and Severe
Impairment Battery (SIB-8)], QoL [measured by the Quality of Life in Late-Stage Dementia (QUALID) scale and
EuroQol-5 Dimensions (EQ-5D)], neuropsychiatric symptoms [measured using the 12-item Neuropsychiatric
Inventory – Nursing Home (NPI-NH)] and depression [measured using the Cornell Scale for Depression in
Dementia (CSDD)]. These are described in detail in Outcome variables.
We received data from the REDIC study team for assessments up to October 2016, including up to five
assessments per participant. Assessments were conducted and supplied in Norwegian, with translation
kindly provided by Professor Sverre Burgh, the REDIC study chief investigator.
Participant inclusion and exclusion criteria
Participants were eligible for inclusion in the REDIC study if they had an expected stay in the nursing
home for > 4 weeks and were excluded if their life expectancy was < 6 weeks. Participants were included
in the Z-drug Evaluation in Dementia (ZED) study if they had a diagnosis of dementia or mild cognitive
impairment (MCI) on admission. These diagnoses were made and recorded by the REDIC study team on
the first visit after admission to the care home.
Medication exposures
Regularly used medication was recorded at each wave, coded according to WHO ATC code and dose,
for up to 18 medications per participant. We coded the presence or absence of three classes of hypnotics
at each visit, based on the following codes: Z-drug (Z) – ATC N05CF; BZD – ATC N05BA, N03AE or N05CD;
and antipsychotic – ATC N05A.
TABLE 1 Clinical data sets assessed for repurposing in the ZED study
Database/study name Study type
Number of
participants
with dementia Included in our study
REDIC (nursing homes
cohort only)
Observational cohort data to understand
socioeconomic consequences of
dementia in Norway
678 Yes: good number of participants
taking Z-drugs (126 at baseline
plus 193 during follow-up)
NACC Observational cohort data –
standardised clinical and
neuropathological research data
17,055 Yes: good number of participants
taking Z-drugs (373 at baseline
plus 72 during follow-up)
WHELD128 A RCT of a training intervention in
69 care homes, UK
926 Yes: good number of participants
taking Z-drugs (123 at baseline
plus 27 at 9 months)
CALM-AD129 A pharmacological RCT of donepezil
and risperidone over 12 weeks, UK
272 No: low Z-drug exposure
MAGD130 A RCT of memantine for agitation in
Alzheimer’s dementia, UK
153 No: low Z-drug exposure
ADCS131 Harmonised data from nine US drug or
dietary supplement RCTs, USA
2609 No: low Z-drug exposure
DOMINO-AD (UK)132 A RCT of donepezil and memantine for
moderate to severe Alzheimer’s disease
Aimed to
recruit 800
No: low Z-drug exposure
ADCS, The Alzheimer’s Disease Cooperative Study; CALM-AD, Trial of a Cholinesterase Inhibitor and Atypical Neuroleptic
in the Management of Agitation in Alzheimer’s Disease; DOMINO-AD, Donepezil and memantine in moderate to severe
Alzheimer’s disease – a multicentre RCT; MAGD, Memantine for Agitation in Alzheimer’s Dementia: A Randomised Double-
Blind Placebo Controlled Trial; NACC, National Alzheimer’s Coordinating Centre; REDIC, Resource Use and Disease Course
in Dementia – Nursing Home; WHELD, Improving Well-being and Health for People with Dementia; ZED, Z-drug Evaluation
in Dementia.
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The MMSE and a short eight-item version of the SIB-8 were administered at each wave.134,135 The MMSE
is a well-known and widely used test of cognitive function across several domains, which is scored from
0 to 30 based on the participant successfully answering questions or performing tasks under instruction.
The MMSE has good test–retest and inter-rater reliability,136–139 and performs fairly well in classifying those
with dementia and MCI.140 The SIB-8 aims to measure cognitive function specifically in more advanced
Alzheimer’s disease and is scored from 0 to 16 based on participants’ responses to eight comparatively
simple tasks. The SIB-8 has been found to accurately measure progression in advanced Alzheimer’s disease
and is able to accurately classify dementia stage.141,142 Both MMSE and SIB-8 are scored with higher scores
reflecting better cognitive function.
Dementia severity was measured at each visit by the Clinical Dementia Rating (CDR).143 In contrast to
MMSE and SIB-8, the CDR is scored based on semistructured interview with informants and participants
to judge cognitive ability rather than participants’ correct responses to specific instructions. The CDR is
scored in two different ways. First, measured as a Clinical Dementia Rating scored according to standard
algorithm (CDR-global) (0 ‘no dementia’, 0.5 ‘minimal dementia’, 1 ‘mild’, 2 ‘moderate’ and 3 ‘severe’
dementia), according to the standard algorithm. Second, the CDR is often scored as Clinical Dementia
Rating – Sum of Boxes (CDR-SOB), which is a simple sum of the level of impairment (scored as 0, 0.5,
1, 2 or 3, as above) in each of the six domains (memory, orientation, judgement and problem-solving,
community affairs, home and hobbies, and personal care). CDR-SOB scores range from 0 to 18, with 18
reflecting the maximum level of impairment.144 The CDR and CDR-SOB have both been reported to have
good content and criterion validity, and good inter-rater reliability.145–147
Quality of life and disability
Quality of life is measured by the QUALID scale and the EQ-5D.148,149 QUALID is scored from 11 to 55
based on observations of 11 aspects of patient mood and behaviour in the week before assessment,
and is scored such that a lower score is reflective of higher QoL. Although not extensively examined,
QUALID has been reported to have good test–retest and inter-rater reliability.148 The EQ-5D used is the
standard assessment of QoL, including a score based on five questions, covering mood and function, as
well as a visual analogue scale (VAS) reflecting a single subjective assessment of health scored from 0 to
100. EQ-5D is scored according to country-specific weights; there is no Norwegian-specific EQ-5D scoring
and so at the recommendation of the REDIC study investigators the Danish weights are used.150 These
were scored using the EQ-5D command for Stata.151 The EQ-5D was completed by participants on around
one-quarter of occasions, otherwise by care staff. As so few participant scores are recorded, and participant
and staff ratings are likely not to be comparable, we used only staff-rated EQ-5D and VAS scores in analysis.
Although the EQ-5D is used extensively to measure QoL in Europe and has good validity and reliability,
when specifically used in people living with dementia, ceiling effects have been reported and issues in
differences across proxy ratings.152
Disability is measured by the observer-rated Lawton Physical Self-Maintenance Scale.153 This scale rates
disability from 1 to 5 within six domains of toileting, feeding, dressing, grooming, physical ambulation and
bathing, and hence has total scores ranging from 7 to 35. Higher scores reflect greater disability.
Confounders
Sleep disturbance
The NPI-NH was administered at each visit.154 This includes a screening question on the presence of sleep
disturbance, and if this is endorsed then questions on the frequency of sleep disturbance, severity and the
extent to which this is occupationally disruptive for the caregiver. The ‘occupationally disruptive’ question
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
is analogous to the ‘carer distress’ question on the original Neuropsychiatric Inventory (NPI). Measures of
severity and frequency of sleep disturbance are multiplied together to give an overall sleep disturbance
score (scored from 0 to 12). The occupational disturbance question is scored separately on a Likert scale
(scored from 0 to 5). If the screening question on sleep disturbance is not endorsed then the occupational
disruption and severity questions are all scored as zero.
In addition, three questions on sleep are asked at each visit as part of the CSDD.155 Informants are asked
to evaluate, over the course of the previous week, if the patient has had ‘difficulty falling asleep’, ‘multiple
awakenings during sleep’ or ‘early morning awakening’. Each symptom can be scored as 0 (absent),
1 (mild/moderate) or 2 (severe).
Anxiety and agitation/aggression
As well as sleep disturbance, hypnotics and antipsychotics are used to manage anxiety, or agitated or
aggressive behaviour in people with dementia. As with sleep disturbance, these are measured in REDIC
study using the NPI-NH [severity, frequency and occupational disruption (distress) associated with anxiety
and agitation/aggression] and as items on the CSDD (two questions: severity of agitation and severity of
anxiety), each of these scored as for sleep disturbance (see Sleep disturbance).
Disability and other covariates
Disability is measured by the observer-rated Lawton Physical Self-Maintenance Scale.153 Participant age at
admission was coded in decades as < 70, 70–79, 80–89 or ≥ 90 years. Educational attainment is coded in
terms of years in education as 0–6, 7 (the modal group in this population), 8–12 and ≥ 13 years.
Recoding of outcome measures for analysis
Sleep, anxiety and agitation
The outcome measures of sleep disturbance, QoL, other psychiatric symptoms and cognitive function are
also likely to be predictors of future use of medications and so also take the role of time-varying covariates
in this analysis.
The distribution of each neuropsychiatric outcome and the Spearman’s rank-order correlations between
pairs of neuropsychiatric outcomes are shown in Appendix 3, Table 41. Each outcome, with the exception
of anxiety (as measured by CSDD), is endorsed in < 50% of assessments, but there are reasonable numbers
of participants who are reported to experience these symptoms in the mild/moderate and severe range.
There are very strong correlations between NPI-NH reports of ‘total’ (severity by frequency) and ‘distress’
caused by each of sleep, anxiety and agitation, such that the ‘total’ and ‘distress’ items can be considered
collinear. For this reason, because of the relatively high missing value rate, and for comparison with other
studies using NPI-NH that do not use the distress variables, the NPI ‘distress’ variables are not included in
any further analysis.
The diagonal of Appendix 3, Table 41, shows the auto-correlation of each measure, that is the correlation
of each measure with its previous value. These show that although there is some correlation between
each measure, there is also considerable fluctuation between waves.
There are some pairwise correlations between other measurements of neuropsychiatric symptoms as
expected, in particular when questions aimed to measure similar constructs. A factor analysis of the NPI-NH
and CSDD questions on sleep, agitation and anxiety suggested a three-factor solution, with factors
corresponding to sleep, agitation and anxiety.
These factor scores are taken forward into future analysis; their distributions are shown in Appendix 4,
Figures 26–28.
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Cognitive measures
Appendix 4, Figures 23–25, show the trajectories of continuous measures across visits, conditional on the
total number of visits completed. The correlation between MMSE and SIB-8 is 0.80, with both measures
having a substantial proportion of missing or 0 values (around 20% of occasions in both cases) when
participants either did not undertake the assessment or got none of the items correct. These are all coded
as 0 for analysis. SIB-8 has a stronger ceiling effect than MMSE, with 10% of SIB-8 scores taking the
maximum possible value (16/16) compared with only one maximum possible MMSE score of 30. However,
both measures have strong floor effects, caused by a significant proportion of participants being unable
to complete any element, hence scoring zero. For this reason, the CDR-SOB was also introduced as a
continuous cognitive measure. The CDR is subjectively measured and is successfully completed in 99% of
visits, with only 7% of observations taking the maximum or minimum value. CDR-SOB is correlated with
MMSE (Spearman’s r = 0.68) and SIB-8 (Spearman’s r = 0.59).
Statistical methods
The sample is described with respect to distribution of exposures, outcomes and covariates at baseline,
stratified by dementia severity. The number of participants completing each visit is described and the
predictors of dropout at subsequent assessment are estimated using logistic regression. The distribution
of each outcome with respect to age, visit number, total number of visits completed, CDR and concurrent
Z-drug use is then described using data from all pooled together.
Dynamics of medication use
The number of occasions on which Z-drugs, BZDs and antipsychotics are continued, started or stopped
between successive visits is shown, along with their co-occurrence. Separate logistic regression models are
then estimated to identify predictors of stopping or starting hypnotics between visits. For each hypnotic,
stopping is defined as there being no use at the current visit, estimated among those with reported use at
the previous visit, whereas starting is defined as use at the current visit estimated among those with no use
at the previous visit. Prior values of exposures, outcome measures and all covariates are used as predictors.
Association between hypnotics and outcomes
Three different analyses are used to explore the association between the use of hypnotics (Z-drugs, BZDs
and antipsychotics) and each outcome measure. Each addresses a slightly different question and so
provides a different perspective on the links.
Change in outcome measure with pattern of medication use between visits
First, each pair of successive visits for each participant is considered as a separate observation, with these
recorded as ‘previous’ and ‘current’ visits. The change in use of each hypnotic between the visits is coded
as ‘no use’, ‘starting use’, ‘stopping use’ or ‘continuous use’, depending on the medication status at the
first (previous) and second (current) visit of the pair. The level of each outcome measure at previous and
current visit is also recorded.
The mean average of each outcome is plotted at the previous and current visit, stratified by the change in
each hypnotic use between visits. This gives a visual indication of whether stopping, starting or continuing
to use each hypnotic affects the change in outcome measures compared with people who do not report
the hypnotic at each visit.
A regression model is then used to estimate the association between pattern of hypnotic use and
change in each measure, adjusting for participant age, their baseline cognitive function and visit number.
One participant can contribute up to four such observations (visits 1 to 2, 2 to 3, 3 to 4 or 4 to 5), and
so clustered standard errors for regression coefficients are used to account for multiple observations
per participant.
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Marginal structural models for time-varying covariates
The models above estimate the rate of change in outcome measures with change in hypnotic use, but do
not adjust for prior values of time-varying covariates of cognitive function or neuropsychiatric symptoms,
which are shown to predict later use of medication and may also affect change scores.
To control for time-varying covariates, inverse probability of treatment weights (IPTW) are generated using
logistic regression models, estimating the probability of treatment at each visit conditional on previous
treatment and previous values of all covariates. Following the method of marginal structural models, these
models are used to generate weights reflecting the inverse probability of observed treatment at the current
visit, and these weights are applied to simple linear regression models estimating the effect of current
hypnotic use on change in outcome measures between waves.
Weights calculated in this way aim to balance values of potential confounders across treatment groups,
so that any observed differences in current outcome values can be attributed to the treatment of interest.
However, some residual differences in prior values remain (as can be seen in Appendix 3, Figures 3–12,
right-hand panels) and so change scores are used as the outcome in regression models as opposed to
mean differences at the current assessment. Hence, these IPTW weighted models reflect the effect of
hypnotic use on change in outcome measures, accounting for differences in prior treatment and prior of
outcome. Standard errors are also corrected for multiple observations per participant.
Fixed-effects regression models
Each of the approaches above considers only pairs of successive observations. So, finally, a longitudinal
analysis using fixed-effects models was also conducted. This model compares, for each participant, the
values of outcome measures on those occasions when hypnotics are used to the values of outcomes when
they are not used. As the comparison is made within participants only, only those participants whose
hypnotic use status changes can be included. In addition, this model automatically accounts for any
measured or unmeasured covariate, so long as its value does not change within participants. However,
it is not possible to correct for time-varying covariates that are also outcome measures. Three fixed-effects
models are estimated for each combination of hypnotic and outcome. The first includes all participants,
the second includes only those participants with no hypnotic use at all at their baseline visit and the third
includes only those participants with minimal or mild dementia (CDR-global score of ≤ 1) at baseline.
The NACC data set
Setting
The NACC data set includes standardised longitudinal patient-level data from Alzheimer’s disease centres
(ADCs) across the USA. Data include clinical evaluations and records of medication use at the time of
assessment. Patients are assessed annually following referral to an ADC, with the first patient entering
the study in 2005, and up to 12 assessments recorded for some participants. Full details of the NACC
data set and the uniform data set that is collected at each assessment are found in successive publications
describing the evolution of the resource over the years and the NACC website (URL: www.alz.washington.edu/;
accessed 6 December 2019). The NACC data set is widely used for dementia research and has been previously
used for looking at the impact of medication use on different outcomes among people with MCI or dementia.156
We requested data from every assessment of all participants included in the NACC data set, with an updated
data extraction supplied to us in August 2018. This data set included 131,354 visits among 38,249 unique
participants.
Participant inclusion and exclusion criteria
For the current analysis, we included only participants with a study diagnosis of dementia at any time
and included only their assessments from the point at which they are first recorded as having dementia.
Whether or not the participant meets clinical criteria for dementia is recorded at each assessment. This
is made according to clinical judgement or by specific criteria, depending on the version of assessment.
In analysis we included only those visits when there is a clinical diagnosis of dementia recorded in the
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study (NACC coded data set variable ‘demented’ takes the value of ‘1’). This reduced data set included
43,286 annual visits among 17,055 unique participants.
Medication exposures
At each annual visit, the medications each participant had used in the 2 weeks before the visit were recorded.
Participants were asked to bring medication to the NACC assessment or a detailed list of their medications.
When this was not available, it was followed up by a telephone call following the assessment.
Outcome variables
Cognitive measures
At each assessment, a battery of cognitive tests and psychiatric assessments was conducted. Cognitive tests
included the MMSE, the Trail Making Test, from which we calculated a delta trail time (trail B time minus
trail A time) and an animal naming test, whereby the patient is asked to name as many distinct animals
as possible in 60 seconds. MMSE measures general cognitive ability, delta trail time measures attention
and task switching, whereas the animal naming test measures language ability and executive function.
The Trail Making Test is reported to have good inter-rater reliability.157
Further cognitive tests, including the Montreal Cognitive Assessment, were included in later assessments
(the third version of the uniform data set), but are not present for the majority of participants and so are
not used in the current analysis.
As in the REDIC study, cognitive tests that rely on communication or patients following specific instruction
have floor effects or are missing for many severely impaired patients. Hence, the CDR scale was also
included: CDR-global was used to stratify patients for descriptive analysis and CDR-SOB was used as an
outcome measure. This measure is present for all participants at all visits.
Neuropsychiatric assessments
Neuropsychiatric evaluations included the NPI, although in contrast to the REDIC study only the severity of
each NPI item is recorded, as opposed to the ‘severity’, ‘frequency ‘and ‘distress’ variables. Hence, relevant
neuropsychiatric symptom, sleep disturbance, anxiety and agitation are assessed at each visit on a
0–3 scale, with 0 corresponding to absence of the symptom, 1 mild, 2 moderate and 3 severe.
To capture the overall burden of neuropsychiatric symptoms, the total NPI score excluding sleep is also
included as an outcome measure.
As with cognitive function, more specific items on sleep disturbance are included only in later versions of
the NACC data set assessment and so are not included in the current analysis.
Depression
Although there is no available direct measure of QoL, the short form of the Geriatric Depression Scale (GDS)
is included in the NACC data set.158 This includes questions on life satisfaction, helplessness, hopelessness
and enjoyment of life that may be considered proxies for a QoL measure, and so GDS is included here as an
additional outcome measure. Note, in contrast to many depression measures the short-form GDS does not
directly assess sleep disturbance and so should not be directly confounded with measures of sleep. The GDS
includes 15 binary items and so is scored from 0 to 15, with higher values indicating more depressive symptoms.
Disability
Disability was measured by 10 questions on the extent to which the participant needed help with each of
10 different activities over the 4 weeks preceding each assessment. The items assessed are writing cheques
or paying bills; dealing with taxes or business affairs; shopping; playing games or working on a hobby;
heating water, making coffee or turning off the stove; preparing a meal; keeping track of current events;
paying attention to a TV show, book or magazine; remembering dates; and travelling.
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Each is scored as 0 (no help needed), 1 (does by self but with difficulty), 2 (requires assistance) or
3 (dependent); hence, the total disability scale is scored from 0 to 30. Missing values are omitted at the
item level and the total is rescaled if there are fewer than five missing items. If there ≥ 5 out of 10 items
missing then the disability score is set as missing.
Statistical methods
Our analysis of the NACC data set follows closely the analysis of the REDIC study data set. First, the
characteristics of participants are described stratified by the CDR-global score and the distribution of the
total number of study visits with dementia for each participant is shown.
Prevalence and dynamics of medication use
The number of occasions on which each medication of interest at baseline and at subsequent visits is used
is described, as well as the dynamics of medication use (number of occasions on which medications are
started/stopped between waves). The distribution of each outcome by Z-drug use, CDR, age and change
over study visits is shown graphically (see Figures 23–32).
Predictors of starting and continuing medication use
Logistic regression models are then estimated for the predictors of medication use at each wave. This model
includes the effects of age, sex, visit number, educational attainment of each participant, along with lagged
value of cognitive function (measured by MMSE), NPI sleep, NPI excluding sleep and GDS. As lagged values
of covariates are included, only data from the second visit onwards are included in these models. Separate
models are estimated for continuing medication use (report of drug among those reporting use at the
previous wave) and starting use (reporting of drug among those not reporting use at the previous wave).
Effect of medication use on outcomes
First, the changes in outcome measures between waves are then described and plotted, stratified by
whether each of Z-drugs, BZDs or antipsychotics are started, stopped, continue or are absent altogether
between waves. These associations between change in outcome measures and change in medication use
status are estimated using a linear regression model, adjusting for age group, baseline cognitive function
and visit number, with clustered standard errors to account for multiple records per person.
Second, a marginal structural model is used to estimate the effect of each medication, with IPTW used
to correct for differences in prior values of outcome measures and exposures between exposed and
unexposed groups.
Finally, fixed-effects longitudinal models are estimated, modelling the association between each medication
use and each outcome, hence automatically accounting for any between-patient effect (thereby automatically
controlling for both measured and unmeasured fixed covariates), although not accounting for time-varying
covariates. The following specific models were estimated, mapping those estimated using the REDIC data set:
l model 1: effect of each drug on each outcome, among all participants with no adjustment for time
varying covariates
l model 2: as model 1 but including only participants with no hypnotic use at baseline
l model 3: as model 1 but including only participants with a CDR-global score of < 2 (i.e. include only
those with mild or minimal dementia at baseline).
Software
Clustered linear models and weighted linear models are estimated using the ‘survey’ package and fixed-
effects linear models are estimated using the ‘plm’ package version 1.6-6 (linear models for panel data)
for R statistical software version 3.5.0 (The R Foundation for Statistical Computing, Vienna, Austria).
The data set was cleaned and coded using R as well as Stata. All other analysis was conducted using R,
with the ‘stargazer’, ‘dplyr’ and ‘ggplot2’ packages for data manipulation, managing outputs and
plotting, respectively.
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This study was undertaken using anonymised data from the WHELD cluster randomised controlled two-arm
trial, covering 69 care homes in England.128,159 The RCT was carried out between January 2013 and
September 2015, with a primary aim to determine whether or not an optimised staff training intervention
improved the QoL and mental health of people with dementia living in nursing homes.
Participant inclusion and exclusion criteria
Care homes and their residents were eligible for inclusion in the WHELD RCT if the:
l care home has > 60% of residents with dementia
l care home was not receiving special support from their local authority
l care home met the five CQC care home quality standard checks
l resident had a diagnosis of dementia or had a score of ≥ 1 on the CDR.
Care homes and their residents were excluded from the WHELD RCT if:
l the care home had insufficient staffing resources or anticipated major change during the study period
l the care home was involved in other research or undergoing a systematic programme of service
improvement
l consent or advice from a consultee could not be obtained for the resident.
A total of 971 participants met the inclusion criteria, with 504 participants randomised to receive
treatment as usual and 467 to receive the WHELD intervention between January 2013 and April 2014.
Follow-up assessments were available for 553 participants 9 months later and non-completion was mainly
due to mortality.
Participants were not included in the ZED analysis if it was not possible to record their medication usage
at baseline or had a reported diagnosis of severe mental illness (schizophrenia or bipolar disorder) at
any assessment.
Medication exposures
Antipsychotic and other psychotropic drugs taken at each assessment were classified according to the BNF.120
Drugs were coded as non-BZD hypnotics, BZDs, antidepressants, carbamazapine, sodium valproate, other
anticonvulsants, memantine, cholinesterase inhibitors, barbiturates, clomethiazole, nuspirone and others.
Outcome variables
The following outcomes were assessed prior to randomisation and after 9 months of the intervention.
Patient quality of life
Measured using the QUALID. Lower scores indicate better QoL.
Neuropsychiatric symptoms (excluding sleep)
The NPI-NH was used to assess neuropsychiatric symptoms in people with dementia.154 The NPI-NH assesses
a broad range of symptoms, including delusions, hallucinations, agitation, depression/dysphoria, anxiety,
euphoria/elation, apathy/indifference, disinhibition, irritability, aberrant motor behaviours, night-time
behaviours and appetite/eating change. Severity scores (1–3) multiplied by frequency score (1–4) were
given for each item, resulting in a score ranging from 0 to 12, with a higher score indicating more severe
symptoms. The question on sleep disturbance was excluded to give a total maximum score of 132.
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Sleep disturbance
The NPI night-time behaviours question ‘Does the patient awaken you during the night, rise too early in
the morning, or take excessive naps during the day?’ was used to assess sleep disturbance in people living
with dementia.
Confounding variables
The following confounding variables were considered at baseline: age, sex, ethnicity (white or not), marital
status (single/widowed, married/long-term partner, divorced/separated), CDR (mild, moderate, severe), sleep
disturbance (a NPI-NH sleep score > 0), Abbey Pain Scale score (0–2 = none, 3–7 =mild, ≥ 8 =moderate/severe),
comorbidity (depression, anxiety, respiratory illness, gastrointestinal illness, cardiovascular condition, endocrine
illness, musculoskeletal disorder and nervous system illness) and co-medication use (BZD, meprobamate/
buspirone, clomethiazole, antidepressant, antipsychotic cholinesterase inhibitor and memantine).
Statistical methods
Care home participant characteristics were described for those who were and were not taking Z-drugs at
baseline. Negative binomial regression was used to estimate IRRs for the association between Z-drug use at
baseline and QUALID, NPI-NH excluding sleep and NPI-NH sleep scores at baseline. Logistic regression was
used to estimate ORs for the association between baseline Z-drug use and mortality by 9-month follow-up.
Linear regression models were used to estimate the mean decline in QUALID, NPI-NH excluding sleep
and NPI-NH sleep scores from baseline to 9-month follow-up for Z-drug use compared with no use at
baseline, as well as for continuing, starting or stopping Z-drug use between baseline and 9-month follow-up
compared with no use. All associations are presented both unadjusted and adjusted for the covariates listed
above. For the analysis comparing changes of Z-drug use across the 9-month follow-up, changes in the use
of antidepressants, memantine, antipsychotics and BZDs were also adjusted for.
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Chapter 4 Study management
Patient and public involvement
Patient and public involvement (PPI) was an important part of the ZED study. In this section, we detail the
different ways in which PPI members contributed to the development and progression of the study during
its course.
There was early engagement of PPI participants during the protocol design process to highlight important
outcomes to investigate, based on their personal experiences of dementia and sleep disturbance, including
its management. PPI members were recruited from Inspire, a PPI group based at the Norfolk and Suffolk
NHS Foundation Trust. PPI members included older people with an interest and experience relevant to
dementia research. A PPI meeting attended by six panel members was conducted in June 2016 during the
initial study stages, from which two members were invited to be part of the annual Study Steering Group
meetings and thus allow the continued contribution of PPI members during the study. Feedback from this
initial meeting influenced protocol design of the CPRD work package. For example, PPI members helped
prioritise the outcomes to be investigated. Their main priority was falls, due to the risk of fractures. They
were also keen to see comparisons of Z-drugs with other, alternative treatments. They were keen to see
the effect of using Z-drugs at different doses, for different durations and when using them sparingly, rather
than every day. There were three Study Steering Group meetings during the study, of which one had
a member of PPI present. Additionally, an update was communicated by e-mail in 2017 to keep all PPI
participants involved in the study as it progressed. A second and final meeting took place in June 2018 to
discuss the results of the study and interpretations from a PPI perspective. We also asked our PPI team for
their advice on dissemination activities and publication strategies.
Health-care professional advisory panel
Hypnotic medication is widely prescribed in different health-care settings; in order to inform on hypnotic
prescribing experience across different health services we had a second public group, a health-care
professional advisory panel consisting of a mental health pharmacist, a clinical doctor specialising in older
person and dementia care, a community nurse and a GP. An initial meeting took place in June 2016,
during protocol development stages, when we sought advice on sleep disturbance coding in primary care
and personal experiences of prescribing hypnotics in people living with dementia. A second meeting took
place in April 2018 to discuss the final results of the study, when we sought advice on interpretations of
the data and on which health-care professionals to target during our dissemination activities.
Patient and public involvement and health-care professional
panel reflections
Although our study was based on secondary data analysis, we found the PPI and health-care professional
input vital. Listening to the various different experiences described by carers in the PPI panel whose family
member had sleep disturbance and the various approaches used in different settings to manage sleep
disturbance described by the health-care professional panel helped us to focus our analyses and interpret
the findings.
The PPI members highlighted the importance of the care setting and who the primary carers were in the
management of sleep disturbance and the outcomes. This encouraged us to code, as best we could, whether
or not the person living with dementia was in a care home.
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The PPI members discussed comorbidities and the impact if, for example, the person living with dementia,
also had a UTI. Hence, we were careful to consider this and include as a potential confounder in our
analyses. The meetings also helped us refine our coding lists for the CPRD, especially regarding different
terms for ‘sleep disturbance’.
Although the outcomes we could examine were limited by the NIHR commissioned call, it was still valuable
for PPI members to discuss the relative importance of these and see if any others needed to be added.
Owing to time constraints, personnel changes and changes within the PPI group, we had limited ability for
the PPI members to contribute to the statistical analysis and interpret the results as they became available.
However, the dissemination meeting was very important to help understand the importance of downplaying
the association between Z-drugs and mortality, emphasising the needs of the carer and the person living
with dementia together, and of clearly communicating absolute risks and risk differences alongside the HRs
of outcomes when reporting the findings.
Study management
A Study Steering Group met regularly throughout the study to provide oversight and expertise. Study
Steering Group meetings were organised throughout the study; PPI representatives were also invited to
take part in these meetings to encourage a public perspective on study plans and progression.
Ethics approval
The primary care study was approved by the Independent Scientific Advisory Committee for CPRD for
CPRD research (reference 16_181). No further ethics approval was required for the analysis of the data.
The CPRD group has obtained ethics approval from a Multicentre Research Ethics Committee for all purely
observational research using CPRD data.
The Regional Ethics Committee for Medical Research in South-Eastern Norway approved the REDIC study
(reference 2011/1738a). The patient’s capacity to consent to participation in the study was considered by
the nursing home staff, including the physician. Written consent for participation was obtained from all
participants with the capacity to consent. For participants lacking the capacity to consent, their next of kin
gave consent on behalf of the patients. The next of kin gave written consent for their own participation in
the study, as they provided information about themselves.
All participants or their legally authorised representatives signed informed consent prior to participation
in the NACC study. The institutional review board overseeing each ADC approved local procedures.
Ethics approval for the WHELD RCT was obtained from the South-Central Oxford Research Ethics Committee C
(reference 11/SC0066). The trial is registered as a clinical trial (ISRCTN40313497). Consent for nursing
home involvement was obtained from the management of the homes. If residents lacked capacity, informed
consent was obtained through the involvement of a nominated or personal consultee who represented the
residents’ interests and wishes in accordance with the Mental Capacity Act.160
Funding
The NIHR HTA programme (reference 14/221/02) funded the Z-drugs in dementia (ZED) study.
Sponsorship
The University of East Anglia was the study sponsor.
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Chapter 5 Primary care study results
Study cohort selection
The CPRD database contained data from 17.1 million patients in the UK in July 2017, of whom 8.3 million
were from English practices with linkage to HES data. Of these, 15,842 patients were diagnosed with
dementia at age ≥ 55 years between 1 January 2000 and 31 March 2016, and met our definition
of having a sleep disturbance on or after the dementia diagnosis (Figure 2). We excluded 8972 patients
from analysis who did not meet our inclusion criteria, as further described in Figure 2. As there was an
insufficient number of patients (n = 61) first prescribed melatonin to analyse the outcomes for this drug,
the patients prescribed melatonin were excluded, leaving 6809 patients in the study cohort for analysis.
Of the included patients, 2952 patients were prescribed a Z-drug on the index date, 1898 patients were
prescribed a low-dose TCA, 308 patients were prescribed a BZD and 1651 patients were not prescribed
sedative medication.
Patients in CPRD database July 2017
(n = 17,148,866)
Patients with HES linkage
(n = 8,328,954)
Patients with dementia diagnosed when aged
≥ 55 years between January 2000 and
March 2016, meeting the ‘sleep disturbance’
definition after dementia
(n = 15,842)
• patients with < 90 days of data history before dementia, n = 857
• patients with severe mental illness or Down syndrome, n = 439
• patients with < 365 days of data history before a sleep
   disturbance, n = 129
• patients with sleep apnoea, sleep-related respiratory failure 
   or alcohol abuse, n = 300
• patients with neuropathic pain in the last 365 days, n = 176
• patients prescribed Z-drugs, TCAs, melatonin, BZDs or other
   sedatives in the last 365 days, n = 6610
• patients newly prescribed other sedatives, other TCAs or
   antipsychotics on index date, n = 342
• patients prescribed a combination of sleep drugs on index date, 
   n = 119
• patients prescribed melatonin on the index date, n = 61
Excluded:
Included in final cohort 
(n = 6809)
FIGURE 2 Selection of patients for the primary care study cohort.
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Patient characteristics
The mean age of included patients at index date was 83 [standard deviation (SD) 7.5] years and 4127
(61%) of the patients were women. General practices were located across England and patients had been
registered with their general practice for a median of 20 [interquartile range (IQR) 12–33] years before
their first recorded sleep disturbance in dementia. As per the study design, 100% of patients in the BZD
and ‘no sleep medication’ cohorts had a diagnosis of sleep disturbance on their index date. A total of
572 (19%) and 73 (4%) of the Z-drug and low-dose TCA cohorts had a diagnosis of sleep disturbance
on the day of their index date. Further patient characteristics, comorbidities and concomitant medications
can be found in Table 2 and in Appendix 2, Table 39.
TABLE 2 Patient demographics and health behaviours by first sleep disturbance treatment
Characteristic




(N= 1898) BZD (N= 308)
No drug
(N= 1651)
Female, n (%) 1723 (58) 1193 (63) 175 (57) 1036 (63)
Age (years), mean (SD) 83.0 (7.7) 82.3 (7.3) 82.9 (7.7) 83.2 (7.1)
White ethnicity, n (%) 2725 (92) 1782 (94) 265 (86) 1503 (91)
Ethnicity missing 165 (6) 86 (5) 37 (12) 111 (7)
Care home residence, n (%) 694 (24) 409 (22) 69 (22) 393 (24)
Residence missing 1059 (36) 727 (38) 113 (37) 439 (27)
Index year, median (IQR) 2009 (2006–12) 2010 (2007–13) 2007 (2004–10) 2008 (2005–12)
General practice region (England), n (%)
North 692 (23) 517 (27) 68 (22) 442 (27)
Midlands 463 (16) 221 (12) 39 (13) 330 (20)
East 326 (11) 179 (9) 49 (16) 247 (15)
South 1184 (40) 847 (45) 134 (44) 503 (30)
London 287 (10) 134 (7) 18 (6) 129 (8)
General practice area IMD quintile, mean (SD) 3.2 (1.4) 3.1 (1.4) 3.1 (1.4) 3.5 (1.4)
Health behaviours
Smoking status, n (%)
Non-smoker 1947 (66) 1233 (65) 203 (66) 1101 (67)
Ex-smoker 635 (22) 472 (25) 58 (19) 374 (23)
Current smoker 257 (9) 147 (8) 31 (10) 129 (8)
Missing 113 (4) 46 (2) 16 (5) 47 (3)
Alcohol user, n (%) 605 (20) 428 (23) 54 (18) 440 (27)
BMI (kg/m2), mean (SD) 24.7 (4.8) 25.0 (4.8) 24.8 (4.7) 24.5 (4.6)
BMI missing, n (%) 932 (32) 511 (27) 111 (36) 435 (26)
Systolic blood pressure (mmHg), mean (SD) 134.0 (19.2) 134.4 (17.9) 134.9 (20.6) 133.8 (19.1)
Blood pressure missing, n (%) 81 (3) 44 (2) 18 (6) 26 (2)
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Examination of predictors of first sleep disturbance medication revealed small differences between the groups
(see Appendix 2, Table 40). Patients had a greater chance of being prescribed Z-drugs if they were a man,
had a history of fractures or hospitalisation, or had recent antipsychotic or analgesic use. Those prescribed BZDs
were more likely to be men, have osteoporosis, have a history of agitation or psychosis, and have recent
antiepileptic and NSAID use. Patients prescribed low-dose TCA had fewer falls and were more likely to have
neuropathic, back and/or neck pain or headaches, and recent NSAIDs, antiplatelets and analgesic use, but less
SSRI or other antidepressant use. Those not prescribed sleep drugs were more likely to be from a deprived
neighbourhood, have a falls history, have more frequent GP visits and have a history of urinary incontinence
and of insomnia before dementia, but not to have a history of prior BZD or Z-drug use. Low-dose TCAs and
Z-drugs were more likely to be prescribed in recent years (2010), whereas BZDs were more likely to be
prescribed in earlier years (2007).
Validation study
A total of 56 (53%) GPs completed our validation questionnaire. The GPs confirmed a diagnosis of dementia
for 54 (96%) of the patients (Table 3). The dementia diagnosis date recorded by the GP was very similar to
the date we recorded (74% were within 1 month). Sleep disturbance was confirmed for fewer patients,
with 35 (63%) patients confirming sleep disturbance.
This varied by which drug cohort the patient was in, such that 82%, 60% and 42% of the patients
in the Z-drug, low-dose TCA and ‘no sleep drug’ cohort were identified by the GP as having sleep
disturbance, respectively.
Further inspection of the patient records revealed that additional information recorded when certain insomnia
and sleep disturbance Read codes were entered resulted in the GP software providing a ‘pop-up screen’ asking
for the GP to record the patients’ ‘sleep pattern’. For 11 of the 13 patients (85%) with a sleep disturbance
code and for whom the GP did not report a sleep disturbance, the record of sleep disturbance also occurred
alongside a record of ‘satisfactory’ ‘sleep pattern’ on the pop-up screen (Table 4).
TABLE 3 Overall results of the GP validation study, by sleep drug at index date
Questionnaire result
Sleep disturbance treatment
Total (N= 106)Z-drug (N= 46) Low-dose TCA (N= 32) No drug (N= 28)
n % n % n % n %
Valid questionnaires returned 22 48 15 47 19 68 56 53
Dementia verified by GP 22 100 14 93 18 95 54 96
Sleep disturbance verified by GP 18 82 9 60 8 42 35 63
TABLE 4 Sleep disturbance validation results for those with sleep disturbance diagnosis on index date
‘Satisfactory’ sleep pattern
coded on index date Number of patients
Number of patients (%) with
sleep disturbance confirmed
Yes 17 6 (35)
No 12 10 (83)
Total 29 16 (55)
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Owing to the validation study findings, we performed a sensitivity analysis with an amended definition of
sleep disturbance that excludes Read codes accompanied by a record of ‘satisfactory sleep pattern’ on the
GP pop-up screen. We also advise caution interpreting any risks estimated with low-dose TCAs, as we could
not confirm that sleep disturbance was the indication for many of these prescriptions, and people living with
dementia with chronic pain may have different risks of the adverse outcomes than those with sleep disturbance.
Patient follow-up
A total of 137, 44 and 135 patients from the ‘no sleep disturbance treatment’ group subsequently met the
criteria for the Z-drug, low-dose TCA and BZD groups, respectively. Hence, each of these patients occur in
the analysis twice.
Patients were followed for a median of 3.2 (IQR 2.3–9.1) months. The main reason for censoring was patients
having no further Z-drug, BZD, or low-dose TCA prescriptions for 90 days, from each cohort, respectively
(Table 5). The second most common reason for censoring was because of a new sedating medication being
prescribed. This resulted in a median follow-up for each cohort of 3.0 (IQR 1.8–5.3), 3.2 (IQR 3.0–8.7), 3.0
(IQR 2.0–5.0) and 8.9 (IQR 2.8–23.9) months for the Z-drug, low-dose TCA, BZD and no sleep disturbance
treatments groups, respectively.
For the sensitivity analysis, of the 3089 patients prescribed Z-drugs, 1274 of them stopped receiving prescriptions
and met the inclusion criteria to be included in a ‘discontinued Z-drugs’ cohort. Their median follow-up was
9.1 (IQR 3.0–22.1) months and the most common reason for censoring was being prescribed a new sedating
medication. A total of only 280 (22%) were censored as a result of receiving another Z-drug prescription.
TABLE 5 Reasons for ceasing follow-up according to sleep drug at index date
Censoring reason












n % n % n % n % n %
Death 351 11 192 10 64 14 261 16 179 14
Transferred out 311 10 165 8 33 7 269 16 209 16
Last practice data extraction 69 2 85 4 7 2 106 6 95 7
New sedative drug 906 29 396 20 119 27 527 32 510 40
Z-drug 0 0 70 4 40 9 149 9 280 22
Low-dose TCA 119 4 0 0 17 4 46 3 30 2
BZD 440 14 167 9 0 0 161 10 115 9
Melatonin 11 0 < 5 0 < 5 0 5 0 < 5 0
Other sedative 35 1 17 1 6 1 24 1 15 1
Antipsychotic 305 10 142 7 55 12 149 9 69 5
No prescription for 90 days 1306 42 921 47 193 44 0 0 0 0
End of study (2 years) 123 4 143 7 23 5 411 25 213 17
End of study (31 March 2016) 23 1 40 2 < 5 1 77 5 68 5
a Includes 137, 44 and 135 patients twice who occur in the ‘no drug’ cohort first and then later in the Z-drug, low-dose TCA
and BZD cohorts, respectively. The 1274 patients in the ‘discontinued Z-drug’ cohort also occur in the ‘Z-drug’ cohort.
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First prescription for sleep disturbance
The first sleep disturbance prescriptions issued to the cohort are described in Table 6. Of the 3089 patients
receiving Z-drugs, the majority (95%) were prescribed zopiclone. The most common daily dose prescribed
of zopiclone was 3.75 mg (80%). The most common low-dose TCA prescribed was amitriptyline (57%)
and the most common BZD prescribed was temazepam (64%).
During the median 3.0 (IQR 1.8–5.3) months’ follow-up for the cohort initiated on Z-drugs, 1484 (48%),
429 (14%), 212 (7%) and 964 (31%) go on to receive none, one, two and three or more further Z-drug
prescriptions.
Fractures, falls and mortality
A total of 368 patients experienced a fracture during follow-up, with around half of these being hip fractures.
A total of 1078 patients reported a fall to their GP or were admitted to hospital with a recorded fall. Overall,
883 patients died during follow-up.
Table 7 displays the incidence rates and HRs for fractures, falls and mortality for the different sleep
disturbance treatments, relative to no prescription for sleep disturbance, adjusted for age and sex, and
adjusted for all potential confounders. Generally, there was little difference between the full adjustment
for confounders and adjustment for just age and sex. The incidence of fractures in patients receiving
Z-drugs was 11.3 per 100 person-years. In patients receiving BZDs, low-dose TCA or no prescriptions for
sleep disturbance, the incidence of fractures was 12.0, 10.2 and 7.3 per 100 person-years, respectively.
After adjustment for potential confounders, prescription of Z-drugs was associated with a greater
incidence of fractures, with a HR of 1.40 (95% CI 1.01 to 1.94).
TABLE 6 First sleep disturbance medication prescription
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The incidence of hip fractures was 5.4 per 100 person-years in those prescribed Z-drugs compared with
3.1 per 100 person-years in those not prescribed medication for sleep disturbance. After adjustment for
confounders there was a trend towards an increased risk of hip fracture with Z-drugs (HR 1.59, 95% CI
1.00 to 2.53), but this did not reach statistical significance (p = 0.052).
There were few reported fractures of the forearm, wrist or hand, with 2.2 per 100 person-years for the
Z-drug group and 1.2 per 100-person years for the no sleep medication group. There was not a statistically
significant association between Z-drug use and forearm fractures when adjusted for age and sex, or all
potential confounders.






Age, sex adjusted Adjusteda
Exposed With outcome HR 95% CI HR 95% CI
Fracture
No sleep drug 1636 108 7.3 1.00 1.00
Low-dose TCA 1913 105 10.2 1.29 0.98 to 1.70 1.12 0.80 to 1.58
BZD 433 20 12.0 1.41 0.87 to 2.29 1.34 0.69 to 2.61
Z-drug 2997 135 11.3 1.39 1.06 to 1.82 1.40 1.01 to 1.94
Hip fracture
No sleep drug 1636 47 3.1 1.00 1.00
Low-dose TCA 1913 56 5.3 1.59 1.06 to 2.38 1.53 0.95 to 2.48
BZD 433 12 7.1 2.01 1.03 to 3.93 2.07 0.72 to 5.97
Z-drug 2997 66 5.4 1.53 1.02 to 2.27 1.59 1.00 to 2.53
Forearm/wrist/hand fracture
No sleep drug 1636 18 1.2 1.00 1.00
Low-dose TCA 1913 16 1.5 1.11 0.57 to 2.19 0.99 0.35 to 2.79
BZD 433 < 5 N/A N/A
Z-drug 2997 27 2.2 1.83 0.94 to 3.56 1.29 0.53 to 3.15
Fall
No sleep drug 1506 328 26.7 1.00 1.00
Low-dose TCA 1864 286 30.4 0.99 0.85 to 1.05 0.84 0.69 to 1.02
BZD 412 65 43.9 1.32 1.00 to 1.73 1.05 0.75 to 1.47
Z-drug 2888 399 37.8 1.11 0.96 to 1.30 1.05 0.87 to 1.25
Mortality
No sleep drug 1651 266 16.9 1.00 1.00
Low-dose TCA 1942 196 18.1 1.00 0.83 to 1.21 0.89 0.72 to 1.11
BZD 443 66 36.7 1.80 1.35 to 2.39 1.38 0.96 to 1.96
Z-drug 3089 355 27.8 1.43 1.21 to 1.69 1.34 1.10 to 1.64
N/A, not applicable; PY, person-year.
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39, except for forearm fracture, which was
also adjusted for eye conditions (ARMD, retinal disorders and glaucoma combined), region as only five categories
(South, East, Midlands, North and London), and not adjusted for ethnicity or systolic blood pressure.
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The incidence of falls was 37.8 per 100 person-years in those prescribed Z-drugs compared with
26.7 per 100 person-years for those not prescribed medication for sleep disturbance. There was no
statistically significant difference in the risk of falls with Z-drug use when adjusted for age and sex, or
all potential confounders.
The mortality rate was 27.8 per 100-person years in the Z-drug group compared with 16.9 per 100 person-
years in the no sleep medication group. After adjustment for potential confounders, Z-drug prescription was
associated with a 34% (95% CI 10% to 64%) increased risk of mortality.
Generally, the risks of fractures, falls and mortality for Z-drugs were similar to those of BZDs (see Appendix 5,
Table 55). Risk of hip fracture with low-dose TCA appeared similar to that of Z-drugs; however, there was
no evidence of increased risk of overall fractures, falls or mortality with low-dose TCA.
There was no evidence that the reported HRs varied over time and there was no evidence of an interaction
between Z-drug use and either age, sex, mortality or fractures. Using different parametrisations for age
had little impact on the findings (see Appendix 5, Table 56).
Absolute risks
The absolute annual risks of fractures, hip fractures and mortality in the unexposed group were 7.4%,
3.2% and 15.4%, respectively. These equate to annual risks of 10.2%, 5.0% and 20.1% for fractures, hip
fractures and mortality when taking Z-drugs if our estimated risks are causal. This is equivalent to a NNH of
36, 54 and 21, and extra cases per 1000 treated of 28, 18 and 47, respectively.
Dose–response
When examining outcomes by cumulative Z-drug dose, we found that fracture risk increased with cumulative
exposure to Z-drugs (Table 8). During periods when cumulative prescriptions totalled < 28 DDDs of Z-drugs,
equivalent to 56 days at the recommended half-dose in the elderly, there were no excess risks of fractures.
For 42–55 prescribed DDDs the HR for a fracture increased to 2.81 (95% CI 1.47 to 5.37).
The picture was similar for hip fractures, with no excess risk when prescribed < 28 DDDs of Z-drugs, rising
to a HR of 3.33 (95% CI 1.41 to 7.91) when cumulatively prescribed 42–55 DDDs. There were few forearm,
wrist or hand fracture outcomes, but there was evidence of a similar pattern to that of fractures with no
risk before 28 DDDs and greater risks after. There was evidence of increased falls risks after > 28 DDDs
of Z-drugs had been prescribed, but this association disappeared after 56 DDDs were prescribed. The risk
of mortality was generally fairly similar, regardless of cumulative exposure to Z-drugs. In addition, we found
no evidence of differences in risk according to whether or not the first Z-drug prescription was PRN
(see Appendix 5, Table 57).
Infections, cardiovascular and agitation or psychosis outcomes
A total of 1104 patients were reported to have an acute bacterial infection during follow-up, with 86%
of these being a UTI or LRTI. Whereas, 188 patients experienced an ischaemic stroke or TIA, 72 patients
reported venous thromboembolism and 340 patients were recorded as having incident agitation or psychosis
during follow-up.
Table 9 displays the incidence and HRs for infections, cardiovascular and agitation or psychosis outcomes
for the different sleep disturbance treatment, relative to no prescription for sleep disturbance, adjusted
for age and sex, and adjusted for all potential confounders. Although the incidence of acute bacterial
infections was greater at 47.7 compared with 34.7 per 100 person-years in patients receiving Z-drugs
compared with no sleep disturbance medications, this association was not statistically significant when
adjusted for potential confounders. There was also no statistically significant difference between Z-drug
prescription and the rate of UTI and LRTI.
DOI: 10.3310/hta25010 HEALTH TECHNOLOGY ASSESSMENT 2021 VOL. 25 NO. 1
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Richardson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
33
TABLE 8 Adjusted HRs for fractures, falls and mortality, by cumulative Z-drug dose




Test for trendHR 95% CI HR 95% CI
Fracture
0 1.00 0.001 1.00 0.002
1–13 0.74 0.39 to 1.41 0.69 0.36 to 1.36
14–27 0.93 0.56 to 1.53 0.91 0.53 to 1.54
28–41 1.90 1.15 to 3.11 1.96 1.15 to 3.33
42–55 2.78 1.54 to 5.04 2.81 1.47 to 5.37
≥ 56 1.48 1.07 to 2.05 1.53 1.04 to 2.25
Hip fracture
0 1.00 0.001 1.00 0.003
1–13 0.83 0.36 to 1.88 0.80 0.35 to 1.84
14–27 0.58 0.26 to 1.29 0.60 0.26 to 1.35
28–41 1.83 0.91 to 3.65 1.98 0.97 to 4.01
42–55 3.30 1.50 to 7.24 3.33 1.41 to 7.91
≥ 56 1.90 1.18 to 3.06 2.03 1.15 to 3.60
Forearm fracture
0 1.00 0.005 1.00 0.16
1–27 0.61 0.17 to 2.26 0.47 0.12 to 1.86
28–41 4.12 1.40 to 12.06 4.15 1.21 to 14.24
42–55 2.27 0.42 to 12.15 1.89 0.27 to 13.22
≥ 56 2.08 1.02 to 4.26 1.37 0.49 to 3.80
Fall
0 1.00 0.14 1.00 0.49
1–13 0.93 0.69 to 1.27 0.83 0.60 to 1.14
14–27 1.11 0.87 to 1.42 1.07 0.83 to 1.39
28–41 1.49 1.12 to 1.98 1.43 1.06 to 1.94
42–55 1.70 1.17 to 2.45 1.59 1.08 to 2.34
≥ 56 1.02 0.82 to 1.25 0.94 0.74 to 1.19
Mortality
0 1.00 0.001 1.00 0.11
1–13 1.30 0.91 to 1.87 1.34 0.91 to 1.97
14–27 1.65 1.23 to 2.22 1.68 1.23 to 2.30
28–41 1.33 0.93 to 1.91 1.32 0.90 to 1.92
42–55 1.75 1.14 to 2.67 1.64 1.05 to 2.57
≥ 56 1.36 1.12 to 1.67 1.21 0.96 to 1.53
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39, except for forearm fracture, which was
also adjusted for eye conditions (ARMD, retinal disorders and glaucoma combined), region as only five categories
(South, East, Midlands, North and London), and not adjusted for ethnicity or systolic blood pressure.
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Although the incidence of ischaemic stroke or TIA was greater at 6.5 compared with 4.2 per 100 person-years
in patients receiving Z-drugs compared with no sleep disturbance medications, this association was not
statistically significant when adjusted for potential confounders.
There were few venous thromboembolism events and, again, we did not detect a statistically significant
difference in their rate between patients prescribed Z-drugs and those not prescribed medications for
sleep disturbance.
The incidence of agitation or psychosis in patients prescribed Z-drugs was 13.6 per 100 person-years,
compared with 6.4 per 100 person-years for those not prescribed medication for sleep disturbance.







Age, sex adjusted Fully adjusteda
Exposed With outcome HR 95% CI HR 95% CI
Acute bacterial infection
No sleep drug 1303 374 34.7 1.00 1.00
Low-dose TCA 1423 273 37.8 1.02 0.87 to 1.19 1.00 0.83 to 1.21
BZD 334 49 38.6 0.92 0.68 to 1.24 0.84 0.59 to 1.21
Z-drug 2267 408 47.7 1.17 1.01 to 1.36 1.09 0.92 to 1.29
UTI/LRTI
No sleep drug 1303 328 29.5 1.00 1.00
Low-dose TCA 1423 226 31.3 0.96 0.81 to 1.14 0.96 0.78 to 1.18
BZD 334 41 31.5 0.90 0.65 to 1.25 0.85 0.58 to 1.26
Z-drug 2267 354 40.2 1.16 0.99 to 1.36 1.10 0.92 to 1.32
Ischaemic stroke/TIA
No sleep drug 1640 64 4.2 1.00 1.00
Low-dose TCA 1933 50 4.7 1.03 0.71 to 1.49 1.20 0.75 to 1.92
BZD 438 15 8.7 1.81 1.01 to 3.26 1.56 0.69 to 3.51
Z-drug 3045 80 6.5 1.45 1.02 to 2.07 1.33 0.85 to 2.07
Venous thromboembolism
No sleep drug 1648 22 1.4 1.00 1.00
Low-dose TCA 1940 24 2.2 1.53 0.88 to 2.67 1.23 0.56 to 2.69
BZD 442 < 5 N/A N/A
Z-drug 3074 26 2.1 1.53 0.86 to 2.72 1.66 0.69 to 3.98
Incident agitation/psychosis
No sleep drug 1282 79 6.4 1.00 1.00
Low-dose TCA 1633 85 9.7 1.36 0.99 to 1.05 1.43 0.96 to 2.13
BZD 313 36 30.5 3.89 2.54 to 5.96 5.61 3.14 to 10.01
Z-drug 2574 140 13.6 1.59 1.20 to 2.11 1.71 1.21 to 2.42
PY, person-year.
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39.
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After adjustment for potential confounders, Z-drug prescription was associated with a HR of 1.71 (95% CI
1.21 to 2.42) for agitation or psychosis. There was no evidence that this association varied by age or sex.
There was no association between low-dose TCA and any of the infection, cardiovascular, or agitation or
psychosis outcomes. There was a greater incidence of ischaemic stroke or TIA in those prescribed BZDs,
but this difference failed to reach statistical significance. BZD prescription was, however, associated with an
increased rate of agitation or psychosis.
Dose–response
When examining outcomes by cumulative Z-drug dose, we found some suggestion of increased acute
bacterial infections with cumulative exposure to Z-drugs (Table 10); however, this was only during periods
when cumulative prescriptions totalled 28–41 DDDs and not for > 42 DDDs. There was no evidence of
increased risks of ischaemic stroke, TIA, or venous thromboembolism with cumulative Z-drug use. However,
the incidence of agitation or psychosis increased with greater cumulative Z-drug prescriptions, such that for
42–55 prescribed DDDs, the HR increased to 2.55 (95% CI 1.31 to 4.98). In addition, we found no evidence
of differences in risk according to whether or not the first Z-drug prescription was PRN (see Appendix 5,
Table 57).
Additional medications
A total of 1124 (16%) patients were prescribed a different class of sleep medication during follow-up
(Table 11). We did not detect a statistically significant increased rate of new medications for sleep
disturbance in the Z-drug or BZD groups. Those prescribed low-dose TCA were 79% (95% CI 65% to
97%) less likely to be prescribed another medication for sleep disturbance. The additional sleep
medications prescribed are described in Table 5.
However, Z-drug users were more likely to be prescribed a new antipsychotic (HR 2.01, 95% CI 1.60 to
2.52), antidepressant (HR 2.05, 95% CI 1.56 to 2.68) and antibiotic during follow-up (HR 1.26, 95% CI
1.12 to 1.42). There was no evidence that these associations varied by age or sex. BZD users had similar
increased rates of antipsychotic, antidepressant and antibiotic prescribing to the Z-drug users (see Appendix 5,
Table 58). No increased rates of antipsychotic or antibiotic prescriptions were detected for low-dose TCA users.
Health-care utilisation
A total of 133,673 GP visits were recorded by the patients in the 2 years following the index date (before
31 March 2016 and before leaving the practice), equivalent to a mean number of visits of 15.9 (SD 20.4).
Patients prescribed Z-drugs visited their GP 922 times per 100 person-years, compared with those not
prescribed medications for sleep disturbance visiting their GP 783 times per 100 person-years (Table 12).
After adjusting for potential confounders, Z-drug users visited their GP on average 14% (95% CI 8% to
19%) more frequently over the next 2 years.
A total of 12,850 hospital admissions were recorded by the patients in the 2 years following the index
date and before 31 March 2016, equivalent to a mean number of admissions of 1.5 (SD 2.3). Patients
prescribed Z-drugs were admitted to hospital 112 times per 100 person-years, compared with 98 times per
100 person-years for those not prescribed medications for sleep disturbance. After adjusting for potential
confounders, Z-drug users were admitted to hospital on average 12% (95% CI 3% to 21%) more
frequently over the next 2 years.
There was no evidence that these associations varied by age or sex. We also did not detect an increased
frequency of GP visits or hospital admission among BZD and low-dose TCA users.
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TABLE 10 Adjusted HRs for infections, stroke, venous thromboembolism and agitation or psychosis, by cumulative
Z-drug dose




Test for trendHR 95% CI HR 95% CI
Acute bacterial infection
0 1.00 0.002 1.00 0.04
1–13 0.82 0.60 to 1.14 0.77 0.55 to 1.08
14–27 0.93 0.71 to 1.21 0.89 0.68 to 1.17
28–41 1.44 1.09 to 1.90 1.38 1.04 to 1.84
42–55 1.18 0.78 to 1.78 1.14 0.74 to 1.74
≥ 56 1.27 1.06 to 1.53 1.17 0.95 to 1.44
UTI/LRTI
0 1.00 0.01 1.00 0.12
1–13 0.87 0.61 to 1.24 0.84 0.58 to 1.21
14–27 0.96 0.72 to 1.28 0.96 0.71 to 1.29
28–41 1.46 1.08 to 1.98 1.43 1.04 to 1.95
42–55 1.12 0.71 to 1.78 1.09 0.68 to 1.75
≥ 56 1.22 1.00 to 1.49 1.13 0.90 to 1.41
Ischaemic stroke/TIA
0 1.00 0.005 1.00 0.11
1–13 0.71 0.29 to 1.74 1.02 0.39 to 2.71
14–27 1.02 0.54 to 1.92 1.09 0.55 to 2.15
28–41 1.77 0.92 to 3.39 1.63 0.79 to 3.36
42–55 0.91 0.27 to 3.06 0.80 0.22 to 2.86
≥ 56 1.69 1.14 to 2.51 1.48 0.90 to 2.42
Venous thromboembolism
0 1.00 0.26 1.00 0.47
1–13 2.08 0.64 to 6.76 1.74 0.55 to 5.56
14–27 1.83 0.64 to 5.22 1.78 0.50 to 6.32
28–41 1.30 0.27 to 6.22 1.58 0.29 to 8.50
≥ 42 1.44 0.72 to 2.85 1.52 0.53 to 4.40
Incident agitation/psychosis
0 1.00 0.001 1.00 0.008
1–13 1.09 0.64 to 1.87 1.38 0.76 to 2.48
14–27 1.45 0.95 to 2.21 1.72 1.08 to 2.74
28–41 1.42 0.83 to 2.43 1.58 0.89 to 2.80
42–55 2.31 1.24 to 4.32 2.55 1.31 to 4.98
≥ 56 1.74 1.20 to 2.52 1.70 1.09 to 2.64
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39.
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TABLE 11 Adjusted HRs for additional medication prescriptions, by sleep disturbance medication







Age, sex adjusted Fully adjusteda
HR 95% CI HR 95% CI
Additional sleep medication
No sleep drug 1651 336 21.4 1.00 1.00
Low-dose TCA 1942 258 23.8 0.89 0.75 to 1.05 0.79 0.65 to 0.97
BZD 443 45 25.0 0.76 0.56 to 1.05 0.63 0.43 to 0.93
Z-drug 3089 485 38.0 1.26 1.08 to 1.46 1.13 0.95 to 1.35
Incident antipsychotic prescription
No sleep drug 1291 175 13.8 1.00 1.00
Low-dose TCA 1618 164 19.1 1.13 0.90 to 1.40 1.17 0.90 to 1.53
BZD 375 66 59.5 2.37 1.75 to 3.21 2.23 1.50 to 3.32
Z-drug 2402 355 39.5 2.03 1.67 to 2.47 2.01 1.60 to 2.52
Incident antidepressant prescription
No sleep drug 1207 113 10.3 1.00 1.00
BZD 326 31 24.4 1.75 1.17 to 2.64 1.77 1.02 to 3.09
Z-drug 2177 236 28.3 2.04 1.61 to 2.57 2.05 1.56 to 2.68
Incident antibiotic prescription
No sleep drug 1364 616 69.8 1.00 1.00
Low-dose TCA 1552 562 93.8 1.21 1.08 to 1.36 1.13 0.99 to 1.29
BZD 357 116 120.8 1.38 1.12 to 1.70 1.35 1.06 to 1.71
Z-drug 2430 818 116.4 1.39 1.25 to 1.55 1.26 1.12 to 1.42
PY, person-year.
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39.
TABLE 12 Adjusted IRRs for health-care utilisation, by sleep disturbance medication







Age, sex adjusted Fully adjusteda
IRR 95% CI IRR 95% CI
Number of GP visits
No sleep drug 1651 25,610 783.2 1.00 1.00
Low-dose TCA 1942 33,530 882.1 1.22 1.15 to 1.30 1.01 0.96 to 1.07
BZD 443 6806 791.4 1.12 1.02 to 1.23 1.05 0.97 to 1.14
Z-drug 3089 47,259 922.5 1.24 1.17 to 1.31 1.14 1.08 to 1.19
Number of hospital admissions
No sleep drug 1651 2484 99.7 1.00 1.00
Low-dose TCA 1942 2991 105.2 1.08 0.97 to 1.19 1.04 0.95 to 1.15
BZD 443 614 98.9 1.00 0.87 to 1.16 0.97 0.84 to 1.13
Z-drug 3089 4836 112.3 1.15 1.05 to 1.26 1.12 1.03 to 1.21
PY, person-year.
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39.
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Multiple testing
Owing to the number of outcomes tested, we would expect some associations to be statistically significant by
chance alone. For the association between Z-drug prescription and the 16 outcomes, we estimated a critical
threshold of p < 0.02 to define statistical significance, such that the false discovery rate was < 5%. Of the 16
outcomes tested, the outcomes of mortality, agitation or psychosis, antipsychotics, antidepressants, antibiotics,
GP visits and hospital admissions, all had associations with Z-drug use with p < 0.02 and, hence, can be
considered statistically significant after accounting for the multiple tests performed. However, the observed
association with fractures, with p = 0.045, would not be considered statistically significant and has an increased
chance of being a false discovery. However, multiple testing procedures vary as to how they define statistical
significance and assume that all outcomes are independent events, which may not be the case here. Regardless,
with a p-value so close to 0.05 for fractures, it would not pass any multiple testing correction. Our findings
need interpretation within this context (i.e. the association between Z-drug prescription and fractures could
be a chance finding due to many outcomes tested). The fracture finding needs to be considered in the
context of its consistency with findings for other outcomes (e.g. specific fractures, falls), consistency within
cumulative dose–response relationships, as well as evidence from other studies.
Sensitivity analysis: missing data
Data were missing for smoking status (for 3% of patients), alcohol use (for 9% of patients), recent BMI
(for 32% of patients), systolic blood pressure (for 2% of patients), care home status (for 34% of patients) and
quantity of tablets prescribed (for < 0.01% of those prescribed Z-drugs). Below, we explore the consequences
of missing data for BMI and care home status, as these variables are missing for > 10% of patients.
Body mass index values were not missing completely at random. Those without a BMI measurement in the
last 5 years were more likely to be older, to be living in a care home, to visit their GP less often, to have
fewer comorbidities, fewer prescriptions and immunisations, to have had dementia for longer with a history
of agitation or psychosis, and to be from a less deprived area. Recent BMI was also more likely to be
recorded in the no sleep drug cohort. Associations between Z-drug use and the adverse events varied in
the patients with and without missing BMI data. For example, the HR for fractures adjusted only for age
and sex was 1.13 (95% CI 0.71 to 1.79) and was 1.56 (95% CI 1.12 to 2.18) in those with and without
missing BMI data.
Care home status was also not missing completely at random. Patients missing their care home status were
more likely to be younger, male and to have fewer comorbidities and prescriptions, except for more lipid-
lowering medications and inhaled corticosteroids. Again, care home status was more likely to be recorded in
the no sleep drug cohort. Associations between Z-drug use and the adverse events varied in the patients
with and without missing care home data. For example, the HR for fractures adjusted only for age and sex
was 1.35 (95% CI 0.99 to 1.83) and was 1.73 (95% CI 0.98 to 3.06) in those with and without care home
status recorded.
A single imputation model recoded 429 (15%) of those with missing care home status as being in a care
home, and the rest as not. Subsequently, a single imputation model including information from BMI values
more than 5 years ago, recategorised 26 (1%), 1598 (69%), 594 (26%), and 87 (4%) patients with
recent BMI missing into values of < 18.5, 18.5–24.9, 25–29.9, and ≥ 30 kg/m2, respectively. Adjustment
for all the covariates included the imputed BMI and care home variables, had little effect on estimates
(see Appendix 5, Tables 59 and 60).
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Sensitivity analysis: sleep disturbance definition
When excluding diagnoses of sleep disturbance in the GP records if they were accompanied by record of a
‘satisfactory’ sleep pattern, only 924 (56%) of the patients in the no sleep medication cohort met this criterion.
These 924 patients were more likely to have a recent fracture, dizziness, faint, hospitalisation, agitation or
psychosis, antipsychotic prescription and to be from less deprived neighbourhoods, and were less likely to have
urinary incontinence, a history of insomnia, to drink alcohol or be in a care home, than those with record of
satisfactory sleep disturbance. Comparing to this group generally decreased the associations with Z-drug use
and the various outcomes (see Appendix 5, Tables 61 and 62). The HR between Z-drug use and fracture,
hip fracture and mortality reduced to 1.34 (95% CI 0.90 to 1.99), 1.33 (95% CI 0.77 to 2.32) and 1.09
(95% CI 0.86 to 1.38), respectively.
Sensitivity analysis: Clinical Practice Research Datalink records only
Appendix 5, Table 63, displays the main analyses when the adverse event outcomes are ascertained only
through the CPRD. In general, omission of the HES- and ONS-linked data resulted in fewer outcomes,
particularly for the Z-drug group than the no sleep medication group. Consequently, associations between
Z-drug use and the outcomes were attenuated closer to the null.
Our main analysis included 368 incident fractures, yet restricting outcome ascertainment to CPRD only
reduced this to 262 fractures (71%). The number of fractures in the Z-drug group reduced by 67% and in
the no sleep medication group by 77%, and this deceased the resulting adjusted HR from 1.40 to 1.27.
Similarly, the number of incident hip fractures reduced to 61% of that in the main analysis in the Z-drug
group and to 74% in the no sleep medication group, leading to a reduced adjusted HR from 1.59 to 1.38.
Besides incident agitation or psychosis, for which only 9% fewer outcomes occur when restricting to CPRD,
all the other adverse events have a reduction of around 28–45% in the number of outcomes recorded.
Sensitivity analysis: discontinuing Z-drugs
The 1274 patients who discontinued Z-drugs generally experienced fewer adverse events in the preceding
period than the 3089 patients who were initiated on Z-drugs. Those initiating Z-drugs had higher rates of
falls, mortality, infections and agitation or psychosis than those who had just discontinued Z-drugs (see
Appendix 5, Table 64). Although the rates of fractures were lower when discontinuing Z-drugs, these
differences did not reach statistical significance. Rates of new antipsychotic, antidepressant and antibiotic
prescribing were lower in those discontinuing Z-drugs.
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Chapter 6 Clinical cohort studies results
The REDIC study results
Participant characteristics
Of the 696 participants recruited to the REDIC study, 17 participants had no dementia or MCI at baseline
and one participant did not provide enough information at their baseline assessment to be included in the
current analysis. Therefore, these participants were excluded from the current analysis, leaving 95 participants
with MCI and 583 participants with dementia at baseline.
The number with usable assessments at each wave, along with the prevalence of use of each hypnotic
reported at each wave, is shown in Appendix 3, Table 42. Forty-two per cent of the sample gave
assessments at visit 5 (2 years after baseline). The rate of Z-drug and BZD use was high, with around 20%
of participants reporting Z-drug use, 20% reporting BZDs and up to 20% reporting antipsychotics at each
visit. Antidepressants were also widely used (30–40% of participants at each wave), with lower numbers
reporting antihistamines or antiepileptics. The distribution of key outcome measures and dementia severity
at baseline stratified by Z-drug, BZD and antipsychotic use is shown in Table 13.
The vast majority of those who left the study between waves had died, but some had refused to continue,
were withdrawn by their nursing home, moved home or had moved to a nursing home not participating in
the REDIC study.
TABLE 13 Participant characteristics at study entry, stratified by CDR-global rating
Participant characteristics
Dementia severity, n (%)
All Very mild Mild Moderate Severe
Sex (female) 415 (64.4) 49 (65.3) 108 (65.1) 187 (68.8) 71 (54.2)
Marital status
Unmarried 57 (8.9) 7 (9.5) 15 (9.1) 24 (8.9) 11 (8.5)
Married 194 (30.5) 19 (25.7) 45 (27.4) 80 (29.7) 50 (38.5)
Widowed or divorced 386 (60.6) 48 (64.9) 104 (63.4) 165 (61.3) 69 (53.1)
Years of education
0–6 25 (3.9) 2 (2.7) 7 (4.2) 12 (4.4) 4 (3.1)
7 212 (32.9) 21 (28) 51 (30.7) 102 (37.5) 38 (29)
8–12 216 (33.5) 34 (45.3) 65 (39.2) 84 (30.9) 33 (25.2)
≥ 13 191 (29.7) 18 (24) 43 (25.9) 74 (27.2) 56 (42.7)
Age group (years)
< 69 26 (4) 1 (1.3) 10 (6) 10 (3.7) 5 (3.8)
70–79 115 (17.9) 8 (10.7) 24 (14.5) 50 (18.4) 33 (25.2)
80–89 318 (49.4) 38 (50.7) 92 (55.4) 130 (47.8) 58 (44.3)
≥ 90 185 (28.7) 28 (37.3) 40 (24.1) 82 (30.1) 35 (26.7)
continued
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Dynamics of hypnotic use throughout the study
The ability to estimate the effect of hypnotics is ultimately derived from within-person comparisons of hypnotic
use compared with no hypnotic use. Hence, the number of transitions between hypnotic use and no hypnotic
use within individuals between visits is crucial. The number of such transitions is shown for Z-drugs, BZDs and
antipsychotics in Table 14, between each of the 1540 pairs of consecutive visits in the REDIC study data set.
There is a positive correlation between use of pairs of medications (e.g. out of 421 occasions where Z-drugs
were reported, BZDs were also reported on 126 occasions) (Table 15).
Predictors of dropout and mortality
A logistic regression model was applied with drop-out at the next wave as the outcome, and hypnotic use,
outcomes and demographics covariates as predictors (see Appendix 3, Table 43). The vast majority of
dropouts from the study were due to death and so the different forms of outcome were not modelled
individually. Clustered standard errors were used to account for multiple data points per individual
contributing to this analysis.
TABLE 13 Participant characteristics at study entry, stratified by CDR-global rating (continued )
Participant characteristics
Dementia severity, n (%)
All Very mild Mild Moderate Severe
Medication use
Z-drug 120 (18.6) 26 (34.7) 32 (19.3) 49 (18.0) 13 (9.9)
BZD 101 (15.7) 23 (30.7) 25 (15.1) 30 (11) 23 (17.6)
Antipsychotics 83 (12.9) 7 (9.3) 18 (10.8) 35 (12.9) 23 (17.6)
Antihistamines 24 (3.7) 3 (4) 6 (3.6) 9 (3.3) 6 (4.6)
Antidepressants 190 (29.5) 24 (32) 43 (25.9) 81 (29.8) 42 (32.1)
Antiepileptics 33 (5.1) 5 (6.7) 8 (4.8) 8 (2.9) 12 (9.2)
Indicationsa
Anxiety 214 (33.4) 21 (28) 43 (25.9) 91 (33.6) 59 (46.1)
Agitation/aggression 196 (30.7) 6 (8) 34 (20.7) 87 (32.1) 69 (53.9)
Sleep disturbance 183 (28.7) 13 (17.6) 37 (22.4) 84 (31.1) 49 (38)
a Anxiety, agitation/aggression and sleep disturbance are measured by any non-zero NPI frequency/severity value.
TABLE 14 The number of participants who start, stop, continue or do not use hypnotics between visits
Medication
No use at previous visit, n (%) With use at previous visit, n (%)
Total No use Starting Total Stopping Continuous use
Z-drugs 1259 (100) 1175 (93) 84 (7) 281 (100) 70 (25) 211 (75)
BZDs 1224 (100) 1121 (92) 93 (8) 316 (100) 76 (24) 240 (76)
Antipsychotics 1295 (100) 1214 (94) 81 (6) 245 (100) 61 (25) 184 (75)
Note
Percentages are based on the numbers who use or do not use hypnotics at previous visit, so reflect the rate of stopping or
starting each drug.
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After adjusting for covariates, those who used Z-drugs were less likely to complete the next assessment
(OR 1.47, 95% CI 1.03 to 2.09), although those using BZDs were more likely. Antipsychotic use did not
predict subsequent loss to follow-up independently of disability and cognitive function (as measured with
CDR-global). Those who were more severely disabled or older were more likely to be lost, but net of this
there was no clear link between dropout and cognitive function. There was little association between
neuropsychiatric symptoms and subsequent loss to follow-up.
Predictors of hypnotic use
Tables 14 and 15 show that medication use at a previous wave is an extremely strong predictor of medication
use at the current wave. Hence, for each medication of interest two logistic models were estimated, one for
stopping and another for starting, conditional on participant characteristics and lagged values of time-varying
covariates. Clustered standard errors were used to account for multiple data points per individual contributing
to this analysis.
Table 16 shows the independent predictors of starting (current use conditional on no prior use) and
Appendix 3, Table 44, shows the factors predicting continuing medication use (current use conditional on
prior use) estimated using these models, which are also used to identify confounding variables to develop
the marginal structural model analysis below.
Z-drugs and BZDs are more commonly started among those with less severe dementia, more strikingly so
for Z-drugs than for BZDs. Conversely, antipsychotics are more commonly started among those with more
severe dementia. Prior use of Z-drugs predicts new use of BZDs. Prior levels of neuropsychiatric symptoms
independently predict new use of hypnotics, in particular prior sleep disturbance predicts new Z-drug and
BZD use, anxiety predicts new use of all three classes. However, a considerable number of participants
started Z-drugs without having any prior sleep disturbance, anxiety or agitation recorded in any previous
assessment (not shown).
There were fewer clear predictors of continuing hypnotic use (equivalently of stopping use) between visits.
In particular, levels of neuropsychiatric symptoms and dementia severity were not significantly linked to use
of any hypnotic if there was use at a previous wave.
Dynamics of outcome measures and estimating the effect of hypnotic use on
outcome measures
Figures 13–22 in Appendix 3 describe how each outcome measure changes between waves and vary
with age, CDR stage and with concurrent Z-drug use. The left-hand panels of Figures 3–12 show how
outcome measures change with changing hypnotic use status. The right-hand panels of Figures 3–12
show the association between current hypnotic use and outcome measures, with weights applied to each
observation such that levels of previous hypnotic use, cognitive function and neuropsychiatric variables
are balanced between those currently using each medication and those not using each medication.
Thus, these graphs show the effect of current medication use controlling for key patient characteristics,
TABLE 15 Pairwise association between use of Z-drugs, BZDs and antipsychotics in all REDIC study visits
Z-drugs BZDs Antipsychotics
Z-drugs 421 126 78
BZDs 2.0 (1.6 to 2.6) 440 122
Antipsychotics 1.3 (0.95 to 1.7) 2.6 (2.0 to 3.4) 349
Note
Diagonal cells contain the total number of occasions among all visits on which each medication was reported, numbers
to the right of the diagonal represent the number of occasions on which each pairwise combination was reported and
numbers to the left of the diagonal contain the OR (95% CI), representing the association between the use of each class.
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TABLE 16 Association between clinical and demographic factors and starting hypnotics at the next visit, among
those with no use at the current visit
Participant characteristics
Starting Z-drugs Starting BZDs Starting antipsychotics
OR 95% CI OR 95% CI OR 95% CI
Age (years)
< 70 0.59 0.14 to 2.46 1.37 0.47 to 4.00 0.82 0.30 to 3.78
70–79 Ref Ref Ref
80–89 1.29 0.66 to 2.54 0.97 0.51 to 1.85 0.51* 0.25 to 1.25
≥ 90 0.76 0.34 to 1.73 0.75 0.33 to 1.67 0.46 0.23 to 1.39
Dementia severity
Minimal 5.31*** 2.15 to 13.12 3.09* 1.30 to 7.34 0.37 0.22 to 2.75
Mild 1.19 0.49 to 2.91 1.47 0.70 to 3.11 0.53 0.37 to 2.23
Moderate 1.50 0.73 to 3.09 0.86 0.44 to 1.67 0.51* 0.28 to 1.18
Severe Ref Ref Ref
Sex (female) 1.46 0.85 to 2.52 1.07 0.63 to 1.81 1.18 0.47 to 2.03
Marital status
Unmarried Ref Ref Ref
Married 3.92 0.90 to 17.06 1.54 0.59 to 3.97 0.51 0.2 to 1.59
Widowed/divorced 4.74* 1.07 to 20.92 1.44 0.54 to 3.87 0.64 0.25 to 1.71
Hypnotic use
BZDs 1.22 0.67 to 2.21 0.99 0.28 to 1.28
Z-drugs 1.64 0.92 to 2.91 1.20 0.52 to 2.37
Antipsychotics 1.45 0.76 to 2.77 0.54 0.25 to 1.17
Neuropsychiatric symptoms
Sleep 1.86*** 1.43 to 2.42 1.05 0.76 to 1.44 1.14 0.92 to 1.76
Anxiety 1.63* 1.08 to 2.44 1.59* 1.10 to 2.30 1.59* 1.52 to 3.67
Agitation 0.63 0.37 to 1.08 1.55 0.97 to 2.48 1.22 0.89 to 2.21
Disability (Lawton Physical
Self-Maintenance Scale), per unit
1 0.95 to 1.05 0.99 0.94 to 1.04 1.01 0.93 to 1.08
Years in education
< 7 2.95 0.95 to 9.19 0.91 0.27 to 3.09 0.65 0.13 to 3.71
7 1.05 0.53 to 2.09 0.62 0.33 to 1.17 0.91 0.37 to 1.65
8–11 1.39 0.73 to 2.65 0.69 0.38 to 1.28 0.84 0.30 to 1.33
≥ 12 Ref Ref Ref
Type of admission
Long stay Ref Ref Ref
Short stay 0.96 0.49 to 1.87 1.80 1.00 to 3.27 0.78 0.40 to 2.10
Nursing 1.83 0.55 to 6.03 0.69 0.16 to 2.91 0.71 0.13 to 3.89
*p < 0.05, ***p < 0.001.
Ref, reference.
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in particular those characteristics that predict new or continuing medication use at the previous wave.
The difference in current mean levels of outcomes between groups can then be interpreted as the effect
of the medication, although when weights do not cause prior levels to perfectly coincide, comparing the
change over time between groups may better estimate the effect.
Cognitive measures
With respect to cognitive outcomes, Appendix 3, Figures 3–5 (SIB-8, MMSE and CDR-SOB), shows that
those who use Z-drugs tend to have better cognitive function than average, those who use antipsychotics
have worse cognitive function than average, but different patterns of changing status are not consistently
associated with different levels of decline in cognitive function between assessments. That is, rates of
decline between assessments do not appear to be systematically different between those who use no
hypnotics, those who start or stop between assessments or those who use hypnotics at both assessments.
Table 17 quantifies these associations, while adjusting for age, the specific visit at which the cognitive
assessment is made and baseline cognitive function. There is some evidence for more decline in SIB-8 score
among those starting BZDs compared with no use, and some worsening by CDR-SOB among those starting
antipsychotics compared with no use. However, these changes are not reflected in other cognitive scores
and are not seen among those starting Z-drugs compared with those with no use. When cognitive measures
are combined there is no evidence for any additional decline with starting or continuing Z-drug use.
Appendix 3, Figures 3–5 and Table 45 (first column), shows the change in cognitive function between waves for
Z-drug users compared with non-users, using IPTW to balance the prior cognitive function and neuropsychiatric
symptoms between groups. Again, these show no effect of any hypnotic on cognitive function. There is some
suggestion that the change in CDR-SOB scores is around 0.5 points higher for those using hypnotics, but this is
TABLE 17 Association between patterns of hypnotic use and change in mean measures of cognitive function and
disability between visits, adjusted for baseline age, baseline cognitive function and visit number
Exposure
Measure, β (95% CI)
MMSE CDR-SOB SIB-8 Disability scale
Z-drug
No use Ref Ref Ref Ref
Starting 0.01 (–1.44 to 1.46) –0.17 (–0.88 to 0.55) –0.58 (–1.72 to 0.55) –0.05 (–0.72 to 0.61)
Stopping –0.51 (–2.04 to 1.01) 0.53 (–0.18 to 1.24) –0.94 (–2.26 to 0.37) 0.53 (–0.38 to 1.44)
Continuing 0.65 (–0.06 to 1.36) –0.14 (–0.51 to 0.24) –0.13 (–0.68 to 0.42) –0.54** (–0.94 to –0.15)
BZD
No use Ref Ref Ref Ref
Starting –0.36 (–1.83 to 1.11) 0.78** (0.20 to 1.37) 0.60 (–0.25 to 1.45) 0.02 (–0.61 to 0.65)
Stopping 0.82 (–0.37 to 2.01) –0.37 (–0.99 to 0.25) 0.40 (–0.67 to 1.47) –0.12 (–0.89 to 0.65)
Continuing 0.44 (–0.20 to 1.08) –0.07 (–0.43 to 0.29) 0.20 (–0.30 to 0.70) –0.30 (–0.67 to 0.08)
Antipsychotic
No use Ref Ref Ref Ref
Starting –1.39** (–2.41 to –0.36) 0.33 (–0.25 to 0.91) –0.49 (–1.35 to 0.37) 0.91 (–0.05 to 1.86)
Stopping –0.42 (–1.79 to 0.94) 0.36 (–0.27 to 0.98) –0.03 (–0.96 to 0.90) 0.11 (–0.60 to 0.82)
Continuing 0.05 (–0.63 to 0.74) –0.06 (–0.44 to 0.33) 0.20 (–0.39 to 0.79) 0.33 (–0.10 to 0.77)
**p < 0.01.
Ref, reference.
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only statistically significant for BZDs and there is no effect on any other cognitive measure. Fixed-effects linear
models (see Appendix 3, Table 45) comparing occasions with hypnotic use with those without within each
participant yield similar results in the whole cohort, and when restricted to those not using any hypnotics at
baseline and among those with mild dementia at baseline.
Sleep disturbance
As seen in Cognitive measures, participants with a sleep disturbance are more likely to start Z-drugs at the next
wave than any other group. This is reflected in Appendix 3, Figure 6, which shows that those who start Z-drugs
have higher prior values of sleep disturbance than each of the other groups. There is a subsequent decline in
sleep disturbance among this group compared with those who do not use Z-drugs; however, when corrected
for baseline sleep disturbance using IPTW weighting, this effect is no longer apparent. In fact, there is some
evidence for an increase in sleep disturbance associated with Z-drug use. Fixed-effects models show no effect
of Z-drugs on sleep after adjusting for between-patient differences.
There are no significant associations between antipsychotics, BZD use and sleep disturbance in any of the
models estimated (see Appendix 3, Table 46).
Anxiety and agitation
Those using BZDs and antipsychotics, or those starting or stopping between waves, had higher levels of
anxiety and agitation than those who did not use either drug (see Appendix 3, Figures 7 and 8). There was
no such association with Z-drugs. There was also was no significant difference in the change in anxiety or
agitation scores in any group compared with those not using hypnotics, except for an apparent decline in
agitation among those continuously using antipsychotics compared with each other group. This difference
was also seen using IPTW models, along with an increase in anxiety among antipsychotic users compared
with those not using antipsychotics and an increase in agitation scores among BZD users (see Appendix 3,
Table 46).
Quality of life and disability
Although few associations were statistically significant, use of any hypnotic medication appears associated
with lower QoL scores when measured by VAS (see Appendix 3, Figure 9), EQ-5D questions (see Appendix 3,
Figure 10) or the QUALID scale (see Appendix 3, Figure 11). This finding is consistent across models (see
Appendix 3, Table 45).
When patterns of starting or stopping are considered, there is some evidence that starting Z-drugs is associated
with lower QoL, but it is not statistically significant. Both stopping and starting antipsychotics was associated
with worse QoL compared with no use at either wave (see Appendix 3, Table 47).
Disability is correlated with CDR-SOB (Spearman’s r = 0.52) and the effect of hypnotics on disability follows a
similar pattern. Those using antipsychotics are more disabled and there is some evidence that those starting
antipsychotics become more disabled than those who do not use them, although this is not statistically
significant except under the fixed-effect model including all participants (see Appendix 3, Figure 12 and
Table 17). There is no evidence for any impact of Z-drug use on disability.
The NACC data set results
Participant characteristics
The distribution of the characteristics of the 17,055 people living with dementia on study entry (defined as
their first assessment with a record of dementia) stratified by baseline CDR-global is shown in Table 18.
The median year of joining the study is 2009 and the median age is 76 (range 21–110, IQR 67–82) years.
Fifty-two per cent of the cohort were female. There is little association between age at study entry and
dementia stage at entry. Although most participants join the study at dementia stage ≤ 1, 14% joined at
CDR 2 (moderate dementia) and 8% at CDR 3 (severe dementia).
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TABLE 18 Description of the NACC data set sample at first visit with a study diagnosis of dementia, stratified by
dementia severity
Participant characteristics
Dementia severity (CDR stage)
Minimal





n 6070 7315 2371 1299








Female, n (%) 3064 (50) 3768 (52) 1334 (56) 755 (58)
Age (years), median (IQR) 74 (67–81) 76 (67–82) 76 (67–83) 76 (66–83)
Drug use, n (%)
Z-drug 146 (2) 149 (2) 39 (2) 39 (3)
BZD 401 (7) 492 (7) 194 (8) 189 (15)
Antipsychotic 163 (3) 466 (6) 382 (16) 443 (35)
Antidepressant 2122 (35) 2983 (41) 1049 (45) 588 (47)
Medication data missing 57 (1) 57 (1) 35 (1) 39 (3)
Cognitive function
Delta trail time, mean (SD) 133.9 (76.0) 155.7 (73.6) 170.0 (59.9) 130.0 (94.6)
Delta trail time data missing, n (%) 1245 (21) 2905 (40) 1756 (74) 1242 (96)
Animal fluency, median (IQR) 12 (9–16) 10 (7–13) 6 (3–9) 2 (0–4)
Animal fluency data missing, n (%) 374 (6) 618 (8) 627 (26) 934 (72)
MMSE, median (IQR) 25 (22–27) 22 (18–25) 14 (9–19) 0 (0–7)
MMSE data missing, n (%) 953 (16) 1016 (14) 269 (11) 163 (13)
CDR-SOB, median (IQR) 3 (2–3.5) 5.5 (4.5–6.5) 11 (10–12) 18 (16–18)
CDR-SOB data missing, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
Neuropsychiatric symptoms
Sleep disturbance, n (%) 1526 (26) 2282 (32) 876 (38) 473 (41)
Sleep disturbance data missing, n (%) 226 (4) 270 (4) 92 (4) 158 (12)
Anxiety, n (%) 1940 (33) 3006 (43) 1110 (49) 517 (45)
Anxiety data missing, n (%) 218 (4) 262 (4) 91 (4) 155 (12)
Agitation, n (%) 1593 (27) 2544 (36) 1079 (47) 610 (53)
Agitation data missing, n (%) 216 (4) 257 (4) 89 (4) 155 (12)
NPI excluding sleep, mean (SD) 3.47 (3.64) 5.12 (4.57) 6.98 (5.33) 7.60 (5.95)
NPI excluding sleep data missing, n (%) 226 (4) 270 (4) 92 (4) 158 (12)
Other outcomes
GDS, median (IQR) 2 (1–4) 2 (1–4) 2 (1–4) 2 (1–5)
GDS data missing, n (%) 330 (5) 687 (9) 579 (24) 999 (77)
Disability, median (IQR) 7 (4–12) 16 (11–21) 26 (22–29) 30 (29–30)
Disability data missing, n (%) 195 (3) 190 (3) 63 (3) 61 (5)
Note
Under each variable, number missing indicates the number and proportion of participants for whom each measure is
not available.
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The reported prevalence of Z-drug and BZD use is far lower in NACC data set than in the REDIC study
cohort. Only 2–3% of participants report Z-drug use, whereas 7–15% report BZD use, with highest levels
of use among those with severe dementia. Antipsychotic use increases markedly with dementia severity,
from 3% (CDR < 1) to 34% (CDR = 3). A substantial proportion of participants at all stages (35–45%)
report use of an antidepressant. On fewer than 2% of visits the medication use form was not completed
(3% among CDR 3 patients).
Neuropsychiatric symptoms are reported relatively frequently at all stages. Some sleep disturbance is reported
for 26–41% of participants across groups; anxiety and agitation have similar numbers. These assessments
are present for 96% of participants in CDR stages 0.5–2 and 88% at CDR stage 3. The average total NPI
symptom score excluding sleep disturbance increases from 3.5 to 7.6 with dementia severity.
Average disability score increases with dementia severity, such that almost all of those with severe dementia
score 29 or 30 out of 30 on the disability scale. In contrast, the level of depression is generally low
(median GDS 2/10, IQR 1–4), but in severe dementia 77% of participants are not able to complete the GDS.
The number of participants completing each annual visit is shown in Appendix 4, Table 48. Only 9889
(59%) participants complete more than one visit, 4020 (24%) of participants complete visit 4, whereas
only 838 (5%) complete visit 7. Prevalence of Z-drugs does not change markedly with visit number,
whereas antipsychotics become more common at later visits.
Dynamics of hypnotic use
The numbers of participants starting and stopping Z-drugs, BZDs and antipsychotics between pairs of
consecutive visits are shown in Appendix 4, Table 49. Only 1% of visits report new Z-drug use, although
this still corresponds to 219 instances of new Z-drug use, which is a reasonable number from which to estimate
changes in outcome measures. Of those who use Z-drugs and return medication data at a subsequent visit,
51% still report Z-drug use. For antipsychotics, the rate of new use (6%) and continuing use (79% of
antipsychotic users still use antipsychotics at the next wave) is higher.
Predictors of starting or stopping hypnotics between waves
Table 19 and Appendix 4, Table 50, show the independent effects of cognitive function, neuropsychiatric
variables and demographic factors at each visit on the use of hypnotics at the subsequent visit, conditional
on current hypnotic use.
Among those not using Z-drugs, sleep disturbance did predict new use of Z-drugs at the next wave, but was
only slightly linked to new BZD use and was not independently linked to new antipsychotic use. Conversely,
anxiety and agitation predicted new use of antipsychotics and BZDs at the subsequent visit. Cognitive
function did not predict new use of Z-drugs, but those with more severe dementia were more likely to start
BZDs and antipsychotics (see Table 19). Independently of cognitive function and symptoms, older people
with dementia were less likely to start BZD or antipsychotics, but there was no age effect with Z-drugs.
Among those using hypnotics there were very few variables that were able to predict which participants
continued to report hypnotics at the next visit (see Appendix 4, Table 50). Older people and those with
more severe cognitive impairment appeared less likely to continue BZDs, but, crucially, current levels of
psychiatric symptoms did not predict whether or not current medications were continued.
Predictors of dropout in the NACC data set
As in the REDIC study, medication use did not strongly predict whether or not each participant completed
a subsequent assessment, but older and more severely impaired participants were more likely to drop out.
Psychiatric symptoms also did not predict dropout. Note, we do not distinguish dropout through leaving
the study, death or censoring and so this should not be interpreted as an assessment of the risk of
hypnotics on any outcome.
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Distribution and dynamics of outcome measures
Appendix 4, Figures 23–32, describes how each outcome measure changes between waves and varies with
age, CDR stage and with concurrent Z-drug use. Delta trail time does not appear to work well among
those with severe cognitive impairment. The score is missing for the vast majority of participants with CDR
stage 3, and for those who do return a score it is often at the maximum allowed time for both trails; hence
the information provided by this measure is likely to be extremely limited.
TABLE 19 The ORs showing the predictors of new use of hypnotics among those not using each drug at the prior wave
Factor
Starting drug at next wave, β (95% CI)
Z-drug BZD Antipsychotic
Drug use
Z-drug 2.31*** (1.62 to 3.30) 1.10 (0.73 to 1.67)
BZD 1.97** (1.30 to 2.99) 1.76*** (1.46 to 2.12)
Antipsychotic 1.48 (0.96 to 2.28) 1.61*** (1.33 to 1.96)
Education (per year) 0.97 (0.92 to 1.01) 1.03*** (1.01 to 1.06) 1.01 (0.99 to 1.03)
Sex (female) 1.11 (0.83 to 1.48) 1.06 (0.92 to 1.23) 0.81*** (0.71 to 0.91)
CDR
Minimal 1 (Ref) 1 (Ref) 1 (Ref)
Mild 0.85 (0.60 to 1.21) 1.25* (1.02 to 1.52) 2.22*** (1.85 to 2.67)
Moderate 1.10 (0.73 to 1.65) 1.94*** (1.56 to 2.41) 4.63*** (3.81 to 5.62)
Severe 0.83 (0.50 to 1.37) 2.17*** (1.70 to 2.78) 4.02*** (3.20 to 5.04)
Age (years)
< 61 1 (Ref) 1 (Ref) 1 (Ref)
61–70 1.44 (0.87 to 2.38) 0.76** (0.62 to 0.93) 0.82* (0.69 to 0.98)
71–80 1.22 (0.75 to 2.00) 0.58*** (0.48 to 0.70) 0.73*** (0.62 to 0.86)
81–90 1.06 (0.62 to 1.81) 0.46*** (0.36 to 0.58) 0.58*** (0.47 to 0.70)
≥ 90 1.38 (0.48 to 3.92) 0.46** (0.27 to 0.79) 0.51** (0.33 to 0.80)
Sleep
None 1 (Ref) 1 (Ref) 1 (Ref)
Mild 1.43 (0.98 to 2.09) 1.21* (1.01 to 1.45) 1.15 (0.99 to 1.34)
Moderate 1.89** (1.28 to 2.80) 1.13 (0.92 to 1.38) 1.13 (0.95 to 1.33)
Severe 2.08** (1.20 to 3.59) 1.09 (0.79 to 1.50) 1.02 (0.78 to 1.32)
Anxiety
None 1 (Ref) 1 (Ref) 1 (Ref)
Mild 0.74 (0.52 to 1.07) 1.29** (1.09 to 1.53) 1.18* (1.03 to 1.36)
Moderate 0.76 (0.49 to 1.17) 1.81*** (1.50 to 2.18) 1.47*** (1.25 to 1.72)
Severe 1.00 (0.53 to 1.88) 1.74*** (1.26 to 2.40) 1.86*** (1.44 to 2.40)
Agitation
None 1 (Ref) 1 (Ref) 1 (Ref)
Mild 1.07 (0.76 to 1.51) 1.08 (0.90 to 1.28) 1.49*** (1.30 to 1.71)
Moderate 0.59* (0.36 to 0.97) 1.36** (1.12 to 1.66) 1.73*** (1.47 to 2.03)
Severe 1.04 (0.55 to 1.95) 1.67*** (1.24 to 2.26) 2.77*** (2.16 to 3.54)
*p < 0.05, **p < 0.01, ***p < 0.001.
Ref, reference.
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Association between each outcome and starting or stopping hypnotic medication
Cognitive outcomes
The change in cognitive function with changing use of hypnotics is shown in Appendix 4, Figure 33–42.
There appears to be little association between Z-drug use and cognitive function, as measured by any
cognitive outcome. Those who use antipsychotics and BZDs have lower cognitive function than those who
do not, and starting both antipsychotics and BZDs appears to be linked to more decline across waves. When
accounting for prior use of medication, neuropsychiatric symptoms and cognition these patterns remain.
Table 20 quantifies the association between change in cognitive outcomes and patterns of hypnotic use,
adjusting for age, baseline cognitive function and the visit number. Those starting BZDs or antipsychotics
have an associated decline in cognitive function across all measures, except delta trail time. Stopping
antipsychotics is associated with improvements in CDR-SOB and animal fluency compared with those who
did not use antipsychotics, but not in MMSE or delta trail time, but there is no significant improvement
associated with stopping BZDs.
Those who continue Z-drugs or BZDs appear to have better cognitive function than those who did not use
Z-drugs or BZDs at all.
TABLE 20 Association between change in cognitive outcomes and change in medication status between visits
Medication
β (95% CI)
CDR-SOB MMSE Animal fluency Delta trail time
Z-drug













































































*p < 0.05, **p < 0.01, ***p < 0.001.
Ref, reference.
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This pattern of effects is confirmed using the marginal structural model approach (see Appendix 4, Table 51),
whereby use of BZDs and antipsychotics is associated with significantly worse cognition after weighting
to balance users and non-users across previous CDR, previous medication use and previous levels of
neuropsychiatric symptoms. There is no evidence for any effect of Z-drugs on cognitive outcomes.
Neuropsychiatric outcomes
Despite the strong association between sleep disturbance and subsequent Z-drug use, there is little
association between starting Z-drugs and change in sleep disturbance between waves (Table 21). There is
a borderline significant increase in agitation associated with starting Z-drugs and some evidence for less
sleep disturbance association with stopping Z-drugs.
Similar patterns are seen for reports of anxiety and agitation, whereby those starting, stopping or
continuing any of Z-drugs, BZDs or antipsychotics have higher symptom levels that those who do not use
the medication at all, with a slight decline in symptoms associated with stopping medications and a
significant association between medication use and symptoms remaining once prior levels of cognitive
function, medication use and symptoms are taken into account.
TABLE 21 Association between mean difference in neuropsychiatric outcomes (as measured by the NPI) and
change in medication status between visits
Medication


















































































*p < 0.05, **p < 0.01, ***p < 0.001.
Ref, reference.
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Depression and disability
As in the REDIC study, the disability measure among people with dementia is closely correlated with
cognitive function, and the patterns of associations with medication use match the associations between
medication use and cognitive measures.
The GDS does not appear to be linked to severity of impairment, and there is no evidence of any association
between changes in depressive status and changes in use of Z-drugs, antipsychotics or BZDs (Table 22).
Fixed-effects models
Each of the results discussed above using marginal structural models is also reflected in the fixed-effects
models (see Appendix 4, Tables 52–54). There is a strong, consistent association seen between worse
cognitive function and greater disability with concurrent BZD and antipsychotic use, but no association
with Z-drug use. Depression is not linked to the use of any hypnotics, except for a positive association
with antipsychotics among those with no hypnotic use on study entry, whereas other neuropsychiatric
symptoms are consistently positively associated with use of hypnotics, as above.
The WHELD trial results
Participant characteristics
After excluding 21 participants with missing medication data and 24 participants with a severe mental
illness diagnosis, the 926 participants in the WHELD trial with dementia were mainly women (n = 659,
71%) and the mean age at study entry was 85.3 (SD 8.8) years. A total of 123 (13%) participants reported
Z-drug use at baseline and a further 27 (3%) participants reported Z-drug use at 9-month follow-up. Those
participants taking Z-drugs were more likely to have a partner, have a nervous system illness and be taking
concurrent BZDs, memantine or antipsychotics (Table 23).






No use 0 (Ref) 0 (Ref)
Starting –0.28 (–0.68 to 0.13) –0.55 (–1.23 to 0.13)
Stopping –0.08 (–0.52 to 0.37) –0.61 (–1.30 to 0.09)
Continuing –0.01 (–0.31 to 0.29) –0.65* (–1.29 to –0.01)
BZDs
No use 0 (Ref) 0 (Ref)
Starting 0.05 (–0.21 to 0.30) 0.48** (0.14 to 0.83)
Stopping –0.24 (–0.52 to 0.04) –0.15 (–0.59 to 0.30)
Continuing –0.07 (–0.24 to 0.10) –0.64*** (–0.90 to –0.38)
Antipsychotics
No use 0 (Ref) 0 (Ref)
Starting 0.15 (–0.07 to 0.37) 0.81*** (0.51 to 1.11)
Stopping –0.11 (–0.52 to 0.31) –1.24*** (–1.59 to –0.88)
Continuing –0.02 (–0.19 to 0.15) –1.48*** (–1.65 to –1.31)
*p < 0.05, **p < 0.01, ***p < 0.001.
Ref, reference.
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TABLE 23 Participant characteristics, by Z-drug use at baseline
Baseline characteristic Z-drug (N= 123) No Z-drug (N= 803)
Female, n (%) 74 (60) 585 (73)
Age (years), mean (SD) 83.9 (9.6) 85.6 (8.6)
White ethnicity, n (%) 116 (94) 761 (95)
Marital status, n (%)a
Single/widowed 71 (58) 578 (72)
Married/partner 42 (34) 162 (20)
Divorced/separated 8 (7) 54 (7)
CDR, n (%)
Mild dementia 17 (14) 174 (22)
Moderate dementia 45 (37) 294 (937)
Severe dementia 61 (50) 335 (42)
NPI-NH score (excluding sleep), median (IQR) 17 (7–34) 9 (3–20)
Any sleep disturbance, n (%) 34 (28) 162 (20)
Pain, n (%)
Mild 34 (28) 232 (29)
Moderate/severe 13 (11) 48 (6)
Comorbidity, n (%)
Depression 12 (10) 99 (12)
Anxiety 4 (3) 29 (4)
Respiratory illness 42 (34) 271 (34)
Gastrointestinal illness 34 (28) 209 (26)
Cardiovascular condition 24 (20) 129 (16)
Endocrine illness 18 (15) 97 (12)
Musculoskeletal disorder 29 (24) 169 (21)
Nervous system illness 15 (12) 43 (5)
Medication use, n (%)
BZD 31 (25) 98 (12)
Meprobamate/buspirone 2 (2) 7 (1)
Clomethiazole 1 (1) 11 (1)
Antidepressant 56 (46) 357 (45)
Antipsychotic 36 (29) 106 (13)
Cholinesterase inhibitor 30 (24) 170 (21)
Memantine 34 (28) 68 (9)
a Missing marital status for two participants taking Z-drugs and nine participants not taking Z-drugs.
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Cross-sectional analysis
The results of the cross-sectional analyses comparing Z-drug use at baseline and baseline QoL and sleep
scores are shown in Table 24.
At baseline, the mean QUALID scores for those taking Z-drugs or not at baseline were 22.9 (SD 8.0) and
21.3 (SD 7.3), respectively. Z-drug use was not associated with any difference in QUALID scores at baseline
(RR 0.96, 95% CI 0.92 to 1.01, adjusted for confounders).
At baseline, the mean NPI-NH sleep scores for those taking Z-drugs or not at baseline were 1.6 (SD 3.0)
and 1.0 (SD 2.5), respectively. There was no significant difference in sleep disturbance at baseline in Z-drug
users (RR 1.42, 95% CI 0.71 to 2.85, adjusted for confounders).
At baseline, the mean NPI-NH score (excluding sleep) for those taking Z-drugs and not taking Z-drugs at
baseline were 21.6 (SD 17.6) and 14.1 (SD 15.1). Greater neuropsychiatric symptoms were reported in
those taking Z-drugs after adjusting for confounders (RR 1.24, 95% CI 1.00 to 1.54).
Mortality analysis
A total of 20 (16%) and 177 (22%) participants taking and not taking Z-drugs, respectively, at baseline
died during follow-up. Baseline Z-drug use was not associated with mortality after adjusting for
confounders (OR 0.66, 95% CI 0.38 to 1.15).
Longitudinal analyses
A total of 627 people living with dementia completed the 9-month follow-up interviews. The mean increase
in QUALID, NPI-NH sleep score and NPI-NH excluding sleep over the 9 months’ follow-up was 0.25 (SD 7.67),
0.11 (SD 0.60) and 0.17 (SD 16.59), respectively. Z-drug use at baseline was not significantly associated with
any greater increase in either score, with adjusted additional average increases in QUALID, NPI-NH sleep,
and NPI-NH excluding sleep scores of 1.43 (95% CI –0.33 to 3.19), 0.08 (95% CI –0.07 to 0.22) and 0.60
(95% CI –3.26 to 4.46), respectively (Table 25).
Considering changes in medication use between baseline and 9-month follow-up, 26 (4%) reported Z-drug
use at baseline but not at 9 months (‘stopping’), 62 (10%) participants reported Z-drug use at both times
(‘continuing’) and 25 (4%) reported Z-drug use at 9 months but not at baseline (‘starting’). Although those
starting, stopping and continuing Z-drugs reported, on average, increased NPI sleep scores over the 9-month
follow-up, none were statistically different from the increase for those not using Z-drugs (see Appendix 6,
Table 65). Although those initiating Z-drugs saw a decline in their NPI score (excluding sleep), this was not
statistically different from those not using Z-drugs. Although those stopping Z-drugs reported a worsening in
their QoL over the 9-month follow-up, this was not statistically different from those not using Z-drugs.
TABLE 24 Adjusted IRRs for QUALID and NPI-NH sleep score, by Z-drug use at baseline
Scale
Baseline
Mean (SD) IRR (95% CI) IRRa (95% CI)Z-drug n
NPI-NH excluding sleep No 803 14.1 (15.1) 1.00 1.00
Yes 123 21.6 (17.6) 1.53 (1.23 to 1.90) 1.24 (1.00 to 1.54)
NPI-NH sleep No 803 1.0 (2.5) 1.00 1.00
Yes 123 1.6 (3.0) 1.57 (0.84 to 2.90) 1.42 (0.71 to 2.85)
QUALID No 803 21.3 (7.3) 1.00 1.00
Yes 122 22.9 (8.0) 1.07 (1.01 to 1.14) 0.96 (0.92 to 1.01)
a Adjusted for age, sex, ethnicity, marital status, CDR, Abbey Pain Scale score, comorbidity and co-medication use.
QUALID scores also adjusted for sleep disturbance (a NPI-NH sleep score > 0).
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TABLE 25 Adjusted additional change in QUALID, NPI-NH and NPI-NH sleep scores, by baseline Z-drug use
Scale
Baseline
Mean change (SD) Beta (95% CI) Betaa (95% CI)Z-drug n
NPI-NH excluding sleep No 539 0.33 (16.28) 0.00 0.00
Yes 88 –0.80 (18.45) –1.13 (–4.87 to 2.62) 0.60 (–3.26 to 4.46)
NPI-NH sleep No 539 0.10 (0.59) 0.00 0.00
Yes 88 0.16 (0.66) 0.06 (–0.08 to 0.19) 0.08 (–0.07 to 0.22)
QUALID No 525 0.20 (7.42) 0.00 0.00
Yes 85 0.52 (9.09) 0.31 (–1.45 to 2.07) 1.43 (–0.33 to 3.19)
a Adjusted for age, sex, ethnicity, marital status, baseline CDR, Abbey Pain Scale score, comorbidity and co-medication
use. Change in QUALID scores also adjusted for baseline sleep disturbance (a NPI-NH sleep score > 0).
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Summary of the main findings
Primary care study
By examining linked primary care and hospital admission data we found evidence of an increased risk of
fractures and, in particular, hip fractures, in people with dementia taking Z-drugs. The risk also increased
with cumulative exposure to Z-drugs, suggesting a causal relationship. However, multiple outcomes were
examined, increasing the risk of false-positive findings. We observed a greater mortality rate in people
living with dementia who were prescribed Z-drugs; however, the association did not vary significantly by
cumulative exposure to Z-drugs, suggesting that this finding may be due to reverse causation (i.e. that
patients in later stage dementia were more probably prescribed Z-drugs).
We did not detect a significantly increased risk of stroke, infection or venous thromboembolism with Z-drug use.
We observed that people living with dementia who were prescribed Z-drugs were more likely to be further
prescribed antipsychotics, antidepressants and antibiotics. People living with dementia who were prescribed
Z-drugs also visited their GP more frequently and were more often admitted to hospital in the next 2 years.
Our study was not sufficiently powered to examine adverse events of BZDs, but the risk estimates for Z-drugs
and fractures and mortality were generally similar to those for BZDs.
We did not find any associations between the use of low-dose TCAs and adverse events; however, these
findings should be interpreted with caution, as we were unable to distinguish whether patients had been
prescribed low-dose TCAs for sleep disturbance or for chronic pain. Patients with chronic or neuropathic
pain may be at a lower risk of fractures than patients with sleep disturbance.
Clinical cohort studies
In cohort studies of people with dementia in Norway (the REDIC study) and the USA (the NACC data set),
we observed no impact of Z-drug use on cognition, neuropsychiatric symptoms, disability or QoL. There was
some suggestion of an association between recurrent Z-drug use and lesser declines in cognition and disability;
however, we believe that this is more likely to reflect the people living with dementia who are stable on their
Z-drugs and not progressing onto using alternative medications, such as antipsychotics or BZDs. In a cohort
study of UK care home residents with dementia (the WHELD trial), we observed greater neuropsychiatric
symptoms in those taking Z-drugs at baseline, but Z-drug use at baseline was not associated with greater
improvement in neuropsychiatric symptoms over the following 9 months. We also observed no greater
mortality risk in those taking Z-drugs.
Strengths and limitations of the study
Primary care study
The primary care study is the first study to examine a range of adverse events for Z-drug use in people with
dementia. We used data from a large number of patients in a population-representative primary care database
linked to hospital records, which allowed detailed analysis of the prescriptions of Z-drugs and patient-relevant
outcomes. We designed the study to aim to minimise possible sources of bias and consequently this reduced
the number of patients and follow-up in the study, reducing our statistical power to detect adverse events.
We shall discuss the strengths and limitations in the context of the main sources of bias.161
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Selection bias
We followed patients from their first Z-drug prescription in dementia, thus allowing for the examination
of early events associated with the drug and for the evaluation of risks that may change over time.162,163
People living with dementia already using Z-drugs when diagnosed with dementia were excluded as they
may bias associations due to being ‘survivors’ of the early period of pharmacotherapy and having differing
characteristics of persistence with their medication. We also selected a cohort of people living with
dementia taking Z-drugs, but no other sedative medications, except for antipsychotics. We ceased follow-up
when a new sedative medication or antipsychotic was prescribed, hence enabling greater confidence that
any effects seen were attributable to the Z-drug, but this reduced statistical power. Having said that, we
applied far fewer exclusion criteria than RCTs164 and, as such, our findings are generalisable to most
of the population with dementia and sleep disturbance. Our selection of patients with dementia was
demonstrated to be valid, with 96% of GPs confirming the dementia diagnosis, similar to other studies
using UK primary care data.165 We are likely to have underestimated the numbers of dementia patients
with sleep disturbance, but not prescribed a Z-drug, as many of these patients may not have their sleep
disturbance reported to their GP. However, as our capture of dementia patients who were prescribed
Z-drugs is likely to be fairly accurate, it is of less concern that we are under-representing the comparator
group. In fact, those patients in the comparison group with sleep disturbance recorded by the GP are more
likely to represent the more severe cases of sleep disturbance and therefore are more comparable to the
group that was prescribed Z-drugs.
Validity of exposures
Although the recording of prescriptions issued in primary care may be accurate, we lack data on medications
prescribed in secondary care and obtained elsewhere. However, the majority of Z-drug prescribing should be
in primary care. We captured only whether or not medications were prescribed and if they were dispensed
or taken. We may have underestimated the effect of Z-drug use on the adverse events, if many patients
prescribed Z-drugs had not taken them. As our adverse event risks were observed only in those with repeat
prescriptions of Z-drugs, these findings suggest that patients returning for further prescriptions were more
likely to have taken them.
We were able to compare the risks of Z-drug use with those of BZDs. However, ensuring that the BZDs were
prescribed for sleep disturbance limited the number of eligible patients and therefore our power to detect
differences between BZDs and Z-drugs. As per our protocol, we also examined the medication class of low-
dose TCAs; however, we advise caution in interpreting these findings as we were unable to determine the
indication for these medications and sleep disturbance was confirmed in only 60% of cases in the validation
study. The Z-drugs prescribed historically in the UK are zopiclone, zolpidem and zaleplon, but with zopiclone
by far in the majority and zaleplon now discontinued. Although comparisons between specific Z-drugs might
be of interest, there is little evidence to suggest that their effects are different and there were insufficient
numbers to be able to make this comparison.
Validity of the outcomes
Patients with diagnoses recorded in the CPRD have generally been shown to have the condition.166,167
Validity studies report around 88–100% of patients coded as having hip fracture, UTI, respiratory tract
infection, venous thromboembolism and psychosis in UK primary care records databases were clinically
confirmed.166,168,169 Rates are slightly lower for stroke, where 66–76% of reported ischaemic strokes or TIAs
are confirmed.170–172 However, the degree of under-reporting in the CPRD has not often been examined.
The validity of our outcomes was improved through linkage to HES and ONS. This reduced bias was due to
not solely relying on the GP who probably wrote the Z-drug prescription to accurately record the outcomes.
Including HES and ONS data increased our number of outcome events by approximately 46%. The number
of additional events was greater in the Z-drug group than in the no sleep medication group, representing
substantial bias if we had relied on the CPRD data alone (e.g. the HR for Z-drug use and fractures decreased
from 1.40 to 1.27 when restricting to only the CPRD data). Other studies found that pneumonia rates
increased substantially when HES linkage was included.173
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Our recording of mortality is likely to be highly accurate as this was based on ONS records, which were
also very similar to that of primary care recorded death dates. We probably underestimated forearm, wrist
and hand fracture incidence, as some may have been reported to accident and emergency departments
without hospital admission and may not have made it onto the primary care record. Similarly, falls are
probably under-reported. GP records of falls may under-represent all falls that occur in the older population,
but more accurately represent ‘injurious falls requiring medical attention’.121 However, they may be under-
reported as a result of their recording being in the GP’s free text, or because the medical consequence of
the fall (e.g. fracture) has been recorded preferentially over the fall.
Some infections may be undetected, but we concentrated on acute bacterial ones for which medical
attention would usually have been sought. We attempted to record incident behavioural and psychological
symptoms of dementia by including any record of agitation, psychosis, hallucinations, delusions or
aggression, but these are probably under-reported and poorly defined. They also may represent late coding
of the indication for the Z-drug or BZD of interest. Hence, we express cautious interpreting of the agitation
or psychosis outcome.
Although some outcomes were potentially under-reported, we do not expect substantial bias in our risk
estimates due to outcome validity. Owing to the inclusion of linked HES and ONS data, we do not expect
differential recording of outcomes among those prescribed Z-drugs or not. However, we examined
multiple outcomes, which increased the risk of false-positive findings.
Confounding
We reduced the impact of confounding by indication by comparing adverse events to people living with
dementia with recorded sleep disturbance. However, sleep disturbance was challenging to identify within
the electronic primary care record. Only 42% of our control group with no sleep disturbance had sleep
disturbance confirmed in our validation study. The issue of the additional pop-up screen recording the
patient’s sleep pattern added confusion to the often contradictory diagnosis of sleep disturbance.
Discussion with health-care professionals identified a mixture of opinion that the patient has no sleep
disturbance when a ‘satisfactory’ sleep pattern was entered, or that the GP may just want to remove the
pop-up screen on sleep patterns by clicking the first option (of ‘satisfactory’). We remain uncertain whether
or not these patients have a sleep disturbance, but 35% and 83% of sleep disturbance was confirmed
when accompanied and not accompanied, respectively, by a ‘satisfactory’ sleep pattern in the validation
study. We performed a sensitivity analysis excluding control patients with a satisfactory sleep pattern and
our effects were reduced. We are not aware of any study that has previously investigated the reliability of
sleep disorder records in primary care, therefore our validation study strengthens future work on sleep
disturbance using primary care data.118
Although the detailed primary care database allowed adjustment for a wide range of potential confounders,
there is the possibility of residual confounding, the most important of which is that we were unable to
measure dementia severity. Although we adjusted for duration since the dementia diagnosis, prescription
of dementia medications and antipsychotics, history of agitation or psychosis and end-of-life care, there is
likely to be residual confounding by dementia severity for the mortality outcome. We were also lacking
information on the severity of the sleep disturbance. As more severe sleep disturbances may involve longer
wandering around at night and hence greater risk of fractures, there may be residual confounding by sleep
disturbance severity for the fracture outcomes. Studies have suggested that dementia severity is unrelated
to fracture risk,174 but residual confounding by stage of dementia cannot be ruled out. We also had no
data on genetic information, environmental factors and cohabiting status, which have been shown to be
important in falls risks in people living with dementia.41
Missing data
Missing data for covariates were generally low. Missing data occurring more frequently for covariates of BMI
and care home, had minimal effects on the associations reported in the sensitivity analyses.
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Clinical cohort studies
Generally, there were few studies reporting the outcomes of interest with sufficient Z-drug use in people
living with dementia. However, the three included cohort studies were of a large size, with frequent follow-up
and detailed outcome recording. Our results varied, and this could reflect differences in the prescribing of
Z-drugs across the USA, UK and Norway, and the settings of nursing homes or the community. We were
limited by not having a record of the outcome measurements just before the Z-drug was first prescribed.
As each study measured outcomes at fixed intervals, this did not necessarily coincide with the initiation of
Z-drugs or the start of a sleep disturbance. We were limited by which outcome measures each study recorded.
With NPI, it is not obvious whether a respondent is reporting on the level of symptoms that are currently
experienced given current treatment, or those that they believe would be experienced if the patient was not
treated. Hence, these findings should be interpreted with caution.
Although in the REDIC study and the NACC data set our analysis was strengthened by using marginal
structural models to balance users and non-users on prior covariates, the extent of balance was not always
perfect and could not be improved using different models for estimating weights. However, balance was
very good for prior CDR, suggesting that our findings are not driven by underlying differences in dementia
severity. Perhaps more importantly, this approach is valid for causal inference only if the assumption of
exchangeability is met, that is after balancing over the covariates included in our model there is no longer
any indirect path from the exposure in question to the outcome measure.175 In our case it is difficult to be
certain of this and, as the exact timing of medication initiation is not known, it is impossible to know
whether the outcome preceded each exposure or vice versa.
Interpretation of the study in light of previous research
Fractures
In the primary care study, we found evidence of a 40% greater risk of fractures with Z-drug use in people
living with dementia, which is lower than that reported in studies in the older population. A systematic
review, including a subgroup analysis of the findings from five observational studies in the older population,
estimated a pooled relative risk for fractures of 1.73 (95% CI 1.31 to 2.27) with zolpidem use.176 However,
none of these studies accounted for sleep disturbance, which is the indication for zolpidem. A further
systematic review and meta-analysis investigated Z-drugs in general and risks for falls and fractures from
14 eligible observational studies.60 They estimated an OR of 1.70 (95% CI 1.36 to 2.12) for Z-drugs and
fractures in the older population, but noted substantial heterogeneity.60
Although several studies have examined the risk of fractures associated with Z-drug use in the older
population, studies targeting people living with dementia have been limited.36 A recent Cochrane systematic
review concluded a distinct lack of evidence to help guide drug treatment of sleep problems in dementia,36
despite being widely prescribed to this large patient group.177 To our knowledge, no studies have previously
examined the risk of general fractures specifically in people living with dementia taking Z-drugs.
Current BZD use was not found to be associated with fractures in a study of 8036 people living with
dementia in London.41 We observed similar rates of fractures among new BZD and new Z-drug use. Other
studies in the older population that compare BZDs with Z-drugs for fracture risk, report varying results,
often dependent on the type of BZD.59,178
We found evidence of a 59% greater risk of hip fractures with Z-drug use in people living with dementia.
A systematic review and meta-analysis pooled the findings from six observational studies in older adults
and estimated a 90% (95% CI 68% to 113%) greater risk of hip fracture with Z-drug use.61 However,
studies suggest that the risk is lower in people living with dementia.57,179 A Finnish study of 67,072
community-dwelling people diagnosed with Alzheimer’s disease reported no association between any history
of BZD or Z-drug use in the 5 years before study entry and incident hip fracture (HR 1.03, 95% CI 0.97
to 1.09); however, this exposure definition may not be sufficiently specific and would not necessarily cover
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medication use immediately prior to most of the incident hip fractures (i.e. was measured only at baseline
and not updated during follow-up).179 A study of 15,528 US nursing home residents estimated an OR for
non-BZD hypnotic drug use and hip fracture in residents with moderate to severe cognitive impairment
of 1.43 (95% CI 1.15 to 1.77), which was lower than in the residents with no or MCI (OR 1.86, 95% CI
1.56 to 2.21).57
We observed that hip fracture risk increased with greater cumulative Z-drug exposure, but then tapered after
56 DDDs. This is consistent with an initial expression then down-regulation of GABA receptors,180,181 or a
depletion of susceptible patients among long-term users.182 Other studies in the older population found similar
findings, but with risks tapering over shorter periods, than we did in dementia.59,183 This perhaps represents
delays getting the prescription dispensed or many people living with dementia not taking their prescribed
Z-drugs during the first month in our sample, or a slower effect of Z-drugs in dementia. We found no effect in
the first 14 days, contrary to other studies in the older population.54,56,57 This could be partly explained if some
patients receiving only one prescription did not take the Z-drugs. Excluding those with only one Z-drug
prescription had little effect on our cumulative Z-drug prescription findings (results available from the authors).
We observed evidence of a greater risk of hip fractures for those prescribed BZDs than Z-drugs, but numbers
of hip fractures were small and this could represent residual confounding by dementia severity. Studies differ
on whether they find those prescribed BZDs or Z-drugs at greater risk of hip fracture,55,56,58,184 but generally
suggest greater risks with long-acting BZDs than with Z-drugs.56,185
Evidence is lacking to indicate that Z-drugs increase the risk of osteoporosis,186 in contrast to other psychotropic
drugs (e.g. antidepressants and antipsychotics).187 Although studies suggest that long-term sleep disturbance
may increase osteoporosis risk though disrupting the rhythm of bone turnover.188,189 The mechanism by which
Z-drugs increase fracture risk is probably due to their effects on gait and balance, although this is contradictory
to our findings on falls outcomes (see Falls).59,186 A trial randomised 25 adults to 5-mg zolpidem or placebo
10 minutes before scheduled sleep and asked them to perform 10 tandem walks on a beam on night-time
awakening.190 The NNH was estimated as one tandem walk failure for every 1.7 (95% CI 1.4 to 2.0) older
adults treated with zolpidem. The trial authors concluded that the ‘use of nonbenzodiazepine hypnotic
medications may have greater consequences for health and safety than previously recognized’.190
In a comprehensive review of the evidence for major adverse outcomes of BZDs and Z-drugs, there was
compelling evidence to establish a causal connection between BZD or Z-drug use and only motor vehicle
accidents, falls and fractures.186 Our study suggests that the increased risk of fractures extends to those
people living with dementia taking Z-drugs.
Falls
Counterintuitive to the fractures findings in the primary care study, we did not find an increased falls risk
with Z-drug use. Similarly, current BZD use was also not found to be associated with falls in a study of 8036
people living with dementia in London, once accounting for differences in ethnicity, living environment and
disability.41 A systematic review published in 2008, reported modest associations (RRs 1.2–1.3) between
BZDs and falls in nursing home residents with dementia,191 and BZDs are consistently associated with around
a 20% increased falls risk in older people.48
Z-drugs were originally claimed to cause fewer falls,51 but a recent meta-analysis estimated an OR for Z-drug
use and falls of 2.40 (95% CI 0.92 to 6.27) when pooling the findings from three observational studies in
adult populations.60 However, there was considerable heterogeneity (97%) between the studies and reasons
for this were cited as difficulty recording falls, particularly in patients with multimorbidity, or recall bias in
the studies relying on self-reported falls. Among 4450 US community-dwelling older men enrolled in the
Osteoporotic Fractures in Men study, Z-drug use was associated with a 37% (95 CI 9% to 71%) greater risk
of a self-reported fall.192
DOI: 10.3310/hta25010 HEALTH TECHNOLOGY ASSESSMENT 2021 VOL. 25 NO. 1
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Richardson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
61
Falls are thought be the main mechanism whereby increased fractures and injury occur in Z-drug users
resulting from the sedation effect. Falls also account for 90% of hip fractures.193 A study of older people
in Taiwan found that high doses of Z-drugs were associated with an increased risk of fall-related injuries
requiring hospitalisation (OR 1.24, 95% CI 1.05 to 1.48), so the lack of association between Z-drug use
and falls in our study might be considered surprising.53
To gain a potential clinical explanation we discussed this finding with our health-care advisory panel, who
suggested that a fracture would be coded in electronic records preferentially over falls as the cause for
their referral or reason for admission to hospital. This does suggest that in such cases, if a fracture is a
direct result of a fall, it could be missed in our analysis due to our reliance on the complete recording of all
required coding during contact with a GP or hospital. Alternatively, although the rate of falls may have
been similar between groups, it is possible that the nature of the falls may have been more severe or of
greater physical impact in patients taking Z-drugs.
Mortality
We observed a 34% increased mortality rate in people living with dementia prescribed Z-drugs, using
primary care data; however, no association in UK nursing homes (the WHELD trial). Other studies have
been conflicting on the effect of hypnotic use on mortality. A study of 31,140 community-dwelling people
with Alzheimer’s disease in Finland, found that BZD use was associated with increased risk of mortality
(HR 1.59, 95% CI 1.35 to 1.88), but not Z-drug use (HR 1.06, 95% CI 0.83 to 1.35), after accounting for
psychotropic drug use, comorbidities, socioeconomic status, hip fractures and stroke.75 In a US study,74
crude mortality rates were higher in people living with dementia taking hypnotics, but the association was
not tested statistically.
A systematic review and meta-analysis examining the effect of hypnotics on mortality estimated a HR of 1.73
(95% CI 0.95 to 3.16) when pooling the findings from five observational studies on Z-drug use and mortality
risk in adults.71 However, there was considerable heterogeneity (I2 = 97%), with three studies reporting no
effect and two with HRs > 3. Two of these studies used similar UK primary data to our study. One matched
2435 Z-drug initiators to two non-initiators on age, sex and general practice in the UK adult population
during 1998–2001, and reported a HR for mortality of 3.32 (95% CI 3.19 to 3.45), adjusted for age, sex,
comorbidities and co-medications, with a fairly constant risk across cumulative Z-drug prescriptions, similar
to our study.194 A further study of 4964 UK patients with pneumonia showed that patients were not at a
greater mortality risk if taking zopiclone (HR 1.11, 95% CI 0.77 to 1.60).64 Studies on Z-drug or BZD use and
mortality have been conflicting,64,70–72,194 and reported associations may simply stem from confounding.73
A large database study of US adults observed an increased mortality rate in 1.25 million BZD initiators
matched to 1.25 million patients not initiating BZDs, but not once accounting for comorbidities, concomitant
medications and health-care utilisation via propensity score matching (HR 0.89, 95% CI 0.85 to 0.94 in
those aged > 65 years).195
We found the same risk of mortality regardless of cumulative Z-drug exposure from our dose–response
analysis, suggesting that the relationship may not be causal between Z-drug use and mortality risk in this
case. We suspect that our findings are at least partially due to residual confounding by indication, whereby
the cohort of patients on Z-drugs are already at increased risk of death.73 However, it could also be speculated
that the increased risk of hip fractures in this group drives an increased mortality rate, given that older adults
have a five- to eightfold increased risk for all-cause mortality during the first 3 months after a hip fracture.196
Infections
In the primary care study we did not find a statistically significant increased risk of infections in Z-drug users
(HR 1.10, 95% CI 0.92 to 1.32 for UTI and LRTI). However, there was a suggestion of an increased infection
risk after 28 DDDs of Z-drugs were prescribed, and we observed a greater rate of antibiotic prescribing.
A Finnish study of community-dwelling adults with Alzheimer’s disease found that BZD use was associated
with increased pneumonia rates and also found a very similar Z-drug use estimate to our study (HR 1.10,
95% CI 0.84 to 1.44).67
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A meta-analysis pooled data from published or Food and Drug Administration RCTs on 2432 participants
randomised to eszopiclone and on 1626 participants randomised to zolpidem, estimated RRs of 1.48
(95% CI 1.25 to 1.74) and 1.99 (95% CI 1.21 to 3.26) for infections, respectively.63 Observational studies in
the adult population vary according to whether or not they detect an increased risk of infection with Z-drug
use. A UK study using similar primary care to our study did not detect a significant association between
Z-drug prescription and influenza-like illness-related pneumonia (HR 1.18, 95% CI 0.89 to 1.56).66 A study in
Taiwan found that patients using zolpidem with cumulative DDDs of 1–28, 29–84 and > 84 had HRs of 1.67
(95% CI 1.32 to 2.11), 1.91 (95% CI 1.47 to 2.49) and 1.62 (95% CI 1.32 to 1.98), respectively, compared
with patients who did not use zolpidem during a 3-year follow-up.65 However, there is probably residual
confounding due to accounting only for a comorbidity score and few co-medications. A later case–control
study in Taiwan in adults with chronic kidney disease found no difference in Z-drug use at the time of
pneumonia (OR 1.07, 95% CI 0.80 to 1.44).197
The mechanism whereby Z-drug use may increase infection is uncertain. It has been speculated that BZDs
may suppress immune surveillance, which is supported by animal study findings.63 Alternatively, Z-drugs
could impair the clearing of oral secretions through inhibiting the swallowing of saliva.68 Another possibility
is that Z-drugs may increase gastro-oesophageal reflux events during sleep by relaxing the lower
oesophageal sphincter.198
Our study and the supporting literature suggest that if there is a greater risk of acute infections with Z-drug
use in people living with dementia, then it is likely to be small and our study was inadequately powered to
detect it.
Cardiovascular outcomes
In the primary care study we did not find a statistically significant increased risk of ischaemic stroke (HR 1.33,
95% CI 0.85 to 2.07) or venous thromboembolism (HR 1.66, 95% CI 0.69 to 3.98) to people living with
dementia prescribed Z-drugs. However, there was a suggestion of an increased stroke risk after 28 DDDs
of Z-drugs were prescribed. A study of 45,050 community-dwelling persons with Alzheimer’s disease in
Finland reported that BZD or Z-drug prescription was associated with a 21% (95% CI 4% to 40%) increased
risk of stroke, and this risk did not vary when stratified by BZD or Z-drug use.77 However, residual confounding
is possible as they were unable to account for sleep disturbance or dementia severity. A case–control study
of adults in Taiwan found that exposure to zolpidem was associated with increased risks of ischaemic stroke
(OR 1.37, 95% CI 1.30 to 1.44), increasing further with greater exposure to zolpidem.78 They also found
that regardless of whether or not a person presented with a sleep disorder, the risk of stroke was increased
with zolpidem use (OR 1.37 without a sleep disorder and 1.41 with a sleep disorder), suggesting that the
increased risk was due to drug use and not the sleep disturbance itself.
Mechanisms for Z-drugs causing increased stroke risk are uncertain, but speculated to relate to a decrease
in local cerebral blood flow.77 However, there is evidence that sleep disturbances increase stroke risk,199
suggesting that residual confounding by indication could underlie reported associations. We are not aware
of any studies examining Z-drug use and risk of venous thromboembolism, although sleep disturbance has
been observed to be a risk factor.200
Prescriptions and health-care utilisation
In the primary care study, we found that people living with dementia who were prescribed Z-drugs were
more likely to be initiated on antipsychotics and antidepressants. In line with our findings, a study in Taiwan
reported that Z-drug users aged > 65 years were more frequently exposed to antipsychotics (OR 1.31,
95% CI 1.14 to 1.50), antidepressants (OR 1.45, 95% CI 1.28 to 1.65) and opioids (OR 2.38, 95% CI 2.07
to 2.73).53 We also found that people living with dementia who were prescribed Z-drugs had more GP and
hospital visits. This could reflect the increased risk of fractures in these patients, which would drive increased
service use. The study in Taiwan also found that older adults who were prescribed Z-drugs were at an
increased risk of fall-related injuries necessitating hospitalisation (OR 1.24, 95% CI 1.05 to 1.48).53
DOI: 10.3310/hta25010 HEALTH TECHNOLOGY ASSESSMENT 2021 VOL. 25 NO. 1
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Richardson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
63
Cognition, quality of life and sleep disturbance
In the clinical cohort studies, we found no evidence that Z-drug use impacts significantly on cognitive
function or QoL. This differs from other studies in older adults with insomnia, which reported that hypnotic
use is associated with reduced HRQoL.101,102 Greater cognitive declines have been reported in people living
with dementia taking BZDs;96 however, to the best of our knowledge, no other studies have examined the
impact of Z-drugs on cognition in people living with dementia.
Estimating the effect of Z-drug use on sleep disturbance was challenging using the observational data sets,
given that sleep scores were not measured immediately prior to Z-drug initiation; however, we observed no
impact of Z-drug use on sleep scores. This is in line with other studies, suggesting that the use of sedating
hypnotics in the general population does not improve sleep, human performance or general health, calling
into doubt their effectiveness.103,104
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Chapter 8 Conclusions
The evidence suggests an increased risk of fractures in people living with dementia and taking Z-drugs,which is cause for concern. However, our study is limited by being observational with possible residual
confounding and the many outcomes examined increases the chances of false-positive findings. In the past,
Z-drugs have been thought of as a safer alternative to BZDs for the management of sleep disturbance, and
their usage has been increasing with drives to decrease antipsychotic and BZD prescribing.110 One meta-
analysis reported a pooled estimate of a 92% increased risk of fractures with zolpidem use (RR 1.92, 95% CI
1.65 to 2.24),176 exceeding the risk reported with BZD use in some studies.55,58 Another meta-analysis
similarly found that Z-drugs were associated with higher risk of hip fracture (RR 1.90, 95% CI 1.68 to 2.13)
than BZD use (RR 1.52, 95% CI 1.37 to 1.68).61 The evidence suggests that Z-drugs may not be a safer
alternative to BZDs, particularly in the context of fractures, and that they may need to be used with
similar caution.
Furthermore, previous studies have mostly targeted the older population, whereas our study specifically
focuses the use of Z-drugs in people living with dementia, for whom fracture rate risk is already higher,
particularly hip fractures.201,202 There has previously been little evidence of the specific effects in people
living with dementia; our study has provided targeted information for this vulnerable and growing patient
group, which will be valuable to both patients and carers but also health-care professionals.62
Clinical implications
It is important to remember that the population with dementia who are taking Z-drugs is likely to include
people with more severe dementia than the population taking no medication for sleep disturbance,
so we cannot assume that the effects we observe are entirely causal. With that in mind, we estimate that
the absolute annual risks of fractures and hip fractures in the unexposed group are 7.4% and 3.2%,
respectively. These equate to annual risks of 10.2% and 5.0% for fractures and hip fractures, respectively,
when taking Z-drugs. If causal, this is equivalent to 36 and 56 people living with dementia being treated
with Z-drugs before a fracture or hip fracture occurs, respectively.
The consequences of hip fracture are particularly serious for older people with dementia. In the UK in 2011
hip fracture cases cost around £1B per year,203 with UK hospital costs alone estimated to be £14,163 and
£2139 in the first and second year following hip fracture in 2012–13.204 In England, 648,465 people have
dementia, of whom 436,416 (67.3%) are diagnosed.205 Using an estimate of the prevalence of Z-drug use in
people living with dementia in Scotland of 9% in 2011, assumes 39,277 people diagnosed with dementia
are taking Z-drugs per year.206 The additional annual hospital cost to the NHS of hip fractures for people with
a diagnosis of dementia who take Z-drugs is likely to be in the order of £11.5M, assuming £16,302 per hip
fracture for the additional 1.8% of the exposed population. The wider NHS and societal costs are likely to be
much higher.
The individual decision to prescribe a sleep drug includes balancing many complex and often competing risks
and benefits for patients and carers. Our estimated increased risks for fractures were also comparatively
small for the individual patient, so patients would need to be reviewed on a case-by-case basis to assess
whether or not their risks outweigh their individual potential benefits from Z-drugs. Further research is also
required to confirm whether or not an increased risk of fractures, hip fracture and potentially mortality
should be considered when prescribing Z-drugs. Our findings suggest that when pharmacological
management of sleep disturbance is initiated, fracture risk management plans may need to be implemented
and monitored to mitigate potential adverse health outcomes.
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Implications for further research
Further research is needed to confirm our findings of an increased fracture risk with Z-drug use in people living
with dementia. Research is needed to better understand whether or not Z-drugs increase the risk of falls, and
to understand the mechanism and type of falls, for example if the risk varies by time of day (e.g. is it through
drowsiness on waking in the morning, or falls from bed or getting to the bathroom at night). In addition,
studies should examine whether or not Z-drugs contribute by any other mechanism to increase fracture risk
(e.g. via increasing the risk of osteoporosis). Although further well-designed observational studies may provide
additional evidence, RCTs are needed to obtain a clear assessment of potential risks. A pragmatic cluster trial
that includes de-prescribing of Z-drugs as part of a multifaceted intervention, delivered in community settings,
would be feasible and could include detailed falls reporting. Our findings suggest that ideally patients should be
de-prescribed Z-drugs soon after starting them, to avoid them developing tolerance to the Z-drugs. Such trials
should also consider the informal carer burden associated with any intervention, as this is often overlooked.207
Our study highlights the lack of existing studies that routinely record outcome information on the carer(s) of
people living with dementia. It was an aim in our original protocol to examine carer outcomes, but we found
very few sufficiently large studies that recorded them. In balancing the risks and benefits of treatments for sleep
disturbance, information on any potential benefits to carers is a key piece in the decision-making that we are
missing. Other research has suggested that informal carers, in general, find medication management for people
living with dementia challenging.208 Particular challenges include monitoring for adverse events and deciding
whether or not to administer an ‘as required’ medication, such as a hypnotic. More research is needed on carer
outcomes to properly be able to weigh up the risks and benefits of Z-drugs in people living with dementia.
Further research is needed into alternative non-pharmacological therapies and whether or not they may be
appropriate as first-line treatments for sleep disturbance in dementia.209 Various studies have examined
artificial light therapy for people living with dementia, but a recent Cochrane review concluded they had no
effect on sleep activity.210 Further studies should pursue activity programmes that include outdoor light, as
some have demonstrated positive benefits on sleep. A daily structured activity programme offered outdoors
was successful in increasing sleep duration in nursing home residents with dementia.211 In addition, a
multidimensional intervention including sunlight exposure, increased activities and improved sleep hygiene
was successful in reducing daytime napping and decreased night-time awakenings in care home residents.212
Programmes with individualised social activities have demonstrated improved sleep outcomes in people living
with dementia, whereas other interventions have had mixed findings.213 However, the previous studies have
been criticised for their inconsistency and for not building on each other.213 Replication is needed in order
to be more confident about the evidence base. Previous studies have also highlighted the need for a
personalised approach to sleep disturbance interventions.213 Research into multicomponent personalised
therapies that combine light therapy and activity components may be fruitful.214 In addition, more research
is needed to better understand the differing types of sleep disturbance in dementia and their underlying
mechanisms in order to better target possible treatments.215,216
This study highlights important issues for sleep disturbance research, using UK patient electronic medical
records. To our knowledge, no previous studies have investigated the validity of sleep disturbance coding
in UK primary care data. However, our validation study identified that only 55% of people living with
dementia coded with a diagnosis or symptom of sleep disturbance had this diagnosis confirmed by their GP,
highlighting some anomalies. We also found that sleep disturbance diagnoses were unlikely to occur within
the primary care Read codes. For example, Z-drugs are prescribed exclusively for sleep disturbance, but only
18% of people living with dementia prescribed a Z-drug had a code for sleep disturbance on the date of the
Z-drug prescription. From conversations with our health-care professional panel it seems that, due to time
constraints during GP appointments, often only the primary conditions are coded. It could also potentially
be an issue of ‘diagnostic overshadowing’, whereby the fact that the patient has a diagnosis of dementia is
taking priority over the recording of other relevant diagnoses.217 This information is important for future
epidemiological research relying on sleep disturbance Read coding in medical records; without free text it
can be problematic to confirm or gain further insight into sleep disturbance issues in patients.
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Another limitation of existing standardised primary care data sets for dementia research is that they lack
information on the severity of dementia or the cognitive state of the people living with dementia. Further
linkages of large primary care databases with secondary care memory clinics and dementia services would
be beneficial to advance research in dementia.
We found that considerable bias would have affected our risk estimates if we had not included linkage to
hospital admissions data. We recommend that research on the effects of medication using UK primary care
data additionally uses linked data sets when possible.218
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Appendix 1 Coding used to identify dementia
and sleep disturbance diagnosis, and outcomes in the
primary care study
The dementia code list is the Quality and Outcomes Framework definition, excluding alcohol-induceddementia, and is very similar to lists other validated studies have used (Table 26).165
TABLE 26 Dementia code list
MedCode Read code Read term
33707 E00..00 Senile and presenile organic psychotic conditions
1916 E00..11 Senile dementia
1350 E00..12 Senile/presenile dementia
7323 E000.00 Uncomplicated senile dementia
15165 E001.00 Presenile dementia
42602 E001000 Uncomplicated presenile dementia
49513 E001100 Presenile dementia with delirium
30032 E001200 Presenile dementia with paranoia
27677 E001300 Presenile dementia with depression
38438 E001z00 Presenile dementia NOS
44674 E002.00 Senile dementia with depressive or paranoid features
18386 E002000 Senile dementia with paranoia
21887 E002100 Senile dementia with depression
41089 E002z00 Senile dementia with depressive or paranoid features NOS
37015 E003.00 Senile dementia with delirium
19477 E004.00 Arteriosclerotic dementia
8634 E004.11 Multi infarct dementia
43089 E004000 Uncomplicated arteriosclerotic dementia
56912 E004100 Arteriosclerotic dementia with delirium
55467 E004200 Arteriosclerotic dementia with paranoia
43292 E004300 Arteriosclerotic dementia with depression
42279 E004z00 Arteriosclerotic dementia NOS
15249 E00y.00 Other senile and presenile organic psychoses
51494 E00y.11 Presbyophrenic psychosis
2882 E00z.00 Senile or presenile psychoses NOS
62132 E02y100 Drug-induced dementia
25386 E041.00 Dementia in conditions EC
7664 Eu00.00 [X]Dementia in Alzheimer’s disease
49263 Eu00000 [X]Dementia in Alzheimer’s disease with early onset
25704 Eu00011 [X]Presenile dementia, Alzheimer’s type
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TABLE 26 Dementia code list (continued )
MedCode Read code Read term
60059 Eu00012 [X]Primary degen dementia, Alzheimer’s type, presenile onset
61528 Eu00013 [X]Alzheimer’s disease type 2
38678 Eu00100 [X]Dementia in Alzheimer’s disease with late onset
46762 Eu00111 [X]Alzheimer’s disease type 1
11379 Eu00112 [X]Senile dementia, Alzheimer’s type
43346 Eu00113 [X]Primary degen dementia of Alzheimer’s type, senile onset
30706 Eu00200 [X]Dementia in Alzheimer’s disease, atypical or mixed type
29386 Eu00z00 [X]Dementia in Alzheimer’s disease, unspecified
8195 Eu00z11 [X]Alzheimer’s dementia unspecified
6578 Eu01.00 [X]Vascular dementia
9565 Eu01.11 [X]Arteriosclerotic dementia
46488 Eu01000 [X]Vascular dementia of acute onset
11175 Eu01100 [X]Multi-infarct dementia
55838 Eu01111 [X]Predominantly cortical dementia
8934 Eu01200 [X]Subcortical vascular dementia
31016 Eu01300 [X]Mixed cortical and subcortical vascular dementia
55313 Eu01y00 [X]Other vascular dementia
19393 Eu01z00 [X]Vascular dementia, unspecified
12621 Eu02.00 [X]Dementia in other diseases classified elsewhere
28402 Eu02000 [X]Dementia in Pick’s disease
54106 Eu02100 [X]Dementia in Creutzfeldt-Jakob disease
37014 Eu02200 [X]Dementia in Huntington’s disease
9509 Eu02300 [X]Dementia in Parkinson’s disease
26270 Eu02500 [X]Lewy body dementia
64267 Eu02y00 [X]Dementia in other specified diseases classified elsewhere
4693 Eu02z00 [X]Unspecified dementia
48501 Eu02z11 [X]Presenile dementia NOS
47619 Eu02z12 [X]Presenile psychosis NOS
34944 Eu02z13 [X]Primary degenerative dementia NOS
4357 Eu02z14 [X]Senile dementia NOS
27935 Eu02z15 [X]Senile psychosis NOS
27759 Eu02z16 [X]Senile dementia, depressed or paranoid type
53446 Eu04100 [X]Delirium superimposed on dementia
1917 F110.00 Alzheimer’s disease
16797 F110000 Alzheimer’s disease with early onset
32057 F110100 Alzheimer’s disease with late onset
11136 F111.00 Pick’s disease
29512 F112.00 Senile degeneration of brain
7572 F116.00 Lewy body disease
59122 Fyu3000 [X]Other Alzheimer’s disease
EC, elsewhere classified; NOS, not otherwise specified.
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Sleep disturbance
The following diagnosis and referral codes are classified according to being ‘probable’ or ‘possible’
evidence of a sleep disorder in a dementia patient (Table 27).
TABLE 27 Sleep disorder codes
MedCode Read code Read term
Possible or probable sleep
disturbance
21305 1B1B.00 Cannot sleep – insomnia Probable
4537 1B1B.11 C/O – insomnia Probable
3523 1B1B000 Initial insomnia Probable
5675 1B1B100 Middle insomnia Probable
4597 1B1B200 Late insomnia Probable
7725 1B1Q.00 Poor sleep pattern Probable
30385 1BN1.00 Wanders at night Probable
94508 1BN2.00 Wanders during the day and at night Probable
42847 1BX0.00 Delayed onset of sleep Probable
60806 1BX2.00 Sleeping pattern Probable
60974 1BX9.00 Light sleep Probable
96037 8G9B.00 Sleep hygiene behaviour education Probable
95887 8HTn.00 Referral to sleep clinic Probable
12072 8Q0..00 Sleep management Probable
107666 9Ngt.00 On melatonin for sleep disorder Probable
7819 E274.00 Non-organic sleep disorders Probable
26546 E274.12 Insomnia due to nonorganic sleep disorder Probable
15515 E274100 Transient insomnia Probable
4023 E274111 Insomnia NOS Probable
16115 E274200 Persistent insomnia Probable
39990 E274B00 Repeated rapid eye movement sleep interruptions Probable
55179 E274C00 Other sleep stage or arousal dysfunction Probable
19514 E274D11 Restless sleep Probable
32987 E274E00 ‘Short-sleeper’ Probable
36745 E274F00 Inversion of sleep rhythm Probable
30626 Eu51000 [X]Nonorganic insomnia Probable
23923 Eu51200 [X]Nonorganic disorder of the sleep-wake schedule Probable
42753 Eu51211 [X]Psychogenic inversion of circadian rhythm Probable
101729 Eu51213 [X]Psychogenic inversion of sleep rhythm Probable
5921 Fy00.00 Disorders of initiating and maintaining sleep Probable
8997 Fy02.00 Disorders of the sleep-wake schedule Probable
8084 R005.00 [D]Sleep disturbances Probable
10349 R005.11 [D]Insomnia – symptom Probable
31236 R005.12 [D]Sleep rhythm problems Probable
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TABLE 27 Sleep disorder codes (continued )
MedCode Read code Read term
Possible or probable sleep
disturbance
750 R005200 [D]Insomnia NOS Probable
16447 R005500 [D]Sleep rhythm inversion Probable
15732 R005600 [D]Sleep rhythm irregular Probable
58911 R005700 [D]Sleep-wake rhythm non-24-hour cycle Probable
54458 R005800 [D]Sleep dysfunction with sleep stage disturbance Probable
22081 Z1M..00 Sleep and rest interventions Probable
101913 Z1M1.00 Disturbing sleep Probable
51397 ZV1B100 [V]Personal history of unhealthy sleep-wake schedule Probable
43397 Z7CCC00 Found wandering the streets Possible
26009 Z7CCB00 Wandering Possible
15407 R005z00 [D]Sleep dysfunction NOS Possible
41737 R005900 [D]Sleep dysfunction with arousal disturbance Possible
1244 R005000 [D]Sleep disturbance, unspecified Possible
15283 K5A2100 Menopausal sleeplessness Possible
53912 Fyu5800 [X]Other sleep disorders Possible
49601 Fy05.00 Nocturnal sleep-related eating disorder Possible
2329 Fy0..00 Sleep disorders Possible
21032 Eu51z11 [X]Emotional sleep disorder NOS Possible
22819 Eu51z00 [X]Nonorganic sleep disorder, unspecified Possible
62925 Eu51y00 [X]Other nonorganic sleep disorders Possible
17687 Eu51511 [X]Dream anxiety disorder Possible
6943 Eu51300 [X]Sleepwalking Possible
24894 Eu51.00 [X]Nonorganic sleep disorders Possible
27649 E274z00 Non-organic sleep disorder NOS Possible
8519 E274y11 Dreams Possible
43098 E274y00 Other non-organic sleep disorder Possible
48783 E274D00 Repetitive intrusions of sleep Possible
47745 E274600 Shifting sleep-work schedule Possible
7409 E274500 Jet lag syndrome Possible
36992 E274300 Transient hypersomnia Possible
16434 E274000 Unspecified non-organic sleep disorder Possible
93615 9Nk0.00 Seen in sleep clinic Possible
103449 1F9C.00 Eats at night Possible
9090 1BN..00 Wandering Possible
8123 1B1O.00 Restless Possible
56809 7065800 Sleep studies Possible
4559 3148 Sleep studies Possible
NOS, not otherwise stated.
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Exclusions: severe mental illness or Down syndrome
Patients will be excluded if they are diagnosed with a severe mental illness or Down syndrome before their
dementia diagnosis (Table 28).
TABLE 28 Patient Read codes excluded if there is a diagnosis of severe mental illness or Down syndrome
MedCode Read code Read term
1543 PJ0..00 Down’s syndrome – trisomy 21
10759 PJ0z.00 Down’s syndrome NOS
18415 PJ0..12 Trisomy 21
23489 PJ0..11 Mongolism
32010 PJ01.00 Trisomy 21, mosaicism
42701 PJ00.00 Trisomy 21, meiotic nondisjunction
61499 PJ02.00 Trisomy 21, translocation
61627 PJ0z.11 Trisomy 21 NOS
101309 PJ02.11 Partial trisomy 21 in Down’s syndrome
107919 PJ01.11 Trisomy 21, mitotic nondisjunction
15958 E1...00 Non-organic psychoses
854 E10..00 Schizophrenic disorders
32222 E100.00 Simple schizophrenia
73295 E100.11 Schizophrenia simplex
15733 E100000 Unspecified schizophrenia
3984 E100200 Chronic schizophrenic
44498 E100400 Acute exacerbation of chronic schizophrenia
58687 E100500 Schizophrenia in remission
53625 E100z00 Simple schizophrenia NOS
25546 E102.00 Catatonic schizophrenia
102427 E102500 Catatonic schizophrenia in remission
1494 E103.00 Paranoid schizophrenia
33383 E103000 Unspecified paranoid schizophrenia
31362 E103200 Chronic paranoid schizophrenia
53032 E103400 Acute exacerbation of chronic paranoid schizophrenia
36172 E103500 Paranoid schizophrenia in remission
9281 E103z00 Paranoid schizophrenia NOS
576 E104.00 Acute schizophrenic episode
96883 E105500 Latent schizophrenia in remission
38063 E106.00 Residual schizophrenia
2117 E107.00 Schizo-affective schizophrenia
58862 E107000 Unspecified schizo-affective schizophrenia
43800 E107200 Chronic schizo-affective schizophrenia
56438 E107500 Schizo-affective schizophrenia in remission
10575 E107z00 Schizo-affective schizophrenia NOS
33338 E10y000 Atypical schizophrenia
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TABLE 28 Patient Read codes excluded if there is a diagnosis of severe mental illness or Down syndrome
(continued )
MedCode Read code Read term
49761 E10yz00 Other schizophrenia NOS
8407 E10z.00 Schizophrenia NOS
14656 E11..00 Affective psychoses
8567 E11..11 Bipolar psychoses
2560 E11..12 Depressive psychoses
26161 E11..13 Manic psychoses
37070 E110.00 Manic disorder, single episode
18909 E110.11 Hypomanic psychoses
20110 E110000 Single manic episode, unspecified
14728 E110100 Single manic episode, mild
70000 E110600 Single manic episode in full remission
36611 E110z00 Manic disorder, single episode NOS
26227 E111.00 Recurrent manic episodes
19967 E111000 Recurrent manic episodes, unspecified
32295 E111400 Recurrent manic episodes, severe, with psychosis
37178 E111600 Recurrent manic episodes, in full remission
46415 E111z00 Recurrent manic episode NOS
32159 E112400 Single major depressive episode, severe, with psychosis
24171 E113400 Recurrent major depressive episodes, severe, with psychosis
3702 E114.00 Bipolar affective disorder, currently manic
17385 E114.11 Manic-depressive – now manic
35738 E114000 Bipolar affective disorder, currently manic, unspecified
36126 E114100 Bipolar affective disorder, currently manic, mild
46434 E114200 Bipolar affective disorder, currently manic, moderate
63784 E114600 Bipolar affective disorder, currently manic, full remission
4677 E115.00 Bipolar affective disorder, currently depressed
12831 E115.11 Manic-depressive – now depressed
35734 E115100 Bipolar affective disorder, currently depressed, mild
27890 E115200 Bipolar affective disorder, currently depressed, moderate
35607 E115300 Bipolar affect disorder, now depressed, severe, no psychosis
63701 E115400 Bipolar affect disorder, now depressed, severe with psychosis
57465 E115600 Bipolar affective disorder, now depressed, in full remission
37296 E115z00 Bipolar affective disorder, currently depressed, NOS
31316 E116.00 Mixed bipolar affective disorder
31535 E116000 Mixed bipolar affective disorder, unspecified
54195 E116400 Mixed bipolar affective disorder, severe, with psychosis
63651 E116500 Mixed bipolar affective disorder, partial/unspecified remission
55064 E116600 Mixed bipolar affective disorder, in full remission
63583 E116z00 Mixed bipolar affective disorder, NOS
14784 E117.00 Unspecified bipolar affective disorder
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TABLE 28 Patient Read codes excluded if there is a diagnosis of severe mental illness or Down syndrome
(continued )
MedCode Read code Read term
49763 E117000 Unspecified bipolar affective disorder, unspecified
68647 E117200 Unspecified bipolar affective disorder, moderate
24230 E117600 Unspecified bipolar affective disorder, in full remission
27986 E117z00 Unspecified bipolar affective disorder, NOS
60178 E11y.00 Other and unspecified manic-depressive psychoses
11596 E11y000 Unspecified manic-depressive psychoses
33426 E11yz00 Other and unspecified manic-depressive psychoses NOS
41992 E11z.00 Other and unspecified affective psychoses
54607 E11z000 Unspecified affective psychoses NOS
33425 E11zz00 Other affective psychosis NOS
4261 E12..00 Paranoid states
14743 E120.00 Simple paranoid state
3890 E121.00 Chronic paranoid psychosis
14971 E122.00 Paraphrenia
50868 E123.11 Folie a deux
31589 E12y.00 Other paranoid states
31455 E12yz00 Other paranoid states NOS
12771 E12z.00 Paranoid psychosis NOS
31984 E13..00 Other nonorganic psychoses
20228 E13..11 Reactive psychoses
8478 E130.00 Reactive depressive psychosis
17770 E130.11 Psychotic reactive depression
29937 E131.00 Acute hysterical psychosis
7332 E132.00 Reactive confusion
15053 E133.00 Acute paranoid reaction
24345 E134.00 Psychogenic paranoid psychosis
16333 E13y.00 Other reactive psychoses
14965 E13z.00 Nonorganic psychosis NOS
3636 E13z.11 Psychotic episode NOS
22188 E1z..00 Non-organic psychosis NOS
61969 E212200 Schizotypal personality
17281 Eu2..00 [X]Schizophrenia, schizotypal and delusional disorders
34236 Eu20.00 [X]Schizophrenia
16764 Eu20000 [X]Paranoid schizophrenia
35877 Eu20213 [X]Schizophrenic catatonia
20785 Eu20400 [X]Post-schizophrenic depression
24107 Eu20511 [X]Chronic undifferentiated schizophrenia
35848 Eu20600 [X]Simple schizophrenia
49420 Eu20y00 [X]Other schizophrenia
94001 Eu20y12 [X]Schizophreniform disord NOS
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TABLE 28 Patient Read codes excluded if there is a diagnosis of severe mental illness or Down syndrome
(continued )
MedCode Read code Read term
18053 Eu20y13 [X]Schizophrenifrm psychos NOS
34966 Eu20z00 [X]Schizophrenia, unspecified
39316 Eu21.00 [X]Schizotypal disorder
26859 Eu21.18 [X]Schizotypal personality disorder
28562 Eu22.00 [X]Persistent delusional disorders
34389 Eu22000 [X]Delusional disorder
2113 Eu22011 [X]Paranoid psychosis
11172 Eu22012 [X]Paranoid state
47947 Eu22013 [X]Paraphrenia – late
4843 Eu22015 [X]Paranoia
62405 Eu22100 [X]Delusional misidentification syndrome
55221 Eu22111 [X]Capgras syndrome
101720 Eu22300 [X]Paranoid state in remission
40981 Eu22y11 [X]Delusional dysmorphophobia
50248 Eu22y12 [X]Involutional paranoid state
49223 Eu22z00 [X]Persistent delusional disorder, unspecified
25019 Eu23.00 [X]Acute and transient psychotic disorders
36720 Eu23000 [X]Acute polymorphic psychotic disorder without symptoms
of schizophrenia
21455 Eu23012 [X]Cycloid psychosis
26143 Eu23112 [X]Cycloid psychosis with symptoms of schizophrenia
44307 Eu23300 [X]Other acute predominantly delusional psychotic disorders
27770 Eu23312 [X]Psychogenic paranoid psychosis
44503 Eu23y00 [X]Other acute and transient psychotic disorders
34168 Eu23z00 [X]Acute and transient psychotic disorder, unspecified
31707 Eu23z11 [X]Brief reactive psychosis NOS
29651 Eu23z12 [X]Reactive psychosis
105606 Eu24.11 [X]Folie a deux
11973 Eu24.13 [X]Induced psychotic disorder
9422 Eu25.00 [X]Schizoaffective disorders
33847 Eu25000 [X]Schizoaffective disorder, manic type
16905 Eu25011 [X]Schizoaffective psychosis, manic type
51903 Eu25012 [X]Schizophreniform psychosis, manic type
11055 Eu25100 [X]Schizoaffective disorder, depressive type
35274 Eu25111 [X]Schizoaffective psychosis, depressive type
33693 Eu25200 [X]Schizoaffective disorder, mixed type
37580 Eu25212 [X]Mixed schizophrenic and affective psychosis
58532 Eu25y00 [X]Other schizoaffective disorders
37681 Eu25z00 [X]Schizoaffective disorder, unspecified
33410 Eu25z11 [X]Schizoaffective psychosis NOS
101987 Eu26.00 [X]Nonorganic psychosis in remission
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TABLE 28 Patient Read codes excluded if there is a diagnosis of severe mental illness or Down syndrome
(continued )
MedCode Read code Read term
30985 Eu2y.00 [X]Other nonorganic psychotic disorders
31738 Eu2y.11 [X]Chronic hallucinatory psychosis
11244 Eu2z.00 [X]Unspecified nonorganic psychosis
694 Eu2z.11 [X]Psychosis NOS
5726 Eu3..00 [X]Mood – affective disorders
12173 Eu30.00 [X]Manic episode
9521 Eu30.11 [X]Bipolar disorder, single manic episode
2741 Eu30000 [X]Hypomania
13024 Eu30100 [X]Mania without psychotic symptoms
21065 Eu30200 [X]Mania with psychotic symptoms
48632 Eu30212 [X]Mania with mood-incongruent psychotic symptoms
32088 Eu30y00 [X]Other manic episodes
44513 Eu30z00 [X]Manic episode, unspecified
4678 Eu30z11 [X]Mania NOS
6874 Eu31.00 [X]Bipolar affective disorder
1531 Eu31.11 [X]Manic-depressive illness
6710 Eu31.12 [X]Manic-depressive psychosis
16808 Eu31000 [X]Bipolar affective disorder, current episode hypomanic
26299 Eu31100 [X]Bipolar affect disorder current episode manic wout psychotic symptoms
28277 Eu31200 [X]Bipolar affect disorder current episode manic with psychotic symptoms
16562 Eu31300 [X]Bipolar affect disorder current episode mild or moderate depress
23713 Eu31400 [X]Bipol affect disorder current episode severe depress, no psychotic symptoms
4732 Eu31500 [X]Bipolar affect disorder current episode severe depress with psychotic symptoms
27584 Eu31700 [X]Bipolar affective disorder, currently in remission
103915 Eu31900 [X]Bipolar affective disorder type II
53840 Eu31y00 [X]Other bipolar affective disorders
73924 Eu31y11 [X]Bipolar II disorder
51032 Eu31y12 [X]Recurrent manic episodes
33751 Eu31z00 [X]Bipolar affective disorder, unspecified
12099 Eu32300 [X]Severe depressive episode with psychotic symptoms
24117 Eu32311 [X]Single episode of major depression and psychotic symptoms
52678 Eu32312 [X]Single episode of psychogenic depressive psychosis
24112 Eu32313 [X]Single episode of psychotic depression
28863 Eu32314 [X]Single episode of reactive depressive psychosis
98417 Eu32800 [X]Major depression, severe with psychotic symptoms
29451 Eu33213 [X]Manic-depress psychosis, depress, no psychotic symptoms
47009 Eu33300 [X]Recurrent depress disorder current episode severe with psychotic symptoms
23731 Eu33311 [X]Endogenous depression with psychotic symptoms
28677 Eu33312 [X]Manic-depress psychosis, depressed type+ psychotic symptoms
32941 Eu33313 [X]Recurrent severe episodes/major depression+ psychotic symptom
continued
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Exclusions: sleep apnoea, sleep-related respiratory failure,
or alcohol abuse
Patients will be excluded if they are diagnosed with sleep apnoea, sleep-related respiratory failure,
or alcohol abuse on or before their index date (Table 29).
TABLE 28 Patient Read codes excluded if there is a diagnosis of severe mental illness or Down syndrome
(continued )
MedCode Read code Read term
31757 Eu33314 [X]Recurrent severe episodes/psychogenic depressive psychosis
16861 Eu33315 [X]Recurrent severe episodes of psychotic depression
37764 Eu33316 [X]Recurrent severe episodes/reactive depressive psychosis
31633 Eu3z.11 [X]Affective psychosis NOS
28168 Eu44.14 [X]Hysterical psychosis
NOS, not otherwise stated.
TABLE 29 Patients Read codes excluded if there is a diagnosis of sleep apnoea, sleep-related respiratory failure,
or alcohol abuse on or before their index date
MedCode Read code Read term
8430 1462 H/O: alcoholism
16237 E01..00 Alcoholic psychoses
16225 E010.00 Alcohol withdrawal delirium
22277 E010.11 DTs – delirium tremens
1476 E010.12 Delirium tremens
20762 E011.00 Alcohol amnestic syndrome
4500 E011000 Korsakov’s alcoholic psychosis
11106 E011100 Korsakov’s alcoholic psychosis with peripheral neuritis
18636 E011200 Wernicke-Korsakov syndrome
41920 E011z00 Alcohol amnestic syndrome NOS
54505 E012.00 Other alcoholic dementia
27342 E012.11 Alcoholic dementia NOS
37946 E012000 Chronic alcoholic brain syndrome
25110 E013.00 Alcohol withdrawal hallucinosis
57939 E014.00 Pathological alcohol intoxication
20407 E014.11 Drunkenness – pathological
30404 E015.00 Alcoholic paranoia
33670 E01y.00 Other alcoholic psychosis
2082 E01y000 Alcohol withdrawal syndrome
68111 E01yz00 Other alcoholic psychosis NOS
67651 E01z.00 Alcoholic psychosis NOS
2084 E23..00 Alcohol dependence syndrome
2081 E23..11 Alcoholism
1399 E23..12 Alcohol problem drinking
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TABLE 29 Patients Read codes excluded if there is a diagnosis of sleep apnoea, sleep-related respiratory failure,
or alcohol abuse on or before their index date (continued )
MedCode Read code Read term
5740 E230.00 Acute alcoholic intoxication in alcoholism
57714 E230.11 Alcohol dependence with acute alcoholic intoxication
40530 E230000 Acute alcoholic intoxication, unspecified, in alcoholism
56947 E230100 Continuous acute alcoholic intoxication in alcoholism
21624 E230200 Episodic acute alcoholic intoxication in alcoholism
59574 E230300 Acute alcoholic intoxication in remission, in alcoholism
36296 E230z00 Acute alcoholic intoxication in alcoholism NOS
31443 E231.00 Chronic alcoholism
37605 E231.11 Dipsomania
43193 E231000 Unspecified chronic alcoholism
24064 E231100 Continuous chronic alcoholism
26106 E231200 Episodic chronic alcoholism
24485 E231300 Chronic alcoholism in remission
33635 E231z00 Chronic alcoholism NOS
6169 E23z.00 Alcohol dependence syndrome NOS
39327 Eu10200 [X]Mental and behaviour disorder due to use alcohol: dependence syndrome
28780 Eu10211 [X]Alcohol addiction
5758 Eu10212 [X]Chronic alcoholism
69691 Eu10213 [X]Dipsomania
20514 Eu10300 [X]Mental and behaviour disorder due to use alcohol: withdrawal state
64101 Eu10400 [X]Men and behaviour disorder due alcohol: withdrawal state with delirium
17259 Eu10411 [X]Delirium tremens, alcohol induced
6467 Eu10511 [X]Alcoholic hallucinosis
65932 Eu10512 [X]Alcoholic jealousy
30162 Eu10513 [X]Alcoholic paranoia
17607 Eu10514 [X]Alcoholic psychosis NOS
11670 Eu10611 [X]Korsakov’s psychosis, alcohol induced
26323 Eu10711 [X]Alcoholic dementia NOS
37691 Eu10712 [X]Chronic alcoholic brain syndrome
47555 F11x000 Cerebral degeneration due to alcoholism
36748 F11x011 Alcoholic encephalopathy
33839 F144000 Cerebellar ataxia due to alcoholism
2925 F375.00 Alcoholic polyneuropathy
31742 F394100 Alcoholic myopathy
7603 Fy03.00 Sleep apnoea
8148 Fy03.11 Obstructive sleep apnoea
38686 Fy04.00 Sleep-related respiratory failure
59155 Fy04.11 Ondine’s curse
4915 G555.00 Alcoholic cardiomyopathy
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Exclusions: neuropathic pain
Patients will be excluded if they are diagnosed with neuropathic pain in the 12 months on or before their
index date (Table 30).
TABLE 29 Patients Read codes excluded if there is a diagnosis of sleep apnoea, sleep-related respiratory failure,
or alcohol abuse on or before their index date (continued )
MedCode Read code Read term
8363 G852300 Oesophageal varices in alcoholic cirrhosis of the liver
23779 H5B..00 Sleep apnoea
20748 H5B0.00 Obstructive sleep apnoea
4506 J153.00 Alcoholic gastritis
10691 J610.00 Alcoholic fatty liver
3216 J611.00 Acute alcoholic hepatitis
4743 J612.00 Alcoholic cirrhosis of liver
21713 J612000 Alcoholic fibrosis and sclerosis of liver
7885 J613.00 Alcoholic liver damage unspecified
17330 J613000 Alcoholic hepatic failure
7943 J617.00 Alcoholic hepatitis
7602 J617000 Chronic alcoholic hepatitis
24984 J671000 Alcohol-induced chronic pancreatitis
48539 R005100 [D]Insomnia with sleep apnoea
36301 R005300 [D]Hypersomnia with sleep apnoea
2506 R005311 [D]Sleep apnoea syndrome
20438 R005312 [D]Syndrome sleep apnoea
7123 ZV11300 [V]Personal history of
NOS, not otherwise stated.
TABLE 30 Patient Read code excluded if there is a diagnosis of neuropathic pain in the last 12 months on or before
the index date
MedCode Read code Read term
1598 A531.11 Post herpetic neuralgia
27403 A531100 Geniculate herpes zoster
7331 A531111 Ramsay – Hunt syndrome
11498 A531200 Postherpetic trigeminal neuralgia
31709 A531300 Postherpetic polyneuropathy
17180 A531500 Postzoster neuralgia
10223 A531511 Postherpetic neuralgia
28333 C373200 Familial neuropathic amyloid
7584 F300.00 Post-herpetic trigeminal neuralgia
1541 F301.00 Other specified trigeminal neuralgia
4912 F301000 Tic douloureux
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TABLE 30 Patient Read code excluded if there is a diagnosis of neuropathic pain in the last 12 months on or before
the index date (continued )
MedCode Read code Read term
6581 F301z00 Trigeminal neuralgia NOS
18016 F336000 Phantom limb syndrome with pain
23768 F337.00 Nerve root and plexus compressions in diseases EC
55335 F337000 Nerve root and plexus compressions in neoplastic disease
33604 F337100 Nerve root and plexus compressions in intervertion discussion disorder
23699 F337200 Nerve root and plexus compressions in spondylosis
24410 F337300 Nerve root and plexus compressions in other dorsopathies
56272 F374.00 Polyneuropathy in disease EC
39692 F374400 Polyneuropathy in herpes zoster
63555 F374z00 Polyneuropathy in disease NOS
93868 Fyu6A00 [X]Other mononeuropathies of upper limb
72922 Fyu6B00 [X]Other mononeuropathies of lower limb
91741 Fyu6C00 [X]Other specified mononeuropathies
107322 Fyu6D00 [X]Other mononeuropathies in diseases classified elsewhere
22238 Fyu6E00 [X]Ilio-inguinal nerve entrapment
55076 Fyu7.00 [X]Polyneuropathies & other disorder of peripheral nervous system
97449 Fyu7000 [X]Other hereditary and idiopathic neuropathies
97479 Fyu7100 [X]Other inflammatory polyneuropathies
97306 Fyu7200 [X]Other specified polyneuropathies
39858 Fyu7B00 [X]Inflammatory polyneuropathy, unspecified
35537 Fyu7C00 [X] Polyneuropathy, unspecified
99855 M271700 Neuropathic foot ulcer
49575 N035.00 Neuropathic arthropathy
8710 N035.11 Charcot’s arthropathy
36643 N035.12 Neuropathic arthritis
37759 N11y200 Neuropathic spondylopathy |
54992 N242.00 Neuralgia, neuritis and radiculitis unspecified
2284 N242000 Neuralgia unspecified
1416 N242100 Neuritis unspecified
769 N242200 Radiculitis unspecified
11544 N242300 Neuropathic pain
23839 N242z00 Neuralgia, neuritis or radiculitis NOS
41736 N242z11 Policeman’s disease
18492 SD72200 Neuropathic foot blister
EC, elsewhere classified; NOS, not otherwise stated.
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Outcomes: codes for the hospital admission and death certificate data
The following ICD-10 codes were used to identify the following outcomes in the HES or ONS data:
l fracture: S02, S12, S22, S32, S42, S52, S62, S72, S82 or S92
l hip fracture: S72.0, S27.1 or S72.2
l forearm/wrist/hand fracture: S52 or S62
l fall: W0 or W1
l acute bacterial infection: A4, B95, B96, H05.0, H60.1, K12.2, L03, J15, J18, N30.0, N30.2, N30.8,
N30.9 or N39.0
l UTI or acute LRTI: J15, J18, N30.0, N30.2, N30.8, N30.9 or N39.0
l ischaemic stroke/TIA: G45 or I63
l venous thromboembolism: I26, I80, I81 or I82
l agitation/psychosis: R44, F29, R45.1, R45.4, R45.5, R45.6 or F06.0.
Outcomes: Read codes in the Clinical Practice Research Datalink
Tables 31–38 show the Read codes that were used to identify outcomes in the CPRD.
TABLE 31 Read codes used to identify hip fractures
MedCode Read code Read term
9792 7K1D01E DHS – Dynamic hip screw primary fixation of neck of femur
12544 7K1D01F Dynamic hip screw primary fixation of neck of femur
6660 7K1L400 Closed reduction of fracture of hip
2225 S30..00 Fracture of neck of femur
1994 S30..11 Hip fracture
19387 S302011 Closed fracture of femur, greater trochanter
8648 S302400 Closed fracture of femur, intertrochanteric
8243 S305.00 Subtrochanteric fracture
24276 S30w.00 Closed fracture of unspecified proximal femur
18273 S30y.00 Closed fracture of neck of femur NOS
10570 S30y.11 Hip fracture NOS
NOS, not otherwise stated.
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TABLE 32 Read codes used to identify forearm, wrist and hand fracture
MedCode Read code Read term
8885 7K1LJ00 Closed reduction of fracture of thumb
6942 7K1LL00 Closed reduction of fracture of radius and or ulna
5951 7K1LM00 Closed reduction of fracture of wrist
1250 S224.11 Elbow fracture – closed
6825 S23..00 Fracture of radius and ulna
43570 S230.00 Closed fracture of proximal radius and ulna
7009 S230600 Closed fracture radius, head
18299 S234.00 Closed fracture of radius and ulna, lower end
203 S234.11 Wrist fracture – closed
343 S234100 Closed Colles’ fracture
1742 S234200 Closed fracture of the distal radius, unspecified
9165 S234300 Closed fracture of ulna, styloid process
40476 S234500 Closed fracture distal ulna, unspecified
199 S23B.00 Fracture of lower end of radius
137 S23x111 Fracture of radius NOS
1073 S23x211 Fracture of ulna NOS
909 S23z.00 Fracture of radius and ulna, NOS
22375 S24..00 Fracture of carpal bone
15666 S240.00 Closed fracture of carpal bone
8056 S242.00 Fracture at wrist and hand level
553 S242000 Fracture of scaphoid
993 S242200 Fracture of other metacarpal bone
25519 S250300 Closed fracture finger metacarpal shaft
12546 S250400 Closed fracture finger metacarpal neck
29111 S251.00 Open fracture of metacarpal bone(s)
441 S26..00 Fracture of one or more phalanges of hand
5260 S26..11 Finger fracture
8302 S260.00 Closed fracture of one or more phalanges of hand
24516 S260D00 Closed fracture finger proximal phalanx
7500 S262.00 Fracture of thumb
6299 S263.00 Fracture of other finger
4582 S26z.00 Fracture of one or more phalanges of hand NOS
18614 S4C..00 Fracture-dislocation or subluxation of wrist
10250 S4D..00 Fracture-dislocation/subluxation finger/thumb
NOS, not otherwise stated.
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TABLE 33 Read codes used to identify fractures (and any of the above codes for hip, forearm, wrist and hand fracture)
MedCode Read code Read term
18962 7K1L500 Closed reduction of fracture of femur
6106 7K1L800 Closed reduction of fracture of ankle
7339 7K1LA00 Closed reduction of fracture of toe
6379 7K1LF00 Closed reduction of fracture of humerus
7428 7K1LG00 Closed reduction of fracture of shoulder
5526 N331.00 Pathological fracture
30616 N331000 Pathological fracture of thoracic vertebra
17377 N331800 Osteoporosis + pathological fracture lumbar vertebrae
12673 N331900 Osteoporosis + pathological fracture thoracic vertebrae
11543 N331G00 Collapse of lumbar vertebra
45736 N331H00 Collapse of cervical vertebra due to osteoporosis
4013 N331L00 Collapse of vertebra due to osteoporosis NOS
11503 N331M00 Fragility fracture due to unspecified osteoporosis
93497 N331N00 Fragility fracture
4409 S10..12 Fracture of vertebra without spinal cord lesion
11296 S100.00 Closed fracture of cervical spine
39887 S100A00 Closed fracture axis, odontoid process
3888 S104.00 Closed fracture lumbar vertebra
8266 S104100 Closed fracture lumbar vertebra, wedge
34403 S10A100 Fracture of second cervical vertebra
9072 S10B400 Fracture of acetabulum
280 S120.00 Closed fracture rib
7831 S120000 Closed fracture of rib, unspecified
9688 S127.00 Fracture of rib
738 S13..00 Fracture or disruption of pelvis
5302 S132.00 Closed fracture pubis
7004 S132000 Closed fracture pelvis, single pubic ramus
6667 S132100 Closed fracture pelvis, multiple pubic rami – stable
46592 S132200 Closed fracture pelvis, multiple pubic rami – unstable
28702 S132z00 Closed fracture pubis NOS
28375 S13y.00 Closed fracture of pelvis NOS
11277 S150.00 Multiple fractures of thoracic spine
6195 S2...00 Fracture of upper limb
5929 S2...11 Arm fracture
483 S20..00 Fracture of clavicle
44715 S200000 Closed fracture of clavicle, unspecified part
29899 S200300 Closed fracture clavicle, lateral end
1177 S21..00 Fracture of scapula
10735 S21..11 Shoulder blade fracture
517 S22..00 Fracture of humerus
11222 S220.00 Closed fracture of the proximal humerus
44721 S220000 Closed fracture of proximal humerus, unspecified part
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TABLE 33 Read codes used to identify fractures (and any of the above codes for hip, forearm, wrist and hand fracture)
(continued )
MedCode Read code Read term
11313 S220100 Closed fracture proximal humerus, neck
11044 S220300 Closed fracture proximal humerus, greater tuberosity
6893 S224100 Closed fracture distal humerus, supracondylar
1548 S228.00 Fracture of lower end of humerus
10382 S22z.00 Fracture of humerus NOS
8891 S3...00 Fracture of lower limb
8040 S31..00 Other fracture of femur
6868 S310.00 Closed fracture of femur, shaft or unspecified part
37662 S310000 Closed fracture of femur, unspecified part
12791 S310011 Thigh fracture NOS
6320 S312100 Closed fracture of femoral condyle, unspecified
5332 S312300 Closed fracture distal femur, supracondylar
8646 S314.00 Fracture of shaft of femur
8589 S315.00 Fracture of lower end of femur
520 S31z.00 Fracture of femur, NOS
235 S32..00 Fracture of patella
27719 S334.00 Closed fracture distal tibia
6839 S339000 Closed fracture of distal fibula
78444 S33A.00 Fracture of tibia
4304 S33x100 Closed fracture of fibula, unspecified part, NOS
4572 S33x200 Closed fracture of tibia and fibula, unspecified part
325 S34..00 Fracture of ankle
7135 S342000 Closed fracture ankle, lateral malleolus, low
7317 S344.00 Closed fracture ankle, bimalleolar
169 S35..11 Metatarsal bone fracture
2710 S35..12 Tarsal bone fracture
8276 S350.00 Closed fracture of calcaneus
3937 S352700 Closed fracture metatarsal
35077 S352E00 Closed fracture metatarsal head
6062 S356.00 Fracture of metatarsal bone
2176 S362.00 Fracture of great toe
2470 S3z..00 Fracture of unspecified bones
358 S3z..11 Fracture NOS
34212 S4J2100 Closed fracture-subluxation of pelvis
NOS, not otherwise stated.
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TABLE 34 Read codes used to identify falls
MedCode Read code Read term
6008 16D..00 Falls
8694 16D1.00 Recurrent falls
46559 16D2.00 Number of falls in last year
98223 16D5.00 Fall onto outstretched hand
108062 16D6.00 Fall
5284 1B65.00 Had a collapse
1634 1B65.11 Collapse – symptom
10412 224..00 O/E – collapsed
105499 8CMW400 Falls care pathway
2307 R002.00 [D]Syncope and collapse
1812 R002300 [D]Collapse
4859 R200.12 [D] Geriatric fall
6815 TC...00 Accidental falls
384 TC...11 Fall – accidental
38818 TC42000 Fall from chair
26432 TC42100 Fall from bed
15112 TC5..00 Fall on same level from slipping, tripping or stumbling
18007 TC50.00 Fall on same level from slipping
7948 TC52.00 Fall on same level from stumbling
8730 TCy..00 Other falls
11308 TCyz.00 Other accidental fall NOS
6835 TCz..00 Accidental falls NOS
7970 U10..00 [X]Falls
43191 U10J000 [X]Other fall on same level, occurrence at home
24776 U10z.00 [X]Unspecified fall
NOS, not otherwise stated; O/E, on examination.
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TABLE 35 Read codes used to identify UTIs or LRTIs
MedCode Read code Read term
23640 H0y..00 Other specified acute respiratory infections
21113 H0z..00 Acute respiratory infection NOS
10086 H2...00 Pneumonia and influenza
1849 H21..00 Lobar (pneumococcal) pneumonia
12061 H22y200 Pneumonia – Legionella
23095 H22z.00 Bacterial pneumonia NOS
25694 H23..00 Pneumonia due to other specified organisms
886 H25..00 Bronchopneumonia due to unspecified organism
16287 H25..11 Chest infection – unspecified bronchopneumonia
572 H26..00 Pneumonia due to unspecified organism
9639 H260.00 Lobar pneumonia due to unspecified organism
3683 H261.00 Basal pneumonia due to unspecified organism
5324 H28..00 Atypical pneumonia
104121 H2B..00 Community acquired pneumonia
389 K15..00 Cystitis
15074 K150.00 Acute cystitis
1353 K155.00 Recurrent cystitis
22682 K15y000 Cystitis cystica
34645 K15y200 Abscess of bladder
1289 K190.00 Urinary tract infection, site not specified
1572 K190.11 Recurrent urinary tract infection
4453 K190100 Pyuria, site not specified
10515 K190300 Recurrent urinary tract infection
2985 K190311 Recurrent UTI
97002 K190500 Urinary tract infection
104141 K190600 Urosepsis
150 K190z00 Urinary tract infection, site not specified NOS
2465 K193.00 Urethral caruncle
507 K197.00 Haematuria
19361 K197.11 Traumatic haematuria
2784 K197200 Microscopic haematuria
7232 K197300 Frank haematuria
5264 K19y300 Pneumaturia
7733 K19y411 Urethral bleeding
NOS, not otherwise stated.
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TABLE 36 Read codes used to identify infection, including any of the codes for UTIs or LRTIs (see Table 35)
MedCode Read code Read term
885 A38..00 Septicaemia
30102 A381000 Septicaemia due to Staphylococcus aureus
10872 A384200 Escherichia coli septicaemia
23991 A384211 E. coli septicaemia
33765 A38z.00 Septicaemia NOS
2136 A38z.11 Sepsis
3382 A3B0.00 Streptococcal infection
1426 A3B1.00 Staphylococcal infection
8673 A3B1100 Meticillin resistant staphylococcus aureus
5534 A3B2.00 Pneumococcal infection
12062 A3B4.00 E. coli infection
8329 A3B4.11 E. coli infection
6856 A3B7.00 Pseudomonas infection
105405 A3BC.00 Infection due to ESBL producing bacteria
5945 A3By800 Coliform bacteria
104028 A3C..00 Sepsis
104150 A3Cy.00 Other specified sepsis
4328 F4G0100 Orbital cellulitis
8852 F501112 Cellulitis, external ear
4456 K284300 Cellulitis of scrotum
4779 M020.00 Cellulitis and abscess of finger
3527 M020000 Cellulitis and abscess of finger unspecified
3960 M021.00 Cellulitis and abscess of toe
3363 M021000 Cellulitis and abscess of toe unspecified
16536 M03..00 Other cellulitis and abscess
3998 M030.00 Cellulitis and abscess of face
10485 M030111 Cellulitis and abscess of nose
1874 M032200 Cellulitis and abscess of back
14937 M032400 Cellulitis and abscess of umbilicus
3461 M033.00 Cellulitis and abscess of arm
1415 M034.11 Cellulitis and abscess of hand
2914 M034000 Cellulitis and abscess of hand unspecified
7865 M036.00 Cellulitis and abscess of leg excluding foot
10326 M036.11 Cellulitis and abscess of leg
25890 M036300 Cellulitis and abscess of lower leg
680 M036z00 Cellulitis and abscess of leg NOS
2089 M037000 Cellulitis and abscess of foot unspecified
7328 M037200 Cellulitis in diabetic foot
309 M03z.00 Cellulitis and abscess NOS
4207 M03z000 Cellulitis NOS
943 M05..00 Impetigo
14934 M05z.00 Impetigo NOS
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TABLE 37 Read codes used to identify ischaemic stroke and TIA
MedCode Read code Read term
8837 G64..00 Cerebral arterial occlusion
5363 G64..11 CVA – cerebral artery occlusion
569 G64..12 Infarction – cerebral
6155 G64..13 Stroke due to cerebral arterial occlusion
16517 G640.00 Cerebral thrombosis
36717 G640000 Cerebral infarction due to thrombosis of cerebral arteries
3149 G64z.00 Cerebral infarction NOS
5602 G64z.12 Cerebellar infarction
10504 G64z300 Right-sided cerebral infarction
504 G65..00 Transient cerebral ischaemia
3132 G65..11 Drop attack
1433 G65..12 Transient ischaemic attack
1469 G66..00 Stroke and cerebrovascular accident unspecified
1298 G66..11 CVA unspecified
6253 G66..12 Stroke unspecified
6116 G66..13 CVA – cerebrovascular accident unspecified
51767 G666.00 Pure sensory lacunar syndrome
12833 G668.00 Right-sided CVA
CVA, cerebrovascular accident; NOS, not otherwise stated.
TABLE 38 Read codes used to identify venous thromboembolism
MedCode Read code Read term
94552 8HTm.00 Referral to deep-vein thrombosis clinic
1266 G401.00 Pulmonary embolism
9701 G401.12 Pulmonary embolus
3576 G801.00 Deep-vein phlebitis and thrombophlebitis of the leg
824 G801.11 Deep-vein thrombosis
3392 G801.13 DVT – deep-vein thrombosis
15382 G801600 Thrombophlebitis of the femoral vein
22038 G801D00 Deep-vein thrombosis of lower limb
100103 G824.00 Axillary vein thrombosis
DVT, deep-vein thrombosis.
TABLE 36 Read codes used to identify infection, including any of the codes for UTIs or LRTIs (see Table 35) (continued)
MedCode Read code Read term
6833 M08..00 Cutaneous cellulitis
1315 M081.00 [X]Cellulitis of other parts of limb
6368 M085.00 Cellulitis of leg
7684 M08B.00 Cellulitis of foot
94868 M08C.00 Cellulitis of toe
ESBL, extended-spectrum beta-lactamase; NOS, not otherwise stated.
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Appendix 2 Additional primary care
patient characteristics
TABLE 39 Further patient characteristics, comorbidities and concurrent medications, by first sleep disturbance
prescription
Characteristic








Months since dementia diagnosis,
median (IQR)a
11.6 (3.5–26.2) 12.5 (4.2–27.2) 11.6 (3.6–26.2) 11.4 (4.1–24.6)
Dementia subtype, n (%)
Alzheimer’s disease 1135 (38) 790 (42) 116 (38) 643 (39)
Vascular dementia 800 (27) 529 (28) 72 (23) 452 (27)
Other/mixed dementia 309 (10) 159 (8) 34 (11) 172 (10)
Unspecified dementia/missing 708 (24) 420 (22) 86 (28) 384 (23)
Anticholinesterase/memantine prescription
in last 90 days, n (%)
670 (23) 485 (26) 51 (17) 313 (19)
Antipsychotic prescription in last
90 days, n (%)
542 (18) 229 (12) 46 (15) 282 (17)
Agitation/psychosis history, n (%) 484 (16) 292 (15) 75 (24) 369 (22)
End-of-life care, n (%) 160 (5) 110 (6) 11 (4) 73 (4)
Sleep disturbance, n (%)
Sleep disturbance diagnosis
pre dementia
644 (22) 335 (18) 65 (21) 532 (32)
History of BZD use 718 (24) 468 (25) 89 (29) 299 (18)
History of Z-drug use 258 (9) 107 (6) 18 (6) 90 (5)
Medical history in past year
Falls, n (%) 820 (28) 440 (23) 82 (27) 473 (29)
Fractures, n (%) 309 (10) 153 (8) 27 (9) 117 (7)
Dizziness/unsteadiness, n (%) 157 (5) 101 (5) 17 (6) 108 (7)
Faints/syncope, n (%) 152 (5) 86 (5) 26 (8) 103 (6)
UTI/acute LRTI, n (%) 766 (26) 441 (23) 77 (25) 368 (22)
Influenza vaccination, n (%) 2049 (69) 1438 (76) 220 (71) 1185 (72)
Pneumonia vaccination, n (%) 138 (5) 75 (4) 13 (4) 97 (6)
Physician consultations, mean (SD) 8.4 (7.3) 8.9 (7.1) 7.8 (6.7) 7.6 (6.7)
Hospital admissions, mean (SD) 1.2 (1.9) 1.1 (1.7) 1.2 (1.8) 0.9 (2.1)
Comorbidities, n (%)
Depression 705 (24) 500 (26) 76 (25) 422 (26)
Depression symptoms 533 (18) 425 (22) 52 (17) 311 (19)
Anxiety 458 (16) 322 (17) 58 (19) 269 (16)
Anxiety symptoms 353 (12) 291 (15) 37 (12) 214 (13)
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TABLE 39 Further patient characteristics, comorbidities and concurrent medications, by first sleep disturbance
prescription (continued )
Characteristic




(N= 1898) BZD (N= 308)
No drug
(N= 1651)
Parkinson’s disease 170 (6) 72 (4) 21 (7) 103 (6)
Urinary incontinence 424 (14) 342 (18) 59 (19) 425 (26)
Benign prostatic hyperplasia 310 (11) 177 (9) 36 (12) 156 (9)
Asthma 292 (10) 212 (11) 26 (8) 143 (9)
Cancer 627 (21) 399 (21) 64 (21) 290 (18)
COPD 223 (8) 181 (10) 23 (7) 120 (7)
Osteoporosis 332 (11) 265 (14) 39 (13) 186 (11)
Other musculoskeletal conditions 363 (12) 265 (14) 51 (17) 211 (13)
Osteoarthritis/rheumatoid arthritis 1160 (39) 855 (45) 116 (38) 664 (40)
Other joint conditions 2426 (82) 1604 (85) 245 (80) 1383 (84)
Headache/migraine 578 (20) 489 (26) 44 (14) 318 (19)
Back/neck pain 1588 (54) 1198 (63) 150 (49) 876 (53)
ARMD 167 (6) 130 (7) 25 (8) 100 (6)
Cataract 832 (28) 585 (31) 84 (27) 479 (29)
Glaucoma 288 (10) 205 (11) 26 (8) 158 (10)
Retinal disorder 248 (8) 176 (9) 28 (9) 122 (7)
Diabetes 432 (15) 302 (16) 44 (14) 218 (13)
Hyperlipidaemia 380 (13) 296 (16) 40 (13) 247 (15)
Hypertension 1521 (52) 1082 (57) 151 (49) 902 (55)
Stroke/TIA 644 (22) 404 (21) 65 (21) 353 (21)
Myocardial infarction 247 (8) 159 (8) 29 (9) 157 (10)
Heart failure 254 (9) 138 (7) 27 (9) 168 (10)
Atrial fibrillation 454 (15) 273 (14) 46 (15) 235 (14)
Angina 435 (15) 279 (15) 44 (14) 278 (17)
Venous thromboembolism 189 (6) 139 (7) 24 (8) 103 (6)
Prescriptions in last 90 days
SSRI 610 (21) 341 (18) 50 (16) 298 (18)
Other antidepressant 183 (6) 93 (5) 15 (5) 122 (7)
Antiepileptic 174 (6) 135 (7) 40 (13) 91 (6)
Analgesic 1249 (42) 1049 (55) 114 (37) 590 (36)
Inhaled corticosteroid 124 (4) 108 (6) 14 (5) 71 (4)
Lipid-regulating medication 986 (33) 712 (38) 88 (29) 532 (32)
Diuretic 917 (31) 583 (31) 90 (29) 520 (31)
Beta-blocker 527 (18) 327 (17) 51 (17) 270 (16)
ACE inhibitor 574 (19) 437 (23) 62 (20) 322 (20)
Angiotensin II receptor antagonist 193 (7) 157 (8) 19 (6) 109 (7)
Calcium channel blocker 526 (18) 389 (20) 38 (12) 295 (18)
Anticoagulant 149 (5) 121 (6) 12 (4) 84 (5)
Antiplatelet 1296 (44) 814 (43) 121 (39) 753 (46)
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TABLE 39 Further patient characteristics, comorbidities and concurrent medications, by first sleep disturbance
prescription (continued )
Characteristic




(N= 1898) BZD (N= 308)
No drug
(N= 1651)
Cardiac glycoside 234 (8) 122 (6) 26 (8) 124 (8)
NSAID 209 (7) 223 (12) 32 (10) 96 (6)
Bisphosphonate 278 (9) 248 (13) 24 (8) 143 (9)
Calcium/vitamin D 514 (17) 398 (21) 44 (14) 282 (17)
Antibiotic (in last 30 days) 622 (21) 376 (20) 56 (18) 287 (17)
ACE, angiotensin-converting enzyme; COPD, chronic obstructive pulmonary disease.
TABLE 40 Adjusted ORs for the association between patient characteristics and sleep disturbance treatment
Characteristic
Z-drug Low-dose TCA BZD
ORa (95% CI) p-value ORa (95% CI) p-value ORa (95% CI) p-value
Women 0.85 (0.73 to 0.98) 0.02 1.00 (0.85 to 1.17) 0.99 0.75 (0.58 to 0.96) 0.02
Age (years), per year 1.00 (0.99 to 1.01) 0.41 0.99 (0.98 to 1.00) 0.07 1.01 (0.99 to 1.02) 0.56
Care home resident
No 1.00 1.00 1.00
Yes 1.07 (0.90 to 1.27) 0.45 1.02 (0.84 to 1.24) 0.83 0.83 (0.61 to 1.12) 0.23
Missing 1.33 (1.15 to 1.55) < 0.01 1.40 (1.18 to 1.65) < 0.01 1.23 (0.94 to 1.60) 0.13
Index date (per year) 1.05 (1.03 to 1.07) < 0.01 1.07 (1.05 to 1.09) < 0.01 0.96 (0.93 to 0.99) 0.02
Region
North East 1.00 1.00 1.00
North West 2.30 (1.49 to 3.54) < 0.01 1.46 (0.96 to 2.24) 0.08 0.65 (0.34 to 1.24) 0.19
Yorkshire and The
Humber
2.58 (1.52 to 4.40) < 0.01 1.26 (0.73 to 2.18) 0.41 1.28 (0.58 to 2.80) 0.54
East Midlands 1.25 (0.73 to 2.12) 0.41 0.61 (0.34 to 1.07) 0.09 0.73 (0.33 to 1.58) 0.42
West Midlands 1.99 (1.28 to 3.10) < 0.01 0.71 (0.45 to 1.11) 0.13 0.49 (0.24 to 0.97) 0.04
East of England 1.60 (1.02 to 2.52) 0.04 0.69 (0.44 to 1.09) 0.11 0.71 (0.36 to 1.40) 0.33
South West 2.42 (1.55 to 3.78) < 0.01 1.33 (0.86 to 2.08) 0.20 1.02 (0.53 to 1.97) 0.94
South Central 2.05 (1.30 to 3.24) < 0.01 1.72 (1.09 to 2.71) 0.02 0.94 (0.48 to 1.87) 0.87
London 2.36 (1.48 to 3.78) < 0.01 0.81 (0.50 to 1.31) 0.39 0.48 (0.23 to 1.02) 0.06
South East Coast 3.37 (2.10 to 5.41) < 0.01 0.93 (0.57 to 1.52) 0.78 1.00 (0.49 to 2.04) 1.00
IMD quintile
1 1.00 1.00 1.00
2 0.91 (0.71 to 1.15) 0.42 1.00 (0.77 to 1.29) 0.99 0.75 (0.50 to 1.12) 0.16
3 0.95 (0.75 to 1.20) 0.64 0.72 (0.55 to 0.93) 0.01 0.53 (0.35 to 0.80) < 0.01
4 0.69 (0.55 to 0.85) < 0.01 0.58 (0.46 to 0.74) < 0.01 0.63 (0.43 to 0.90) 0.01
5 0.74 (0.59 to 0.93) 0.01 0.54 (0.42 to 0.70) < 0.01 0.63 (0.43 to 0.92) 0.02
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TABLE 40 Adjusted ORs for the association between patient characteristics and sleep disturbance treatment
(continued )
Characteristic
Z-drug Low-dose TCA BZD
ORa (95% CI) p-value ORa (95% CI) p-value ORa (95% CI) p-value
Smoking status
Non-smoker 1.00 1.00 1.00
Ex-smoker 0.97 (0.82 to 1.13) 0.66 1.10 (0.93 to 1.31) 0.27 1.05 (0.79 to 1.39) 0.75
Current smoker 1.26 (0.99 to 1.60) 0.06 1.10 (0.83 to 1.44) 0.51 1.14 (0.75 to 1.72) 0.55
Missing 0.83 (0.53 to 1.32) 0.44 0.60 (0.35 to 1.02) 0.06 0.45 (0.22 to 0.95) 0.04
Alcohol user
No 1.00 1.00 1.00
Yes 0.80 (0.68 to 0.93) < 0.01 0.83 (0.70 to 0.99) 0.03 0.79 (0.59 to 1.05) 0.10
Missing 1.53 (1.12 to 2.11) 0.01 1.79 (1.27 to 2.53) < 0.01 1.33 (0.81 to 2.18) 0.27
BMI (kg/m2)
< 18.5 1.00 1.00 1.00
18.5–24.9 1.04 (0.78 to 1.38) 0.80 1.02 (0.74 to 1.41) 0.89 0.64 (0.38 to 1.10) 0.11
25–29.9 1.06 (0.78 to 1.43) 0.73 1.17 (0.84 to 1.65) 0.36 0.87 (0.49 to 1.52) 0.62
≥ 30 1.30 (0.92 to 1.84) 0.14 1.21 (0.82 to 1.78) 0.34 0.93 (0.48 to 1.80) 0.83
Missing 1.36 (1.01 to 1.83) 0.05 1.29 (0.92 to 1.81) 0.14 1.59 (0.94 to 2.68) 0.08
Systolic blood pressure (mmHg)
< 110 1.00 1.00 1.00
110–119 1.18 (0.87 to 1.60) 0.28 1.50 (1.05 to 2.13) 0.03 1.13 (0.68 to 1.88) 0.64
120–139 1.12 (0.86 to 1.45) 0.40 1.39 (1.03 to 1.88) 0.03 0.80 (0.52 to 1.24) 0.32
140–159 1.20 (0.92 to 1.57) 0.17 1.45 (1.06 to 1.99) 0.02 1.03 (0.66 to 1.62) 0.89
≥ 160 1.31 (0.95 to 1.80) 0.11 1.69 (1.17 to 2.45) 0.01 1.20 (0.70 to 2.04) 0.51




× in last 90 days




1.31 (1.10 to 1.56) < 0.01 0.81 (0.66 to 1.00) 0.05 0.78 (0.57 to 1.07) 0.12
Agitation/psychosis
history
0.64 (0.54 to 0.75) < 0.01 0.72 (0.60 to 0.87) < 0.01 1.35 (1.03 to 1.77) 0.03




0.58 (0.50 to 0.68) < 0.01 0.45 (0.37 to 0.54) < 0.01 0.46 (0.33 to 0.64) < 0.01
History of BZD use 1.63 (1.38 to 1.93) < 0.01 1.65 (1.37 to 1.99) < 0.01 1.95 (1.44 to 2.64) < 0.01
History of Z-drug use 1.83 (1.39 to 2.40) < 0.01 1.15 (0.84 to 1.58) 0.39 1.21 (0.69 to 2.11) 0.51
Medical history in past year
Falls 0.77 (0.66 to 0.91) < 0.01 0.65 (0.54 to 0.78) < 0.01 0.86 (0.65 to 1.14) 0.30
Fractures 1.44 (1.11 to 1.86) 0.01 1.08 (0.80 to 1.44) 0.62 1.00 (0.63 to 1.59) 0.99
Influenza vaccination 0.93 (0.81 to 1.07) 0.33 1.17 (0.99 to 1.38) 0.06 1.16 (0.90 to 1.50) 0.24
Pneumonia
vaccination
0.91 (0.69 to 1.21) 0.53 0.79 (0.56 to 1.09) 0.15 0.46 (0.26 to 0.83) 0.01
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TABLE 40 Adjusted ORs for the association between patient characteristics and sleep disturbance treatment
(continued )
Characteristic
Z-drug Low-dose TCA BZD
ORa (95% CI) p-value ORa (95% CI) p-value ORa (95% CI) p-value
GP consultations
0–3 1.00 1.00 1.00
4–5 1.00 (0.82 to 1.21) 0.97 1.24 (0.99 to 1.54) 0.06 1.11 (0.79 to 1.56) 0.55
6–8 1.13 (0.93 to 1.36) 0.21 1.37 (1.10 to 1.69) < 0.01 1.27 (0.91 to 1.77) 0.16
9–13 1.05 (0.86 to 1.27) 0.63 1.40 (1.13 to 1.74) < 0.01 1.05 (0.75 to 1.49) 0.77
14–77 1.28 (1.03 to 1.59) 0.03 1.57 (1.23 to 2.00) < 0.01 1.15 (0.77 to 1.70) 0.49
Hospital admissions
0 1.00 1.00 1.00
1 1.48 (1.26 to 1.74) < 0.01 1.31 (1.09 to 1.56) < 0.01 1.39 (1.05 to 1.84) 0.02
≥ 2 1.92 (1.61 to 2.30) < 0.01 1.51 (1.23 to 1.84) < 0.01 1.59 (1.16 to 2.16) < 0.01
Comorbidities
ARMD 0.97 (0.74 to 1.27) 0.82 1.34 (1.00 to 1.78) 0.05 1.42 (0.90 to 2.25) 0.13
Back/neck pain 0.97 (0.84 to 1.11) 0.62 1.17 (1.00 to 1.36) 0.05 0.59 (0.46 to 0.76) < 0.01
Migraine/headache 1.00 (0.85 to 1.18) 0.98 1.27 (1.06 to 1.52) 0.01 0.65 (0.45 to 0.92) 0.02
Depression symptoms 0.83 (0.70 to 1.00) 0.05 1.09 (0.90 to 1.32) 0.37 0.76 (0.54 to 1.09) 0.14
Hypertension 0.83 (0.72 to 0.95) 0.01 0.93 (0.80 to 1.09) 0.37 0.61 (0.48 to 0.79) < 0.01
Heart failure 0.82 (0.65 to 1.03) 0.08 0.74 (0.57 to 0.96) 0.02 0.63 (0.40 to 1.00) 0.05
Osteoporosis 0.91 (0.73 to 1.14) 0.43 0.95 (0.74 to 1.21) 0.67 1.62 (1.10 to 2.40) 0.02
Other joint conditions 0.72 (0.61 to 0.85) < 0.01 0.79 (0.65 to 0.96) 0.02 0.31 (0.24 to 0.41) < 0.01
Other musculoskeletal
conditions
1.02 (0.84 to 1.24) 0.85 1.01 (0.82 to 1.25) 0.94 1.50 (1.09 to 2.08) 0.01
Parkinson’s disease 0.89 (0.68 to 1.17) 0.41 0.57 (0.41 to 0.79) < 0.01 0.66 (0.39 to 1.11) 0.12
Urinary incontinence 0.52 (0.44 to 0.61) < 0.01 0.67 (0.56 to 0.81) < 0.01 0.72 (0.53 to 0.98) 0.04
Prescriptions in last 90 days
ACE inhibitor 1.04 (0.88 to 1.23) 0.65 1.15 (0.96 to 1.38) 0.13 1.39 (1.04 to 1.88) 0.03
Analgesic 1.29 (1.13 to 1.49) < 0.01 2.09 (1.79 to 2.44) < 0.01 1.24 (0.97 to 1.58) 0.09
Antiepileptic 0.97 (0.73 to 1.28) 0.81 1.12 (0.83 to 1.50) 0.46 3.70 (2.57 to 5.34) < 0.01
Antihistamine 0.76 (0.53 to 1.09) 0.13 0.98 (0.67 to 1.42) 0.91 1.48 (0.84 to 2.61) 0.17
Beta-blocker 1.10 (0.92 to 1.31) 0.30 0.91 (0.75 to 1.10) 0.33 1.18 (0.86 to 1.62) 0.31
Bisphosphonate 0.98 (0.77 to 1.26) 0.89 1.32 (1.01 to 1.71) 0.04 0.83 (0.52 to 1.32) 0.43
NSAID 1.22 (0.94 to 1.59) 0.14 1.73 (1.32 to 2.27) < 0.01 1.95 (1.29 to 2.94) < 0.01
SSRI 1.17 (0.99 to 1.39) 0.07 0.80 (0.66 to 0.98) 0.03 0.95 (0.69 to 1.29) 0.73
Other antidepressant 0.79 (0.61 to 1.02) 0.08 0.52 (0.38 to 0.70) < 0.01 0.78 (0.49 to 1.25) 0.30
Antibiotic (in last
30 days)
1.18 (1.00 to 1.40) 0.05 1.00 (0.83 to 1.21) 0.97 1.01 (0.75 to 1.36) 0.93
ACE, angiotensin-converting enzyme.
a Adjusted for all covariates in the table.
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Appendix 3 Additional REDIC study analyses
DOI: 10.3310/hta25010 HEALTH TECHNOLOGY ASSESSMENT 2021 VOL. 25 NO. 1
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Richardson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
115


































Anxiety total 81 (4) 1344 (63) 498 (23) 295 (14) 0.52
Agitation total 82 (4) 1448 (68) 456 (21) 232 (11) 0.21 0.55
Sleep total 82 (4) 1637 (77) 322 (15) 177 (8) 0.17 0.21 0.46
Anxiety distress 356 (16) 1197 (64) 402 (22) 263 (14) 0.87 0.25 0.19 0.53
Agitation distress 376 (17) 1212 (66) 297 (16) 333 (18) 0.23 0.91 0.23 0.30 0.64
Sleep distress 463 (21) 1278 (73) 252 (14) 216 (12) 0.17 0.23 0.91 0.21 0.26 0.52
CSDD
Agitation 33 (1) 1700 (78) 319 (15) 166 (8) 0.29 0.41 0.18 0.33 0.43 0.21 0.47
Anxiety 51 (2) 787 (36) 949 (44) 431 (20) 0.53 0.20 0.18 0.50 0.20 0.18 0.32 0.51
Difficulty falling asleep 59 (3) 1826 (85) 243 (11) 90 (4) 0.17 0.08 0.31 0.15 0.11 0.29 0.13 0.18 0.29
Frequent waking 68 (3) 1487 (69) 487 (23) 176 (8) 0.19 0.10 0.59 0.18 0.11 0.55 0.14 0.21 0.44 0.38
Waking early 54 (2) 1889 (88) 197 (9) 78 (4) 0.17 0.10 0.25 0.15 0.08 0.23 0.15 0.17 0.33 0.38 0.21
Notes
For illustration, NPI-NH ‘total’ variables are recoded from the product of ‘severity’ and ‘frequency’ variables (‘none’ = 0, ‘mild/moderate’ = 1–4, ‘severe’ = 6–12). Distress variables as coded as ‘none’ = 0,
‘mild/moderate’ = 1–2, ‘severe’ = 3–5.
CSDD variables are coded as initially recorded.
Diagonals of the correlation matrix show the Spearman’s correlation coefficient between current and previous assessments among participants. Off-diagonal elements show correlation between
concurrent values of each pair of variables.
















TABLE 42 The number and proportion of the sample who provided assessments at each follow-up interview, and the proportion of those assessed who were using each class
of medication at each visit









1 (baseline) 678 (100.0) 126 (18.6) 107 (15.8) 84 (12.4) 26 (3.8) 196 (28.9) 37 (5.5)
2 (6 months) 496 (73.2) 106 (21.4) 97 (19.6) 85 (17.1) 23 (4.6) 193 (38.9) 33 (6.7)
3 (12 months) 417 (61.5) 74 (17.7) 93 (22.3) 66 (15.8) 18 (4.3) 169 (40.5) 26 (6.2)
4 (18 months) 341 (50.3) 62 (18.2) 83 (24.3) 68 (19.9) 19 (5.6) 135 (39.6) 29 (8.5)







































































































































































TABLE 43 Multiple logistic regression showing the association between clinical and demographic factors
and dropout before the next REDIC study visit
OR (drop out at next wave) 95% CI
Hypnotic use
BZD 0.64* 0.44 to 0.92
Z-drug 1.47* 1.03 to 2.09
Antipsychotic 0.88 0.60 to 1.29
Age (years)
< 70 0.54 0.22 to 1.32
70–79 1 1.00 to 1.00
80–89 1.47 0.96 to 2.26
≥ 90 1.63* 1.03 to 2.59
Dementia severity
Minimal 1.06 0.62 to 1.81
Mild 1.15 0.78 to 1.70
Moderate 0.61** 0.43 to 0.86
Severe 1 1.00 to 1.00
Sex: female (vs. male) 1.13 0.84 to 1.53
Marital status
Unmarried 1 1.00 to 1.00
Married 1.01 0.59 to 1.73
Widowed/divorced 1 0.59 to 1.69
Neuropsychiatric symptoms
Sleep 1.12 0.96 to 1.31
Anxiety 1.22 0.98 to 1.51
Agitation 0.76 0.56 to 1.03
Disability (Lawton Physical
Self-Maintenance Scale), per unit
1.12*** 1.08 to 1.15
Years in education
< 7 0.82 0.39 to 1.74
7 0.70* 0.49 to 1.00
8–11 0.77 0.55 to 1.09
≥ 12 1 1.00 to 1.00
Type of admission
Long stay 1 1.00 to 1.00
Short stay 1.52* 1.07 to 2.15
Nursing 1.08 0.59 to 1.99
*p < 0.05, **p < 0.01, ***p < 0.001.
Note
Neuropsychiatric symptoms are coded as factor scores combining NPI-NH and CSDD assessments.
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TABLE 44 Association between clinical and demographic factors and continuing to use hypnotics at the next visit,
among those who report use at the current visit
Continuing Z-drugs Continuing BZDs Continuing antipsychotics
OR 95% CI OR 95% CI OR 95% CI
Age (years)
< 70 3.1 0.24 to 40.08 0.99 0.14 to 7.12 2.36 0.41 to 13.48
70–79 Ref Ref Ref
80–89 0.66 0.28 to 1.57 1.26 0.50 to 3.17 0.79 0.32 to 1.96
≥ 90 1.11 0.37 to 3.33 0.71 0.23 to 2.19 0.73 0.22 to 2.47
Dementia severity
Minimal 1.75 0.62 to 4.98 1.68 0.47 to 6.03 0.57 0.14 to 2.33
Mild 0.93 0.37 to 2.37 0.97 0.32 to 2.94 1.91 0.54 to 6.79
Moderate 1.9 0.81 to 4.48 1.06 0.43 to 2.57 1.24 0.52 to 2.96
Severe Ref Ref Ref
Sex: female (vs. male) 0.9 0.34 to 2.37 0.93 0.45 to 1.92 0.54 0.23 to 1.26
Marital status
Unmarried Ref Ref Ref
Married 1.02 0.21 to 4.92 0.3 0.06 to 1.46 1.38 0.48 to 3.93
Widowed/divorced 0.91 0.19 to 4.29 0.4 0.10 to 1.68 0.61 0.23 to 1.62
Hypnotic use
BZDs 2.02 0.97 to 4.20 1.19 0.58 to 2.43
Z-drugs 1.49 0.72 to 3.11 1.19 0.47 to 2.98
Antipsychotics 0.8 0.38 to 1.68 1.79 0.81 to 3.97
Neuropsychiatric symptoms
Sleep 0.88 0.58 to 1.34 0.88 0.60 to 1.29 0.89 0.59 to 1.34
Anxiety 0.98 0.59 to 1.61 0.87 0.50 to 1.50 1.15 0.66 to 1.98
Agitation 0.75 0.35 to 1.61 1.31 0.70 to 2.47 0.95 0.46 to 1.96
Disability (Lawton Physical
Self-Maintenance Scale), per unit
0.95 0.88 to 1.03 1.03 0.96 to 1.12 0.97 0.89 to 1.06
Years in education
< 7 3.92 0.55 to 28.12 1.66 0.20 to 14.06 0.35 0.04 to 3.18
7 1.67 0.63 to 4.42 0.32** 0.13 to 0.76 0.65 0.25 to 1.64
8–11 1.8 0.78 to 4.20 0.85 0.37 to 1.95 0.5 0.22 to 1.17
≥ 12 Ref Ref Ref
Type of admission
Long stay Ref Ref Ref
Short stay 0.81 0.32 to 2.03 0.56 0.26 to 1.22 1.31 0.49 to 3.49
Nursing 1.59 0.14 to 17.81 0.46 0.12 to 1.75 0.66 0.02 to 20.89
*p < 0.05, **p < 0.01, ***p < 0.001.
Ref, reference.
DOI: 10.3310/hta25010 HEALTH TECHNOLOGY ASSESSMENT 2021 VOL. 25 NO. 1
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Richardson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
TABLE 45 Association between hypnotic use status and change in outcome at previous and current visits, estimated using modelling approaches (described fully in text)
Outcome Exposure
Estimate of effect, β (95% CI)
Marginal structural model
Fixed effects model 1
(all participants)
Fixed effects model 2
(new users)
Fixed effects model 3
(mild dementia)
Sleep disturbance Z-drugs 0.20 (–0.02 to 0.43) –0.01 (–0.15 to 0.13) –0.13 (–0.38 to 0.11) 0.25 (–0.02 to 0.52)
BZDs –0.08 (–0.43 to 0.28) –0.01 (–0.15 to 0.12) –0.02 (–0.24 to 0.20) 0.03 (–0.25 to 0.32)
Antipsychotics 0.05 (–0.21 to 0.31) –0.08 (–0.24 to 0.08) –0.10 (–0.35 to 0.14) 0.21 (–0.28 to 0.70)
Agitation Z-drugs 0.01 (–0.17 to 0.19) 0.07 (–0.01 to 0.16) 0.25*** (0.11 to 0.40) 0.11 (–0.05 to 0.28)
BZDs 0.11* (0.00 to 0.21) –0.02 (–0.11 to 0.06) 0.04 (–0.08 to 0.17) 0.07 (–0.09 to 0.24)
Antipsychotics 0.13* (0.01 to 0.26) 0.07 (–0.02 to 0.16) 0.13 (–0.02 to 0.27) 0.00 (–0.29 to 0.29)
Anxiety Z-drugs 0.04 (–0.09 to 0.17) 0.01 (–0.09 to 0.12) 0.00 (–0.18 to 0.18) 0.03 (–0.17 to 0.24)
BZDs 0.09 (–0.06 to 0.24) 0.04 (–0.06 to 0.14) 0.05 (–0.10 to 0.21) 0.13 (–0.08 to 0.35)
Antipsychotics 0.32** (0.12 to 0.51) 0.11 (0.00 to 0.23) 0.21* (0.03 to 0.39) 0.22 (–0.15 to 0.59)
QUALID Z-drugs 0.18 (–1.46 to 1.82) 1.01* (0.06 to 1.96) 0.44 (–1.09 to 1.97) 0.74 (–1.03 to 2.51)
BZDs 1.04 (–0.48 to 2.56) 0.49 (–0.43 to 1.42) –0.47 (–1.85 to 0.91) 1.91* (0.18 to 3.65)
Antipsychotics 1.63* (0.30 to 2.95) 1.21* (0.20 to 2.23) 1.20 (–0.27 to 2.66) 2.52 (–0.51 to 5.54)
EQ-5D (staff rated) Z-drugs –0.02 (–0.07 to 0.03) –0.02 (–0.06 to 0.03) –0.02 (–0.10 to 0.06) –0.05 (–0.15 to 0.04)
BZDs –0.02 (–0.07 to 0.04) 0.00 (–0.05 to 0.05) 0.05 (–0.02 to 0.12) 0.00 (–0.09 to 0.09)
Antipsychotics –0.06 (–0.16 to 0.04) –0.04 (–0.09 to 0.01) –0.03 (–0.11 to 0.04) –0.13 (–0.26 to 0.01)
VAS (staff rated) Z-drugs –5.37 (–12.76 to 2.03) –6.76* (–12.73 to –0.79) –3.88 (–14.80 to 7.04) –1.11 (–14.62 to 12.41)
BZDs –4.33 (–15.73 to 7.06) –2.00 (–8.58 to 4.59) –1.74 (–12.08 to 8.59) 1.18 (–12.52 to 14.87)

















Estimate of effect, β (95% CI)
Marginal structural model
Fixed effects model 1
(all participants)
Fixed effects model 2
(new users)
Fixed effects model 3
(mild dementia)
MMSE Z-drugs –0.43 (–1.91 to 1.05) 0.10 (–0.78 to 0.99) –0.16 (–1.63 to 1.30) –1.20 (–3.50 to 1.10)
BZDs 0.28 (–1.06 to 1.61) –0.55 (–1.42 to 0.32) –0.82 (–2.16 to 0.51) 0.85 (–1.45 to 3.15)
Antipsychotics –0.44 (–1.56 to 0.68) –0.33 (–1.29 to 0.62) –0.11 (–1.53 to 1.30) –0.91 (–4.91 to 3.10)
SIB-8 Z-drugs –0.84 (–2.03 to 0.35) 0.33 (–0.38 to 1.04) 0.16 (–1.04 to 1.37) –0.14 (–1.87 to 1.59)
BZDs 0.43 (–0.55 to 1.41) –0.14 (–0.84 to 0.56) 0.20 (–0.90 to 1.30) 0.37 (–1.36 to 2.09)
Antipsychotics –0.01 (–0.91 to 0.90) 0.05 (–0.71 to 0.81) –0.27 (–1.44 to 0.90) –0.39 (–3.40 to 2.61)
CDR Z-drugs 0.51 (–0.16 to 1.18) –0.10 (–0.53 to 0.34) 0.66 (–0.07 to 1.39) –0.44 (–1.29 to 0.41)
BZDs 0.69* (0.12 to 1.26) 0.52* (0.09 to 0.95) 0.71* (0.05 to 1.37) 0.39 (–0.45 to 1.23)
Antipsychotics 0.53 (–0.19 to 1.25) 0.41 (–0.06 to 0.88) 0.31 (–0.40 to 1.01) 0.61 (–0.85 to 2.07)
Disability Z-drugs –0.07 (–0.75 to 0.60) –0.17 (–0.69 to 0.35) 0.29 (–0.60 to 1.18) –0.52 (–1.53 to 0.49)
BZDs 0.08 (–0.60 to 0.75) –0.11 (–0.62 to 0.40) –0.07 (–0.88 to 0.74) 0.26 (–0.75 to 1.27)
Antipsychotics 0.50 (–0.32 to 1.33) 0.74** (0.18 to 1.31) 0.56 (–0.30 to 1.42) 1.24 (–0.52 to 3.00)







































































































































































TABLE 46 Association between patterns of hypnotic use and change in measures of agitation, anxiety and sleep




Z-drugs No use Ref Ref Ref
Starting 0.09 (–0.06 to 0.25) –0.27 (–0.58 to 0.03) 0.02 (–0.16 to 0.20)
Stopping –0.02 (–0.14 to 0.10) –0.10 (–0.35 to 0.16) 0.03 (–0.13 to 0.20)
Continuing 0.05 (–0.02 to 0.12) –0.03 (–0.14 to 0.08) 0.00 (–0.09 to 0.08)
BZDs No use Ref Ref Ref
Starting 0.04 (–0.13 to 0.21) 0.16 (–0.11 to 0.44) 0.01 (–0.18 to 0.19)
Stopping 0.01 (–0.14 to 0.16) 0.24 (–0.02 to 0.50) 0.00 (–0.20 to 0.19)
Continuing –0.01 (–0.08 to 0.05) –0.01 (–0.13 to 0.11) 0.05 (–0.04 to 0.14)
Antipsychotics No use Ref Ref Ref
Starting 0.15 (–0.06 to 0.36) 0.02 (–0.27 to 0.31) 0.22 (–0.02 to 0.46)
Stopping 0.15 (–0.03 to 0.32) 0.15 (–0.08 to 0.38) 0.12 (–0.10 to 0.34)
Continuing –0.10* (–0.19 to –0.01) –0.10 (–0.24 to 0.05) –0.01 (–0.13 to 0.12)
*p < 0.05.
Ref, reference.
TABLE 47 Association between patterns of hypnotic use and change in measures of QoL between visits, adjusted
for baseline age, baseline cognitive function and visit number
Exposure
β (95% CI)
VAS QUALIDa EQ-5D (staff)
Z-drugs
No use Ref Ref Ref
Starting –7.13 (–16.88 to 2.61) 0.59 (–1.07 to 2.26) –0.01 (–0.08 to 0.06)
Stopping 4.02 (–3.11 to 11.15) –0.60 (–2.35 to 1.15) 0.06 (–0.01 to 0.13)
Continuing 4.04 (–0.56 to 8.64) –0.17 (–0.94 to 0.60) 0.03 (–0.01 to 0.08)
BZDs
No use Ref Ref Ref
Starting –0.67 (–12.81 to 11.48) 0.83 (–0.66 to 2.31) 0.05 (–0.02 to 0.12)
Stopping 7.38 (–7.13 to 21.89) –0.97 (–2.60 to 0.66) 0.09* (0.01 to 0.16)
Continuing –1.07 (–6.52 to 4.39) –0.23 (–0.94 to 0.48) 0.03 (0.00 to 0.07)
Antipsychotics
No use Ref Ref Ref
Starting –9.95* (–19.75 to –0.14) 1.66 (–0.19 to 3.50) –0.03 (–0.10 to 0.05)
Stopping –15.44*** (–24.03 to –6.85) 0.42 (–1.66 to 2.51) –0.03 (–0.12 to 0.05)
Continuing –5.96* (–11.74 to –0.17) –0.01 (–0.98 to 0.96) –0.01 (–0.05 to 0.04)
*p < 0.05, **p < 0.01, ***p < 0.001.
Ref, reference.
a For QUALID, higher scores correspond to lower QoL.
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FIGURE 3 Association between changing hypnotic use status between previous and current visit on SIB-8 scores
(higher scores represent better cognitive function) at previous and current visit (a, c and e). Mean scores stratified
by current hypnotic use, with inverse probability weights used to account for differences in prior predictors of hypnotic
use (b, d and f). Data from the REDIC-NH study. AP, antipsychotic. (continued )
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FIGURE 3 Association between changing hypnotic use status between previous and current visit on SIB-8 scores
(higher scores represent better cognitive function) at previous and current visit (a, c and e). Mean scores stratified
by current hypnotic use, with inverse probability weights used to account for differences in prior predictors of hypnotic
use (b, d and f). Data from the REDIC-NH study. AP, antipsychotic.
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FIGURE 4 Association between changing hypnotic use status between previous and current visit on MMSE scores
(higher scores represent better cognitive function) at previous and current visit (a, c and e). Mean scores stratified
by current hypnotic use, with inverse probability weights used to account for differences in prior predictors of
hypnotic use (b, d and f). Data from the REDIC-NH study. AP, antipsychotic. (continued )
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FIGURE 4 Association between changing hypnotic use status between previous and current visit on MMSE scores
(higher scores represent better cognitive function) at previous and current visit (a, c and e). Mean scores stratified
by current hypnotic use, with inverse probability weights used to account for differences in prior predictors of
hypnotic use (b, d and f). Data from the REDIC-NH study. AP, antipsychotic.
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FIGURE 5 Association between changing hypnotic use status between previous and current visit on mean CDR-SOB
scores (high scores represent more cognitive impairment) at previous and current visit (a, c and e). Mean scores
stratified by current hypnotic use, with inverse probability weights used to account for differences in prior
predictors of hypnotic use (b, d and f). Data from the REDIC-NH study. AP, antipsychotic. (continued )
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FIGURE 5 Association between changing hypnotic use status between previous and current visit on mean CDR-SOB
scores (high scores represent more cognitive impairment) at previous and current visit (a, c and e). Mean scores
stratified by current hypnotic use, with inverse probability weights used to account for differences in prior
predictors of hypnotic use (b, d and f). Data from the REDIC-NH study. AP, antipsychotic.
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FIGURE 6 Association between changing hypnotic use status between previous and current visit on sleep
disturbance scores at previous and current visit (a, c and e). Mean scores stratified by current hypnotic use, with
inverse probability weights used to account for differences in prior predictors of hypnotic use (b, d and f). Data
from the REDIC-NH study. AP, antipsychotic. (continued )
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FIGURE 6 Association between changing hypnotic use status between previous and current visit on sleep
disturbance scores at previous and current visit (a, c and e). Mean scores stratified by current hypnotic use, with
inverse probability weights used to account for differences in prior predictors of hypnotic use (b, d and f). Data
from the REDIC-NH study. AP, antipsychotic.
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FIGURE 7 Association between changing hypnotic use status between previous and current visit on mean agitation
scores at previous and current visit (a, c and e). Mean scores stratified by current hypnotic use, with inverse
probability weights to account for differences in prior predictors of hypnotic use (b, d and f). Data from the REDIC-NH
study. AP, antipsychotic. (continued )
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FIGURE 7 Association between changing hypnotic use status between previous and current visit on mean agitation
scores at previous and current visit (a, c and e). Mean scores stratified by current hypnotic use, with inverse
probability weights to account for differences in prior predictors of hypnotic use (b, d and f). Data from the REDIC-NH
study. AP, antipsychotic.
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FIGURE 8 Association between changing hypnotic use status between previous and current visit on mean anxiety
scores at previous and current visit (a, c and e). Mean scores stratified by current hypnotic use, with inverse
probability weights used to account for differences in prior predictors of hypnotic use (b, d and f). Data from the
REDIC-NH study. AP, antipsychotic. (continued )
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FIGURE 8 Association between changing hypnotic use status between previous and current visit on mean anxiety
scores at previous and current visit (a, c and e). Mean scores stratified by current hypnotic use, with inverse
probability weights used to account for differences in prior predictors of hypnotic use (b, d and f). Data from the
REDIC-NH study. AP, antipsychotic.
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FIGURE 9 Association between changing hypnotic use status between previous and current visit on VAS scores
(higher scores represent better QoL) at previous and current visit (a, c and e). Mean scores stratified by current hypnotic
use, with inverse probability weights used to account for differences in prior predictors of hypnotic use (b, d and f).
Data from the REDIC-NH study. AP, antipsychotic. (continued )
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FIGURE 9 Association between changing hypnotic use status between previous and current visit on VAS scores
(higher scores represent better QoL) at previous and current visit (a, c and e). Mean scores stratified by current hypnotic
use, with inverse probability weights used to account for differences in prior predictors of hypnotic use (b, d and f).
Data from the REDIC-NH study. AP, antipsychotic.
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FIGURE 10 Association between changing hypnotic use status between previous and current visit on EQ-5D scores
(higher scores represent better QoL) at previous and current visit (a, c and e). Mean scores stratified by current hypnotic
use, with inverse probability weights used to account for differences in prior predictors of hypnotic use (b, d and f).
Data from the REDIC-NH study. AP, antipsychotic. (continued )
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FIGURE 10 Association between changing hypnotic use status between previous and current visit on EQ-5D scores
(higher scores represent better QoL) at previous and current visit (a, c and e). Mean scores stratified by current hypnotic
use, with inverse probability weights used to account for differences in prior predictors of hypnotic use (b, d and f).
Data from the REDIC-NH study. AP, antipsychotic.
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FIGURE 11 Association between changing hypnotic use status between previous and current visit on QUALID scores
(higher scores represent lower QoL) at previous and current visit (a, c and e). Mean scores stratified by current
hypnotic use, with inverse probability weights used to account for differences in prior predictors of hypnotic use
(b, d and f). Data from the REDIC-NH study. AP, antipsychotic. (continued )
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FIGURE 11 Association between changing hypnotic use status between previous and current visit on QUALID scores
(higher scores represent lower QoL) at previous and current visit (a, c and e). Mean scores stratified by current
hypnotic use, with inverse probability weights used to account for differences in prior predictors of hypnotic use
(b, d and f). Data from the REDIC-NH study. AP, antipsychotic.
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FIGURE 12 Association between changing hypnotic use status between previous and current visit on disability
scores (higher scores represent more disability) at previous and current visit (a, c and e). Mean scores stratified by
current hypnotic use, with inverse probability weights used to account for differences in prior predictors of hypnotic
use (b, d and f). Data from the REDIC-NH study. AP, antipsychotic. (continued )
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FIGURE 12 Association between changing hypnotic use status between previous and current visit on disability
scores (higher scores represent more disability) at previous and current visit (a, c and e). Mean scores stratified by
current hypnotic use, with inverse probability weights used to account for differences in prior predictors of hypnotic
use (b, d and f). Data from the REDIC-NH study. AP, antipsychotic.
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FIGURE 13 (a) Distribution of SIB-8 with respect to dementia severity; (b) distribution of SIB-8 with respect to Z-drug
use; (c) mean score over REDIC visit, stratified by age group; and (d) mean score over REDIC visit, stratified by number
of visits completed.
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FIGURE 14 (a) Distribution of MMSE with respect to dementia severity; (b) distribution of MMSE with respect to Z-drug
use; (c) mean score over REDIC visit, stratified by age group; and (d) mean score over REDIC visit, stratified by number of
visits completed.
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FIGURE 15 (a) Distribution of CDR-SOB with respect to dementia severity; (b) distribution of CDR-SOB with respect
to dementia and Z-drug; (c) mean score over REDIC visit, stratified by age group; and (d) mean score over REDIC
visit, stratified number of visits completed.
DOI: 10.3310/hta25010 HEALTH TECHNOLOGY ASSESSMENT 2021 VOL. 25 NO. 1
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Richardson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
145


































































FIGURE 16 (a) Distribution of sleep disturbance with respect to dementia severity; (b) distribution of sleep
disturbance with respect to Z-drug use; (c) mean score over REDIC visit, stratified by age group; and (d) mean score
over REDIC visit, stratified by number of visits completed.
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FIGURE 17 (a) Distribution of agitation with respect to dementia severity; (b) distribution of agitation with respect
to Z-drug use; (c) mean score over REDIC visit, stratified by age group; and (d) mean score over REDIC visit,
stratified by number of visits completed.
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FIGURE 18 (a) Distribution of anxiety with respect to dementia severity; (b) distribution of anxiety with respect to
Z-drug use; (c) mean score over REDIC visit, stratified by age group; and (d) mean score over REDIC visit, stratified
by number of visits completed.
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FIGURE 19 (a) Distribution of VAS with respect to dementia severity; (b) distribution of VAS with respect to Z-drug
use; (c) mean score over REDIC visit, stratified by age group; and (d) mean score over REDIC visit, stratified by
number of visits completed.
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FIGURE 20 (a) Distribution of EQ-5D with respect to dementia severity; (b) distribution of EQ-5D with respect to Z-drug;
(c) mean score over REDIC visit, stratified by age group; and (d) mean score over REDIC visit, stratified by number of
visits completed.
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FIGURE 21 (a) Distribution of QUALID with respect to dementia severity; (b) distribution of QUALID with respect to
Z-drug use; (c) mean score over REDIC visit, stratified by age group; and (d) mean score over REDIC visit, stratified
by number of visits completed.
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FIGURE 22 (a) Distribution of disability (Lawton Physical Self-Maintenance Scale) with respect to dementia severity;
(b) distribution of disability (Lawton Physical Self-Maintenance Scale) with respect to Z-drug use; (c) mean score over
REDIC visit, stratified by age group; and (d) mean score over REDIC visit, stratified by number of visits completed.
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Appendix 4 Additional NACC study analyses
TABLE 48 The number of participants who underwent each visit and provided medication data as a percentage of
the initial cohort, and the proportion of visits at which Z-drugs, BZDs, antipsychotics and antidepressants were
reported at each
Visit number Visits, n (%) Z-drugs, n (%) BZDs, n (%) Antipsychotics, n (%) Antidepressants, n (%)
1 16,862 (100) 373 (2) 1276 (8) 1454 (9) 6742 (40)
2 9890 (59) 198 (2) 776 (8) 1070 (11) 4397 (44)
3 6375 (38) 121 (2) 557 (9) 845 (13) 3011 (47)
4 4020 (24) 75 (2) 371 (9) 637 (16) 1980 (49)
5 2441 (14) 42 (2) 265 (11) 420 (17) 1212 (50)
6 1469 (9) 26 (2) 164 (11) 275 (19) 741 (50)
7 838 (5) 12 (1) 86 (10) 167 (20) 388 (46)
8 437 (3) 8 (2) 39 (9) 87 (20) 206 (47)
9 238 (1) 2 (1) 23 (10) 50 (21) 116 (49)
10 111 (1) 1 (1) 15 (14) 28 (25) 51 (46)
11 51 (0.3) 1 (2) 8 (16) 11 (22) 26 (51)
12 19 (0.1) 0 (0) 5 (26) 6 (32) 13 (68)
TABLE 49 The number of participants continuing, stopping or starting Z-drugs, BZDs or antipsychotics between
NACC visits













Z-drugs 25,289 (100) 25,070 (99) 219 (1) 522 (100) 257 (49) 265 (51)
BZDs 23,851 (100) 22,898 (96) 953 (4) 1960 (100) 615 (31) 1345 (69)
Antipsychotics 23,102 (100) 21,658 (94) 1444 (6) 2709 (100) 572 (21) 2137 (79)
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Drug use Z-drug use 0.72 (0.43 to 1.22) 0.73 (0.38 to 1.08)
BZD use 0.93 (0.53 to 1.64) 1.01 (0.75 to 1.27)
AP use 1.26 (0.72 to 2.21) 1.48** (1.13 to 1.94)
Education Per year 0.96 (0.92 to 1.00) 0.99 (0.96 to 1.02) 0.99 (0.96 to 1.02)
Sex Female 1.00 (0.65 to 1.52) 0.86 (0.68 to 1.08) 0.81* (0.63 to 0.98)
CDR Minimal 1 (Ref) 1 (Ref) 1 (Ref)
Mild 1.41 (0.88 to 2.25) 0.92 (0.70 to 1.22) 1.30 (0.76 to 1.84)
Moderate 0.72 (0.39 to 1.34) 0.73 (0.53 to 1.02) 1.44 (0.83 to 2.05)
Severe 0.87 (0.46 to 1.67) 0.63** (0.45 to 0.88) 1.08 (0.64 to 1.52)
Age (years) < 61 1 (Ref) 1 (Ref) 1 (Ref)
61–70 0.81 (0.43 to 1.52) 0.70* (0.50 to 0.99) 1.05 (0.71 to 1.38)
71–80 0.80 (0.43 to 1.46) 0.55*** (0.40 to 0.77) 0.98 (0.68 to 1.29)
81–90 0.70 (0.36 to 1.36) 0.60** (0.41 to 0.88) 0.93 (0.61 to 1.25)
≥ 90 0.87 (0.27 to 2.78) 0.62 (0.25 to 1.52) 1.29 (–0.005 to 2.58)
Sleep None 1 (Ref) 1 (Ref) 1 (Ref)
Mild 0.97 (0.60 to 1.57) 0.78 (0.58 to 1.04) 1.21 (0.87 to 1.55)
Moderate 0.85 (0.49 to 1.47) 1.15 (0.85 to 1.57) 1.04 (0.75 to 1.34)
Severe 0.58 (0.28 to 1.22) 1.11 (0.72 to 1.73) 1.00 (0.61 to 1.39)
Anxiety None 1 (Ref) 1 (Ref) 1 (Ref)
Mild 1.23 (0.77 to 1.98) 0.98 (0.77 to 1.26) 1.06 (0.78 to 1.33)
Moderate 0.93 (0.54 to 1.62) 0.86 (0.65 to 1.14) 0.85 (0.61 to 1.09)
Severe 1.59 (0.55 to 4.59) 0.92 (0.60 to 1.40) 0.95 (0.56 to 1.35)
Agitation None 1 (Ref) 1 (Ref) 1 (Ref)
Mild 0.76 (0.47 to 1.21) 1.20 (0.93 to 1.56) 1.07 (0.81 to 1.32)
Moderate 0.76 (0.42 to 1.37) 1.03 (0.76 to 1.40) 1.50** (1.07 to 1.93)
Severe 0.92 (0.35 to 2.39) 1.18 (0.77 to 1.81) 1.30 (0.78 to 1.81)
*p < 0.05, **p < 0.01, ***p < 0.001.
AP, antipsychotic; Ref, reference.




CDR-SOB 0.21 (–0.25 to 0.67) 1.37*** (1.10 to 1.65) 1.98*** (1.73 to 2.23)
MMSE 0.17 (–0.40 to 0.75) –1.26*** (–1.76 to –0.77) –1.81*** (–2.27 to –1.36)
Animal fluency 0.25 (–0.42 to 0.92) –0.47* (–0.88 to –0.06) –0.92*** (–1.30 to –0.53)
Delta trail time –5.14 (–23.14 to 12.85) –0.87 (–11.34 to 9.60) 1.85 (–8.61 to 12.30)
Sleep 0.23** (0.08 to 0.38) 0.11** (0.03 to 0.18) 0.18*** (0.11 to 0.24)
Agitation 0.14* (0.00 to 0.28) 0.19*** (0.12 to 0.27) 0.35*** (0.28 to 0.42)
Anxiety 0.05 (–0.08 to 0.18) 0.24*** (0.16 to 0.31) 0.18*** (0.12 to 0.25)
NPI (excluding sleep) 0.13 (–0.56 to 0.82) 1.16*** (0.81 to 1.51) 1.62*** (1.29 to 1.95)
GDS –0.29 (–0.72 to 0.13) 0.00 (–0.25 to 0.26) 0.18 (–0.05 to 0.41)
Disability –0.19 (–0.93 to 0.56) 1.27*** (0.81 to 1.72) 2.25*** (1.77 to 2.72)
*p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 23 (a) Distribution of disability with respect to dementia severity; (b) distribution of disability with respect
to Z-drug use; (c) mean score over NACC visit, stratified by age group; and (d) mean score over NACC visit,
stratified by number of visits completed.
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FIGURE 24 (a) Distribution of animal fluency with respect to dementia severity; (b) distribution of animal fluency
with respect to Z-drug use; (c) mean score over NACC visit, stratified by age group; and (d) mean score over NACC
visit, stratified by number of visits completed.
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FIGURE 25 (a) Distribution of CDR-SOB with respect to dementia severity; (b) distribution of CDR-SOB with respect
to Z-drug use; (c) mean score over NACC visit, stratified by age group; and (d) mean score over NACC visit,
stratified by number of visits completed.
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FIGURE 26 (a) Distribution of delta trail time with respect to dementia severity; (b) distribution of delta trail time
with respect to Z-drug use; (c) mean score over NACC visit, stratified by age group; and (d) mean score over NACC
visit, stratified by number of visits completed.
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FIGURE 27 (a) Distribution of GDS with respect to dementia severity; (b) distribution of GDS with respect to Z-drug
use; (c) mean score over NACC visit, stratified by age group; and (d) mean score over NACC visit, stratified by
number of visits completed.
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FIGURE 28 (a) Distribution of MMSE with respect to dementia severity; (b) distribution of MMSE with respect to
Z-drug use; (c) mean score over NACC visit, stratified by age group; and (d) mean score over NACC visit, stratified
by number of visits completed.
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FIGURE 29 (a) Distribution of agitation with respect to dementia severity; (b) distribution of agitation with respect
to Z-drug use; (c) mean score over NACC visit, stratified by age group; and (d) mean score over NACC visit, stratified
by number of visits completed.
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FIGURE 30 (a) Distribution of anxiety with respect to dementia severity; (b) distribution of anxiety with respect to
Z-drug use; (c) mean score over NACC visit, stratified by age group; and (d) mean score over NACC visit, stratified
by number of visits completed.
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FIGURE 31 (a) Distribution of NPI (excluding sleep) with respect to dementia severity; (b) distribution of NPI
(excluding sleep) with respect to Z-drug use; (c) mean score over NACC visit, stratified by age group; and (d) mean
score over NACC visit, stratified by number of visits completed.
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FIGURE 32 (a) Distribution of sleep disturbance with respect to dementia severity; (b) distribution of sleep
disturbance with respect to Z-drug use; (c) mean score over NACC visit, stratified by age group; and (d) mean score
over NACC visit, stratified by number of visits completed.
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FIGURE 33 Association between changing hypnotic use status between previous and current visit on depression
(measured by GDS, higher scores represent more depressive symptoms) scores at previous and current visit (a–c).
Mean scores stratified by current hypnotic use, with inverse probability weights used to account for differences in
prior predictors of hypnotic use (d–f). (a) Z-drug; (b) BZD; and (c) antipsychotics. Data from the NACC data set.
(continued )
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FIGURE 33 Association between changing hypnotic use status between previous and current visit on depression
(measured by GDS, higher scores represent more depressive symptoms) scores at previous and current visit (a–c).
Mean scores stratified by current hypnotic use, with inverse probability weights used to account for differences in
prior predictors of hypnotic use (d–f). (a) Z-drug; (b) BZD; and (c) antipsychotics. Data from the NACC data set.
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FIGURE 34 Association between changing hypnotic use status between previous and current visit on MMSE scores
(higher scores represent better cognitive function) at previous and current visit (a–c). Mean scores stratified by
current hypnotic use, with inverse probability weights used to account for differences in prior predictors of
hypnotic use (d–f). (a) Z-drug; (b) BZD; and (c) antipsychotics. Data from the NACC data set. (continued )
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FIGURE 34 Association between changing hypnotic use status between previous and current visit on MMSE scores
(higher scores represent better cognitive function) at previous and current visit (a–c). Mean scores stratified by
current hypnotic use, with inverse probability weights used to account for differences in prior predictors of
hypnotic use (d–f). (a) Z-drug; (b) BZD; and (c) antipsychotics. Data from the NACC data set.
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FIGURE 35 Association between changing hypnotic use status between previous and current visit on anxiety scores
at previous and current visit (a–c). Mean scores stratified by current hypnotic use, with inverse probability weights
used to account for differences in prior predictors of hypnotic use (d–f). (a) Z-drug; (b) BZD; and (c) antipsychotics.
Data from the NACC data set. (continued )
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FIGURE 35 Association between changing hypnotic use status between previous and current visit on anxiety scores
at previous and current visit (a–c). Mean scores stratified by current hypnotic use, with inverse probability weights
used to account for differences in prior predictors of hypnotic use (d–f). (a) Z-drug; (b) BZD; and (c) antipsychotics.
Data from the NACC data set.
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FIGURE 36 Association between changing hypnotic use status between previous and current visit on agitation
scores at previous and current visit (a–c). Mean scores stratified by current hypnotic use, with inverse probability
weights used to account for differences in prior predictors of hypnotic use (d–f). (a) Z-drug; (b) BZD; and
(c) antipsychotics. Data from the NACC data set. (continued )
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FIGURE 36 Association between changing hypnotic use status between previous and current visit on agitation
scores at previous and current visit (a–c). Mean scores stratified by current hypnotic use, with inverse probability
weights used to account for differences in prior predictors of hypnotic use (d–f). (a) Z-drug; (b) BZD; and
(c) antipsychotics. Data from the NACC data set.
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FIGURE 37 Association between changing hypnotic use status between previous and current visit on NPI (excluding
sleep question) scores at previous and current visit (a–c). Mean scores stratified by current hypnotic use, with
inverse probability weights used to account for differences in prior predictors of hypnotic use (d–f). (a) Z-drug;
(b) BZD; and (c) antipsychotics. Data from the NACC data set. (continued )
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FIGURE 37 Association between changing hypnotic use status between previous and current visit on NPI (excluding
sleep question) scores at previous and current visit (a–c). Mean scores stratified by current hypnotic use, with
inverse probability weights used to account for differences in prior predictors of hypnotic use (d–f). (a) Z-drug;
(b) BZD; and (c) antipsychotics. Data from the NACC data set.
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FIGURE 38 Association between changing hypnotic use status between previous and current visit on NPI sleep
disturbance scores at previous and current visit (a–c). Mean scores stratified by current hypnotic use, with inverse
probability weights used to account for differences in prior predictors of hypnotic use (d–f). (a) Z-drug; (b) BZD;
and (c) antipsychotics. Data from the NACC data set. (continued )
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FIGURE 38 Association between changing hypnotic use status between previous and current visit on NPI sleep
disturbance scores at previous and current visit (a–c). Mean scores stratified by current hypnotic use, with inverse
probability weights used to account for differences in prior predictors of hypnotic use (d–f). (a) Z-drug; (b) BZD;
and (c) antipsychotics. Data from the NACC data set.
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FIGURE 39 Association between changing hypnotic use status between previous and current visit on animal fluency
scores (higher scores represent better cognitive function) at previous and current visit (a–c). Mean scores stratified
by current hypnotic use, with inverse probability weights used to account for differences in prior predictors of
hypnotic use (d–f). (a) Z-drug; (b) BZD; and (c) antipsychotics. Data from the NACC data set. (continued )
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FIGURE 39 Association between changing hypnotic use status between previous and current visit on animal fluency
scores (higher scores represent better cognitive function) at previous and current visit (a–c). Mean scores stratified
by current hypnotic use, with inverse probability weights used to account for differences in prior predictors of
hypnotic use (d–f). (a) Z-drug; (b) BZD; and (c) antipsychotics. Data from the NACC data set.
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FIGURE 40 Association between changing hypnotic use status between previous and current visit on CDR-SOB
scores (higher scores represent more cognitive impairment) at previous and current visit (a–c). Mean scores
stratified by current hypnotic use, with inverse probability weights used to account for differences in prior
predictors of hypnotic use (d–f). (a) Z-drug; (b) BZD; and (c) antipsychotics. Data from the NACC data set.
(continued )
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FIGURE 40 Association between changing hypnotic use status between previous and current visit on CDR-SOB
scores (higher scores represent more cognitive impairment) at previous and current visit (a–c). Mean scores
stratified by current hypnotic use, with inverse probability weights used to account for differences in prior
predictors of hypnotic use (d–f). (a) Z-drug; (b) BZD; and (c) antipsychotics. Data from the NACC data set.
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FIGURE 41 Association between changing hypnotic use status between previous and current visit on delta trail
time scores (higher scores represent more cognitive impairment) at previous and current visit (a–c). Mean scores
stratified by current hypnotic use, with inverse probability weights used to account for differences in prior
predictors of hypnotic use (d–f). (a) Z-drug; (b) BZD; and (c) antipsychotics. Data from the NACC data set.
(continued )
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FIGURE 41 Association between changing hypnotic use status between previous and current visit on delta trail
time scores (higher scores represent more cognitive impairment) at previous and current visit (a–c). Mean scores
stratified by current hypnotic use, with inverse probability weights used to account for differences in prior
predictors of hypnotic use (d–f). (a) Z-drug; (b) BZD; and (c) antipsychotics. Data from the NACC data set.
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FIGURE 42 Association between changing hypnotic use status between previous and current visit on disability
scores (higher scores represent more disability) at previous and current visit (a–c). Mean scores stratified by current
hypnotic use, with inverse probability weights used to account for differences in prior predictors of hypnotic use (d–f).
(a) Z-drug; (b) BZD; and (c) antipsychotics. Data from the NACC data set. (continued )
DOI: 10.3310/hta25010 HEALTH TECHNOLOGY ASSESSMENT 2021 VOL. 25 NO. 1
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Richardson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
























































FIGURE 42 Association between changing hypnotic use status between previous and current visit on disability
scores (higher scores represent more disability) at previous and current visit (a–c). Mean scores stratified by current
hypnotic use, with inverse probability weights used to account for differences in prior predictors of hypnotic use (d–f).
(a) Z-drug; (b) BZD; and (c) antipsychotics. Data from the NACC data set.
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TABLE 52 Association between hypnotic use and cognitive outcomes, estimated using fixed effects models in
specified subgroups of the NACC sample
Subgroup and
medication
Outcome, β (95% CI)
CDR-SOB MMSE Animal naming Delta trail time
All participants
Z-drugs –0.02 (–0.29 to 0.26) 0.02 (–0.54 to 0.59) –0.15 (–0.58 to 0.29) 2.25 (–7.96 to 12.45)
BZDs 1.01*** (0.86 to 1.15) –1.43*** (–1.77 to –1.08) –0.65*** (–0.91 to –0.39) 4.44 (–2.22 to 11.09)
Antipsychotics 1.87*** (1.74 to 1.99) –1.98*** (–2.27 to –1.69) –1.19*** (–1.42 to –0.95) 3.00 (–3.64 to 9.64)
New users only
Z-drugs –0.30 (–0.86 to 0.27) 0.79 (–0.34 to 1.93) –0.10 (–0.99 to 0.79) 5.02 (–17.18 to 27.23)
BZDs 1.46*** (1.20 to 1.72) –1.88*** (–2.52 to –1.24) –0.58* (–1.09 to –0.07) –8.75 (–23.25 to 5.75)
Antipsychotics 2.17*** (1.97 to 2.37) –2.58*** (–3.04 to –2.11) –1.21*** (–1.58 to –0.84) –4.14 (–16.02 to 7.74)
Mild/minimal dementia
Z-drugs 0.04 (–0.29 to 0.37) 0.15 (–0.50 to 0.81) –0.08 (–0.55 to 0.40) –0.44 (–11.03 to 10.16)
BZDs 1.11*** (0.94 to 1.28) –1.55*** (–1.94 to –1.16) –0.72*** (–1.00 to –0.43) 1.81 (–5.17 to 8.78)
Antipsychotics 2.12*** (1.97 to 2.27) –2.44*** (–2.78 to –2.09) –1.27*** (–1.54 to –1.01) 1.78 (–5.21 to 8.78)
*p < 0.05, ***p < 0.001.
TABLE 53 Association between hypnotic use and neuropsychiatric outcomes, estimated using fixed-effects models
in specified subgroups of the NACC sample
Subgroup and
medication
Outcome, β (95% CI)
Sleep Agitation Anxiety NPI excluding sleep
All participants
Z-drugs 0.18*** (0.09 to 0.27) 0.08 (–0.003 to 0.17) 0.04 (–0.05 to 0.12) 0.25 (–0.15 to 0.65)
BZDs 0.08*** (0.03 to 0.13) 0.15*** (0.10 to 0.19) 0.11*** (0.06 to 0.15) 0.88*** (0.66 to 1.09)
Antipsychotics 0.10*** (0.06 to 0.14) 0.25*** (0.21 to 0.29) 0.10*** (0.06 to 0.14) 1.28*** (1.10 to 1.46)
New users only
Z-drugs 0.28** (0.10 to 0.45) 0.31*** (0.14 to 0.48) 0.08 (–0.09 to 0.24) 0.74 (–0.05 to 1.53)
BZDs 0.12** (0.04 to 0.20) 0.22*** (0.15 to 0.30) 0.15*** (0.07 to 0.23) 1.34*** (0.97 to 1.71)
Antipsychotics 0.12*** (0.06 to 0.19) 0.30*** (0.24 to 0.36) 0.07* (0.01 to 0.13) 1.56*** (1.28 to 1.84)
Mild/minimal dementia at baseline
Z-drugs 0.16** (0.06 to 0.26) 0.04 (–0.05 to 0.14) 0.03 (–0.07 to 0.13) 0.17 (–0.27 to 0.61)
BZDs 0.10*** (0.04 to 0.15) 0.10*** (0.05 to 0.15) 0.10*** (0.05 to 0.15) 0.83*** (0.59 to 1.06)
Antipsychotics 0.12*** (0.08 to 0.17) 0.26*** (0.21 to 0.30) 0.10*** (0.05 to 0.14) 1.36*** (1.16 to 1.57)
*p < 0.05, **p < 0.01, ***p < 0.001.
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TABLE 54 Association between hypnotic use, disability and depression, estimated using fixed-effects models in
specified subgroups of the NACC sample
Subgroup and medication
Outcome, β (95% CI)
Disability Depression
All participants
Z-drugs 0.09 (–0.43 to 0.61) –0.13 (–0.39 to 0.13)
BZDs 0.68*** (0.40 to 0.96) 0.16 (–0.01 to 0.32)
Antipsychotics 1.58*** (1.35 to 1.82) 0.14 (–0.01 to 0.28)
New users only (no Z-drug, BZD or antipsychotic use at baseline)
Z-drugs –0.12 (–1.20 to 0.97) –0.44 (–0.93 to 0.06)
BZDs 0.89*** (0.39 to 1.40) –0.13 (–0.42 to 0.16)
Antipsychotics 1.37*** (0.98 to 1.75) 0.44*** (0.22 to 0.66)
Mild/minimal dementia at baseline
Z-drugs 0.17 (–0.44 to 0.79) –0.07 (–0.35 to 0.20)
BZDs 0.85*** (0.53 to 1.18) 0.13 (–0.04 to 0.30)
Antipsychotics 1.73*** (1.44 to 2.01) 0.18* (0.02 to 0.34)
*p < 0.05, ***p < 0.001.
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Appendix 5 Additional primary care study analyses
Further primary care study results tables, as referred to in the text (Tables 55–64).






Age, sex adjusted Fully adjusteda
Exposed With outcome HR 95% CI HR 95% CI
Fracture
Z-drug 2997 135 11.3 1.00 1.00
Low-dose TCA 1913 105 10.2 0.94 0.73 to 1.22 0.91 0.64 to 1.23
BZD 433 20 12.0 1.05 0.66 to 1.68 0.92 0.53 to 1.62
Hip fracture
Z-drug 2997 66 5.4 1.00 1.00
Low-dose TCA 1913 56 5.3 1.05 0.73 to 1.51 1.09 0.70 to 1.70
BZD 433 12 7.1 1.30 0.71 to 2.41 1.16 0.51 to 2.65
Forearm fracture
Z-drug 2997 27 2.2 1.00 1.00
Low-dose TCA 1913 16 1.5 0.71 0.37 to 1.36 0.89 0.43 to 1.82
BZD 433 < 5 N/A N/A
Fall
Z-drug 2888 399 37.8 1.00 1.00
Low-dose TCA 1864 286 30.4 0.90 0.77 to 1.05 0.86 0.73 to 1.02
BZD 412 65 43.9 1.16 0.89 to 1.50 1.15 0.87 to 1.54
Mortality
Z-drug 3089 355 27.8 1.00 1.00
Low-dose TCA 1942 196 18.1 0.74 0.62 to 0.88 0.75 0.62 to 0.92
BZD 443 66 36.7 1.31 1.00 to 1.73 1.22 0.90 to 1.65
Acute bacterial infection
Z-drug 2267 408 47.7 1.00 1.00
Low-dose TCA 1423 273 37.8 0.87 0.75 to 1.02 0.91 0.76 to 1.08
BZD 334 49 38.6 0.81 0.60 to 1.09 0.85 0.62 to 1.17
UTI or acute LRTI
Z-drug 2267 354 40.2 1.00 1.00
Low-dose TCA 1423 226 31.3 0.85 0.71 to 1.00 0.89 0.74 to 1.07
BZD 334 41 31.5 0.79 0.57 to 1.10 0.83 0.58 to 1.19
Ischaemic stroke/TIA
Z-drug 3045 80 6.5 1.00 1.00
Low-dose TCA 1933 50 4.7 0.77 0.54 to 1.11 0.74 0.49 to 1.12
BZD 438 15 8.7 1.35 0.78 to 2.34 1.50 0.77 to 2.91
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Age, sex adjusted Fully adjusteda
Exposed With outcome HR 95% CI HR 95% CI
Venous thromboembolism
Z-drug 3074 26 2.1 1.00 1.00
Low-dose TCA 1940 24 2.2 1.16 0.66 to 2.05 1.02 0.50 to 2.06
BZD 442 < 5 N/A N/A
Incident agitation/psychosis
Z-drug 2574 140 13.6 1.00 1.00
Low-dose TCA 1633 85 9.7 0.78 0.60 to 1.02 0.84 0.63 to 1.13
BZD 313 36 30.5 2.19 1.53 to 3.13 1.86 1.21 to 2.87
N/A, not applicable; PY, person-year.
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39, except for forearm fracture, which was
also adjusted for eye conditions (ARMD, retinal disorders and glaucoma combined), region as only five categories
(South, East, Midlands, North and London), and not adjusted for ethnicity or systolic blood pressure.
TABLE 56 Adjusted HRs for adverse events using different parametrisations of age, by sleep disturbance
medication
Outcome and sleep medication
Age parametrisation
Restricted cubic splines Fractional polynomials
HRa 95% CI HRa 95% CI
Fracture
No sleep drug 1.00 1.00
Low-dose TCA 1.12 0.80 to 1.58 1.12 0.80 to 1.58
BZD 1.37 0.70 to 2.66 1.34 0.69 to 2.61
Z-drug 1.42 1.02 to 1.98 1.42 1.02 to 1.97
Hip fracture
No sleep drug 1.00 1.00
Low-dose TCA 1.54 0.95 to 2.50 1.54 0.95 to 2.49
BZD 2.10 0.70 to 6.27 2.11 0.72 to 6.12
Z-drug 1.61 1.01 to 2.56 1.60 1.00 to 2.55
Forearm/wrist/hand fracture
No sleep drug 1.00 1.00
Low-dose TCA 1.03 0.36 to 2.96 0.99 0.35 to 2.80
Z-drug 1.37 0.58 to 3.25 1.32 0.55 to 3.17
Fall
No sleep drug 1.00 1.00
Low-dose TCA 0.84 0.69 to 1.02 0.84 0.69 to 1.02
BZD 1.05 0.75 to 1.48 1.05 0.75 to 1.47
Z-drug 1.05 0.87 to 1.25 1.05 0.87 to 1.25
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TABLE 56 Adjusted HRs for adverse events using different parametrisations of age, by sleep disturbance
medication (continued )
Outcome and sleep medication
Age parametrisation
Restricted cubic splines Fractional polynomials
HRa 95% CI HRa 95% CI
Mortality
No sleep drug 1.00 1.00
Low-dose TCA 0.89 0.72 to 1.11 0.89 0.72 to 1.11
BZD 1.39 0.98 to 1.99 1.38 0.97 to 1.97
Z-drug 1.33 1.09 to 1.63 1.34 1.10 to 1.64
Acute bacterial infection
No sleep drug 1.00 1.00
Low-dose TCA 1.00 0.83 to 1.21 1.00 0.83 to 1.21
BZD 0.84 0.59 to 1.21 0.84 0.59 to 1.21
Z-drug 1.09 0.92 to 1.29 1.09 0.92 to 1.29
UTI or acute LRTI
No sleep drug 1.00 1.00
Low-dose TCA 0.97 0.79 to 1.19 0.96 0.78 to 1.18
BZD 0.86 0.58 to 1.28 0.85 0.58 to 1.26
Z-drug 1.10 0.92 to 1.32 1.10 0.92 to 1.32
Ischaemic stroke/TIA
No sleep drug 1.00 1.00
Low-dose TCA 1.24 0.78 to 1.99 1.21 0.76 to 1.93
BZD 1.56 0.70 to 3.46 1.56 0.69 to 3.52
Z-drug 1.35 0.86 to 2.10 1.33 0.85 to 2.08
Venous thromboembolism
No sleep drug 1.00 1.00
Low-dose TCA 1.23 0.56 to 2.69 1.26 0.57 to 2.76
Z-drug 1.71 0.69 to 4.24 1.68 0.70 to 4.05
Incident agitation/psychosis
No sleep drug 1.00 1.00
Low-dose TCA 1.43 0.96 to 2.13 1.43 0.96 to 2.13
BZD 5.66 3.13 to
10.26
5.60 3.15 to 9.98
Z-drug 1.72 1.21 to 2.44 1.71 1.21 to 2.42
a Adjusted for the covariates listed in Table 2 and Appendix 2, Table 39, except for forearm fracture, which was also
adjusted for eye conditions (ARMD, retinal disorders and glaucoma combined), region as only five categories
(South, East, Midlands, North and London), and not adjusted for ethnicity or systolic blood pressure.
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TABLE 57 Adjusted HRs for adverse events, according to Z-drug PRN prescription relative to no Z-drug use
Outcome and sleep
medication
Patients (n) Age, sex adjusted Fully adjusteda
Test for
equalityExposed With outcome HR 95% CI HR 95% CI
Fracture
No sleep drug 1636 108 1.00 1.00 0.88
Z-drug PRN 488 24 1.62 1.03 to 2.56 1.47 0.86 to 2.50
Z-drug not PRN 1848 79 1.36 1.00 to 1.86 1.41 0.98 to 2.03
Hip fracture
No sleep drug 1636 47 1.00 1.00 0.45
Z-drug PRN 488 13 1.98 1.05 to 3.73 2.18 1.00 to 4.75
Z-drug not PRN 1848 38 1.48 0.93 to 2.33 1.63 0.96 to 2.77
Forearm fracture
No sleep drug 1636 18 1.00 1.00 0.36
Z-drug PRN 488 < 5 1.34 0.39 to 4.63 1.16 0.24 to 5.64
Z-drug not PRN 1848 22 2.49 1.24 to 4.99 2.42 0.92 to 6.31
Fall
No sleep drug 1506 328 1.00 1.00 0.65
Z-drug PRN 461 62 1.19 0.90 to 1.57 1.10 0.82 to 1.48
Z-drug not PRN 1786 240 1.11 0.94 to 1.33 1.03 0.84 to 1.26
Mortality
No sleep drug 1651 266 1.00 1.00 0.57
Z-drug PRN 499 51 1.47 1.21 to 1.79 1.31 1.06 to 1.63
Z-drug not PRN 1894 184 1.33 1.18 to 1.51 1.24 1.08 to 1.42
Acute bacterial infection
No sleep drug 1303 374 1.00 1.00 0.48
Z-drug PRN 354 61 1.23 0.93 to 1.62 1.15 0.85 to 1.56
Z-drug not PRN 1429 235 1.10 0.92 to 1.30 1.03 0.85 to 1.24
UTI or acute LRTI
No sleep drug 1303 328 1.00 1.00 0.45
Z-drug PRN 354 53 1.24 0.92 to 1.66 1.17 0.84 to 1.62
Z-drug not PRN 1429 199 1.08 0.90 to 1.30 1.03 0.84 to 1.26
Ischaemic stroke/TIA
No sleep drug 1640 64 1.00 1.00 0.62
Z-drug PRN 487 12 1.53 0.81 to 2.89 1.76 0.85 to 3.66
Z-drug not PRN 1877 50 1.48 1.00 to 2.19 1.46 0.86 to 2.46
Venous thromboembolism
No sleep drug 1648 22 1.00 1.00 0.58
Z-drug PRN 498 < 5 1.24 0.36 to 4.20 1.44 0.29 to 7.02
Z-drug not PRN 1889 18 1.69 0.91 to 3.16 2.18 0.81 to 5.85
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TABLE 57 Adjusted HRs for adverse events, according to Z-drug PRN prescription relative to no Z-drug use (continued)
Outcome and sleep
medication
Patients (n) Age, sex adjusted Fully adjusteda
Test for
equalityExposed With outcome HR 95% CI HR 95% CI
Incident agitation/psychosis
No sleep drug 1282 79 1.00 1.00 0.06
Z-drug PRN 408 13 1.01 0.56 to 1.82 0.92 0.47 to 1.81
Z-drug not PRN 1576 90 1.69 1.24 to 2.31 1.80 1.23 to 2.63
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39, except for forearm fracture, which was
also adjusted for eye conditions (ARMD, retinal disorders and glaucoma combined), region as only five categories
(South, East, Midlands, North and London), and not adjusted for ethnicity or systolic blood pressure.
TABLE 58 Adjusted HRs for additional medication prescriptions and IRRs for health-care utilisation, by sleep









Age, sex adjusted Fully adjusteda
HR 95% CI HR 95% CI
Additional sleep medication
Z-drug 3089 485 38.0 1.00 1.00
Low-dose TCA 1942 258 23.8 0.69 0.59 to 0.80 0.65 0.55 to 0.77
BZD 443 45 25.0 0.66 0.48 to 0.89 0.59 0.42 to 0.83
Incident antipsychotic prescription
Z-drug 2402 355 39.5 1.00 1.00
Low-dose TCA 1618 164 19.1 0.55 0.46 to 0.67 0.56 0.46 to 0.70
BZD 375 66 59.5 1.25 0.95 to 1.64 1.12 0.84 to 1.51
Incident antidepressant prescription
Z-drug 2177 236 28.3 1.00 1.00
BZD 326 31 24.4 0.86 0.59 to 1.26 1.09 0.71 to 1.68
Incident antibiotic prescription
Z-drug 2430 818 116.4 1.00 1.00
Low-dose TCA 1552 562 93.8 0.88 0.97 to 1.21 0.87 0.77 to 0.98
BZD 357 116 120.8 1.00 0.82 to 1.23 1.04 0.83 to 1.30
Number of GP visitsb
Z-drug 3089 47,259 922.5 1.00 1.00
Low-dose TCA 1942 33,530 882.1 0.97 0.92 to 1.02 0.91 0.87 to 0.95
BZD 443 6806 791.4 0.91 0.82 to 1.00 0.98 0.90 to 1.06
Number of hospital admissionsb
Z-drug 3089 4836 112.3 1.00 1.00
Low-dose TCA 1942 2991 105.2 0.94 0.85 to 1.03 0.96 0.88 to 1.05
BZD 443 614 98.9 0.88 0.76 to 1.02 0.92 0.79 to 1.06
PY, person-year.
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39.
b IRRs estimated, not HRs.
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TABLE 59 Adjusted HRs for adverse events, by approach towards missing values of BMI and care home status
Outcome and sleep medication
Approach to missing BMI and care home data
Missing category Imputation
HRa 95% CI HRa 95% CI
Fracture
No sleep drug 1.00 1.00
Low-dose TCA 1.12 0.80 to 1.58 1.08 0.77 to 1.52
BZD 1.34 0.69 to 2.61 1.38 0.72 to 2.65
Z-drug 1.40 1.01 to 1.94 1.39 1.00 to 1.93
Hip fracture
No sleep drug 1.00 1.00
Low-dose TCA 1.53 0.95 to 2.48 1.46 0.91 to 2.36
BZD 2.07 0.72 to 5.97 1.97 0.68 to 5.67
Z-drug 1.59 1.00 to 2.53 1.56 0.98 to 2.48
Forearm fracture
No sleep drug 1.00 1.00
Low-dose TCA 0.99 0.35 to 2.79 0.96 0.34 to 2.73
Z-drug 1.29 0.53 to 3.15 1.29 0.54 to 3.09
Fall
No sleep drug 1.00 1.00
Low-dose TCA 0.84 0.69 to 1.02 0.83 0.68 to 1.00
BZD 1.05 0.75 to 1.47 1.04 0.74 to 1.45
Z-drug 1.05 0.87 to 1.25 1.04 0.87 to 1.24
Mortality
No sleep drug 1.00 1.00
Low-dose TCA 0.89 0.72 to 1.11 0.92 0.74 to 1.14
BZD 1.38 0.96 to 1.96 1.46 1.04 to 2.05
Z-drug 1.34 1.10 to 1.64 1.35 1.11 to 1.65
Acute bacterial infection
No sleep drug 1.00 1.00
Low-dose TCA 1.00 0.83 to 1.21 1.00 0.83 to 1.21
BZD 0.84 0.59 to 1.21 0.86 0.60 to 1.22
Z-drug 1.09 0.92 to 1.29 1.09 0.93 to 1.29
UTI or acute LRTI
No sleep drug 1.00 1.00
Low-dose TCA 0.96 0.78 to 1.18 0.96 0.79 to 1.18
BZD 0.85 0.58 to 1.26 0.86 0.58 to 1.27
Z-drug 1.10 0.92 to 1.32 1.10 0.92 to 1.32
Ischaemic stroke/TIA
No sleep drug 1.00 1.00
Low-dose TCA 1.20 0.75 to 1.92 1.19 0.74 to 1.91
BZD 1.56 0.69 to 3.51 1.54 0.67 to 3.54
Z-drug 1.33 0.85 to 2.07 1.33 0.85 to 2.08
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TABLE 59 Adjusted HRs for adverse events, by approach towards missing values of BMI and care home status
(continued )
Outcome and sleep medication
Approach to missing BMI and care home data
Missing category Imputation
HRa 95% CI HRa 95% CI
Venous thromboembolism
No sleep drug 1.00 1.00
Low-dose TCA 1.23 0.56 to 2.69 1.27 0.59 to 2.72
Z-drug 1.66 0.69 to 3.98 1.67 0.67 to 4.13
Incident agitation/psychosis
No sleep drug 1.00 1.00
Low-dose TCA 1.43 0.96 to 2.13 1.39 0.93 to 2.06
BZD 5.61 3.14 to 10.01 5.38 2.99 to 9.68
Z-drug 1.71 1.21 to 2.42 1.71 1.22 to 2.42
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39, except for forearm fracture, which was
also adjusted for eye conditions (ARMD, retinal disorders and glaucoma combined), region as only five categories
(South, East, Midlands, North and London), and not adjusted for ethnicity or systolic blood pressure.
TABLE 60 Adjusted HRs for additional medication prescriptions and IRRs for health-care utilisation, by approach
towards missing values of BMI and care home status
Outcome and sleep drug
Approach to missing BMI and care home data
Missing category Imputation
HRa 95% CI HRa 95% CI
Additional sleep medication
No sleep drug 1.00 1.00
Low-dose TCA 0.79 0.65 to 0.97 0.79 0.65 to 0.96
BZD 0.63 0.43 to 0.93 0.63 0.43 to 0.92
Z-drug 1.13 0.95 to 1.35 1.14 0.95 to 1.36
Incident antipsychotic prescription
No sleep drug 1.00 1.00
Low-dose TCA 1.17 0.90 to 1.53 1.17 0.90 to 1.53
BZD 2.23 1.50 to 3.32 2.19 1.47 to 3.27
Z-drug 2.01 1.60 to 2.52 2.00 1.59 to 2.51
Incident antidepressant prescription
No sleep drug 1.00 1.00
BZD 1.77 1.02 to 3.09 1.73 1.00 to 2.98
Z-drug 2.05 1.56 to 2.68 2.05 1.56 to 2.68
continued
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TABLE 60 Adjusted HRs for additional medication prescriptions and IRRs for health-care utilisation, by approach
towards missing values of BMI and care home status (continued )
Outcome and sleep drug
Approach to missing BMI and care home data
Missing category Imputation
HRa 95% CI HRa 95% CI
Incident antibiotic prescription
No sleep drug 1.00 1.00
Low-dose TCA 1.13 0.99 to 1.29 1.14 0.99 to 1.30
BZD 1.35 1.06 to 1.71 1.36 1.07 to 1.72
Z-drug 1.26 1.12 to 1.42 1.26 1.12 to 1.43
Number of GP visitsb
No sleep drug 1.00 1.00
Low-dose TCA 1.01 0.96 to 1.07 1.01 0.96 to 1.07
BZD 1.05 0.97 to 1.14 1.05 0.97 to 1.14
Z-drug 1.14 1.08 to 1.19 1.14 1.09 to 1.20
Number of hospital admissionsb
No sleep drug 1.00 1.00
Low-dose TCA 1.04 0.95 to 1.15 1.03 0.94 to 1.14
BZD 0.97 0.84 to 1.13 0.95 0.82 to 1.11
Z-drug 1.12 1.03 to 1.21 1.11 1.02 to 1.21
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39.
b IRRs estimated, not HRs.
TABLE 61 Adjusted HRs for adverse events, by sleep disturbance medication relative to no medication in patients
diagnosed with sleep disturbance (excluding mention of a satisfactory sleep pattern)
Outcome and sleep medication
Age, sex adjusted Fully adjusteda
HR 95% CI HR 95% CI
Fracture
No sleep drug 1.00 1.00
Low-dose TCA 1.22 0.88 to 1.70 1.00 0.66 to 1.52
BZD 1.31 0.76 to 2.26 1.62 0.70 to 3.75
Z-drug 1.32 0.95 to 1.84 1.34 0.90 to 1.99
Hip fracture
No sleep drug 1.00 1.00
Low-dose TCA 1.35 0.85 to 2.14 1.17 0.64 to 2.14
Z-drug 1.28 0.81 to 2.02 1.33 0.77 to 2.32
Forearm/wrist/hand fracture
No sleep drug 1.00 1.00
Low-dose TCA 0.86 0.39 to 1.89 0.94 0.30 to 2.90
Z-drug 1.45 0.65 to 3.23 1.24 0.43 to 3.60
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TABLE 61 Adjusted HRs for adverse events, by sleep disturbance medication relative to no medication in patients
diagnosed with sleep disturbance (excluding mention of a satisfactory sleep pattern) (continued )
Outcome and sleep medication
Age, sex adjusted Fully adjusteda
HR 95% CI HR 95% CI
Fall
No sleep drug 1.00 1.00
Low-dose TCA 0.83 0.69 to 1.00 0.72 0.58 to 0.90
BZD 1.06 0.79 to 1.44 0.88 0.60 to 1.30
Z-drug 0.90 0.75 to 1.07 0.87 0.71 to 1.07
Mortality
No sleep drug 1.00 1.00
Low-dose TCA 0.87 0.70 to 1.08 0.78 0.61 to 1.01
BZD 1.51 1.09 to 2.08 0.98 0.64 to 1.52
Z-drug 1.23 1.00 to 1.51 1.09 0.86 to 1.38
Acute bacterial infection
No sleep drug 1.00 1.00
Low-dose TCA 0.91 0.76 to 1.10 0.92 0.74 to 1.15
BZD 0.78 0.56 to 1.10 0.68 0.43 to 1.06
Z-drug 1.06 0.89 to 1.27 0.98 0.80 to 1.19
UTI or acute LRTI
No sleep drug 1.00 1.00
Low-dose TCA 0.86 0.70 to 1.05 0.86 0.68 to 1.09
BZD 0.82 0.57 to 1.17 0.76 0.46 to 1.23
Z-drug 1.04 0.86 to 1.26 0.97 0.79 to 1.19
Ischaemic stroke/TIA
No sleep drug 1.00 1.00
Low-dose TCA 0.99 0.63 to 1.56 1.11 0.64 to 1.93
BZD 1.66 0.84 to 3.28 1.38 0.22 to 8.71
Z-drug 1.42 0.91 to 2.22 1.17 0.68 to 2.03
Venous thromboembolism
No sleep drug 1.00 1.00
Low-dose TCA 1.16 0.62 to 2.18 0.93 0.39 to 2.17
Z-drug 1.16 0.60 to 2.22 1.37 0.61 to 3.10
Incident agitation/psychosis
No sleep drug 1.00 1.00
Low-dose TCA 0.89 0.63 to 1.26 1.04 0.68 to 1.58
BZD 2.64 1.65 to 4.21 4.11 2.15 to 7.84
Z-drug 1.06 0.77 to 1.45 1.10 0.77 to 1.56
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39, except for hip fracture and forearm
fracture outcomes, which were also adjusted for eye conditions (ARMD, retinal disorders and glaucoma combined),
region as only five categories (South, East, Midlands, North and London), and not adjusted for ethnicity or systolic blood
pressure; and for ischaemic stroke/TIA and venous thromboembolism outcomes, which were also adjusted for eye
conditions (ARMD, retinal disorders and glaucoma combined), and not adjusted for region, ethnicity, systolic blood
pressure or BMI.
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TABLE 62 Adjusted HRs for additional medication prescriptions and IRRs for health-care utilisation, by sleep
disturbance medication relative to patients diagnosed with sleep disturbance (excluding mention of satisfactory
sleep pattern)
Outcome and sleep drug
Age, sex adjusted Fully adjusteda
HR 95% CI HR 95% CI
Additional sleep medication
No sleep drug 1.00 1.00
Low-dose TCA 0.58 0.48 to 0.69 0.56 0.46 to 0.69
BZD 0.50 0.36 to 0.70 0.45 0.30 to 0.66
Z-drug 0.82 0.70 to 0.96 0.80 0.67 to 0.96
Incident antipsychotic prescription
No sleep drug 1.00 1.00
Low-dose TCA 0.76 0.60 to 0.98 0.75 0.57 to 1.00
BZD 1.45 1.04 to 2.03 1.16 0.76 to 1.79
Z-drug 1.39 1.11 to 1.74 1.34 1.05 to 1.73
Incident antidepressant prescription
No sleep drug 1.00 1.00
BZD 1.33 0.86 to 2.05 1.47 0.74 to 2.92
Z-drug 1.47 1.12 to 1.93 1.69 1.25 to 2.30
Incident antibiotic prescription
No sleep drug 1.00 1.00
Low-dose TCA 1.02 0.89 to 1.17 1.02 0.87 to 1.19
BZD 1.20 0.96 to 1.52 1.29 0.99 to 1.70
Z-drug 1.17 1.03 to 1.34 1.13 0.98 to 1.30
Number of GP visitsb
No sleep drug 1.00 1.00
Low-dose TCA 1.09 1.01 to 1.17 0.98 0.92 to 1.04
BZD 1.05 0.94 to 1.16 1.01 0.92 to 1.11
Z-drug 1.14 1.06 to 1.21 1.09 1.03 to 1.15
Number of hospital admissionsb
No sleep drug 1.00 1.00
Low-dose TCA 1.00 0.90 to 1.12 0.97 0.87 to 1.08
BZD 0.91 0.79 to 1.06 0.91 0.78 to 1.07
Z-drug 1.07 0.97 to 1.18 1.04 0.95 to 1.14
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39.
b IRRs estimated, not HRs.
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outcome in CPRD (n)
Per cent of main
analysis outcomes
Age, sex adjusted Fully adjusteda
HR 95% CI HR 95% CI
Fracture
No sleep drug 83 77 1.00 1.00
Low-dose TCA 76 72 1.25 0.91 to 1.73 1.07 0.72 to 1.60
BZD 13 65 1.21 0.68 to 2.18 1.05 0.44 to 2.51
Z-drug 90 67 1.23 0.89 to 1.68 1.27 0.87 to 1.87
Hip fracture
No sleep drug 35 74 1.00 1.00
Low-dose TCA 37 66 1.46 0.91 to 2.35 1.38 0.78 to 2.44
BZD 7 58 1.71 0.74 to 3.94 2.35 0.54 to 10.11
Z-drug 40 61 1.38 0.85 to 2.23 1.38 0.75 to 2.52
Forearm fracture
No sleep drug 13 72 1.00 1.00
Low-dose TCA 11 69 1.04 0.45 to 2.41 0.87 0.22 to 3.51
Z-drug 20 74 1.82 0.82 to 4.07 1.63 0.56 to 4.75
Fall
No sleep drug 245 75 1.00 1.00
Low-dose TCA 183 64 0.84 0.70 to 1.03 0.77 0.61 to 0.96
BZD 46 71 1.26 0.91 to 1.74 1.09 0.74 to 1.62
Z-drug 269 67 1.01 0.84 to 1.21 1.03 0.83 to 1.27
Acute bacterial infection
No sleep drug 239 64 1.00 1.00
Low-dose TCA 165 60 0.97 0.79 to 1.19 0.99 0.77 to 1.27
BZD 37 76 1.11 0.78 to 1.58 1.01 0.67 to 1.54
Z-drug 243 60 1.13 0.93 to 1.36 1.14 0.91 to 1.42
UTI or acute LRTI
No sleep drug 206 63 1.00 1.00
Low-dose TCA 127 56 0.86 0.69 to 1.07 0.90 0.69 to 1.17
BZD 30 73 1.07 0.73 to 1.58 1.00 0.63 to 1.60
Z-drug 184 52 0.98 0.80 to 1.21 1.01 0.79 to 1.28
Ischaemic stroke/TIA
No sleep drug 47 73 1.00 1.00
Low-dose TCA 37 74 1.02 0.66 to 1.58 1.17 0.67 to 2.06
BZD 12 80 1.92 0.98 to 3.74 2.88 1.10 to 7.52
Z-drug 52 65 1.21 0.79 to 1.85 1.22 0.72 to 2.08
Venous thromboembolism
No sleep drug 14 64 1.00 1.00
Low-dose TCA 12 50 1.32 0.61 to 2.86 1.12 0.29 to 4.34
Z-drug 14 54 1.18 0.56 to 2.49 1.06 0.36 to 3.12
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outcome in CPRD (n)
Per cent of main
analysis outcomes
Age, sex adjusted Fully adjusteda
HR 95% CI HR 95% CI
Incident agitation/psychosis
No sleep drug 74 94 1.00 1.00
Low-dose TCA 77 91 1.30 0.93 to 1.81 1.51 1.01 to 2.27
BZD 34 94 3.88 2.50 to 6.02 5.76 3.22 to 10.28
Z-drug 126 90 1.53 1.14 to 2.06 1.77 1.24 to 2.54
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39, except for forearm fracture and venous
thromboembolism, which were also adjusted for eye conditions (ARMD, retinal disorders and glaucoma combined) and
not adjusted for region, ethnicity or systolic blood pressure.
TABLE 64 Adjusted HRs for adverse events, for patients initiating Z-drugs compared with patients discontinuing
Z-drugs




Age, sex adjusted Fully adjusteda
Exposed With outcome HR 95% CI HR 95% CI
Fracture
Discontinued Z-drug 1265 80 8.2 1.00 1.00
New Z-drug 2997 135 11.3 1.24 0.94 to 1.65 1.31 0.94 to 1.84
Hip fracture
Discontinued Z-drug 1265 45 4.5 1.00 1.00
New Z-drug 2997 66 5.4 1.13 0.77 to 1.65 1.01 0.63 to 1.62
Forearm fracture
Discontinued Z-drug 1265 17 1.7 1.00 1.00
New Z-drug 2997 27 2.2 1.24 0.65 to 2.39 1.60 0.75 to 3.41
Fall
Discontinued Z-drug 1236 221 25.7 1.00 1.00
New Z-drug 2888 399 37.8 1.25 1.06 to 1.47 1.30 1.06 to 1.58
Mortality
Discontinued Z-drug 1274 182 17.8 1.00 1.00
New Z-drug 3089 355 27.8 1.47 1.23 to 1.77 1.45 1.17 to 1.81
Acute bacterial infection
Discontinued Z-drug 1029 251 35.5 1.00 1.00
New Z-drug 2267 408 47.7 1.21 1.03 to 1.42 1.34 1.11 to 1.63
UTI or acute LRTI
Discontinued Z-drug 1029 211 28.9 1.00 1.00
New Z-drug 2267 354 40.0 1.24 1.04 to 1.48 1.38 1.12 to 1.70
Ischaemic stroke/TIA
Discontinued Z-drug 1268 43 4.3 1.00 1.00
New Z-drug 3045 80 6.5 1.44 0.97 to 2.12 1.23 0.76 to 1.97
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TABLE 64 Adjusted HRs for adverse events, for patients initiating Z-drugs compared with patients discontinuing
Z-drugs (continued )




Age, sex adjusted Fully adjusteda
Exposed With outcome HR 95% CI HR 95% CI
Venous thromboembolism
Discontinued Z-drug 1273 12 1.2 1.00 1.00
New Z-drug 3074 26 2.1 1.68 0.83 to 3.41 2.71 0.88 to 8.31
Incident agitation/psychosis
Discontinued Z-drug 1039 41 4.9 1.00 1.00
New Z-drug 2574 140 13.6 2.26 1.60 to 3.19 2.16 1.47 to 3.17
Incident antipsychotic prescription
Discontinued Z-drug 1274 107 13.8 1.00 1.00
New Z-drug 2402 355 39.5 2.09 1.59 to 2.75 2.66 2.09 to 3.40
Incident antidepressant prescription
Discontinued Z-drug 825 66 10.6 1.00 1.00
New Z-drug 2177 236 28.3 2.09 1.59 to 2.75 2.20 1.62 to 2.99
Incident antibiotic prescription
Discontinued Z-drug 1087 483 88.8 1.00 1.00
New Z-drug 2430 818 116.4 1.14 1.02 to 1.27 1.21 1.07 to 1.37
PY, person-year.
a Adjusted for age2 and the covariates listed in Table 2 and Appendix 2, Table 39, except for forearm fracture, which was
also adjusted for eye conditions (ARMD, retinal disorders and glaucoma combined) and not adjusted for region, ethnicity
or systolic blood pressure.
DOI: 10.3310/hta25010 HEALTH TECHNOLOGY ASSESSMENT 2021 VOL. 25 NO. 1
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Richardson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
199

Appendix 6 Additional WHELD trial analyses
TABLE 65 Adjusted additional change in QUALID, NPI-NH and NPI-NH sleep scores, by pattern of Z-drug use
Scale
Z-drug
Pattern n Mean change (SD) Beta (95% CI) Betaa (95% CI)
NPI-NH excluding sleep None 514 0.44 (16.06) 0.00 0.00
Stopping 26 0.65 (17.02) 0.22 (–6.34 to 6.77) 1.46 (–5.49 to 8.40)
Starting 25 –1.84 (20.44) –2.28 (–8.96 to 4.40) –2.52 (–10.07 to 5.03)
Continuing 62 –1.40 (19.12) –1.84 (–6.23 to 2.55) 0.09 (–4.51 to 4.69)
NPI-NH sleep None 514 0.10 (0.59) 0.00 0.00
Stopping 26 0.27 (0.53) 0.17 (–0.07 to 0.41) 0.11 (–0.14 to 0.37)
Starting 25 0.16 (0.62) 0.06 (–0.18 to 0.30) 0.05 (–0.23 to 0.33)
Continuing 62 0.11 (0.70) 0.01 (–0.15 to 0.17) 0.07 (–0.10 to 0.24)
QUALID None 502 0.22 (7.34) 0.00 0.00
Stopping 26 1.88 (6.26) 1.66 (–1.37 to 4.70) 2.28 (–0.79 to 5.34)
Starting 23 –0.17 (9.16) –0.40 (–3.61 to 2.82) –0.33 (–3.79 to 3.13)
Continuing 59 –0.09 (10.07) –0.31 (–2.38 to 1.77) 0.86 (–1.23 to 2.95)
a Adjusted for age, sex, ethnicity, marital status, baseline CDR, Abbey Pain Scale score, comorbidity and changes in
co-medication use. Change in QUALID scores also adjusted for baseline sleep disturbance (a NPI-NH sleep score > 0).
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